data_5z31_residue ############################ # Computer software used # ############################ save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 5z31 _Structure_validation_residue.Date_analyzed 2019-02-01 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 56.2 m . . . . . 0 C--O 1.232 0.151 0 CA-C-O 120.864 0.364 . . . . 71.41 110.866 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -55.17 -26.54 39.5 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.132 -0.486 . . . . 73.41 110.917 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 15.2 t -65.87 -12.61 14.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.183 -0.462 . . . . 71.34 111.153 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.65 -23.52 2.68 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.103 -0.499 . . . . 72.2 111.138 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 2.3 mtm-85 -48.6 -25.77 1.9 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.219 -0.446 . . . . 75.33 110.892 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.57 -46.46 23.64 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.711 -0.757 . . . . 52.41 112.474 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' TRP . . . . . 0.456 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.1 p90 -126.52 -125.34 0.24 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.837 0.351 . . . . 71.13 110.883 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.18 -122.22 2.43 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.715 -0.755 . . . . 75.15 112.512 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.7 ptp85 -125.45 -32.68 2.89 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.89 0.376 . . . . 75.22 110.892 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.57 -25.78 3.02 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.152 -0.476 . . . . 72.41 110.883 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -82.94 133.87 47.7 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.638 0.733 . . . . 73.43 110.856 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . 0.448 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.4 Cg_endo -69.77 -33.78 15.86 Favored 'Trans proline' 0 C--O 1.232 0.19 0 C-N-CA 122.648 2.232 . . . . 74.42 112.311 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.448 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.66 -55.18 0.55 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.239 -0.437 . . . . 71.05 110.92 179.994 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.456 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 5.8 m-85 -128.21 15.08 6.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.154 -0.476 . . . . 73.02 110.89 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 C-N-CA 120.775 -0.726 . . . . 64.02 112.482 -179.942 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 39.1 m . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.864 0.364 . . . . 73.44 110.829 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -54.08 -26.92 29.56 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.167 -0.469 . . . . 73.53 110.843 -179.949 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.0 t -62.07 -16.68 16.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.189 -0.46 . . . . 72.55 111.134 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.33 -23.76 2.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.177 -0.465 . . . . 70.3 111.069 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.07 -24.99 1.81 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 74.4 110.898 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.82 -46.11 31.58 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.703 -0.76 . . . . 72.4 112.512 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' TRP . . . . . 0.422 ' HZ2' ' CD1' ' A' ' 17' ' ' PHE . 2.9 p90 -126.26 -125.45 0.24 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.829 0.347 . . . . 74.32 110.926 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.74 -122.05 2.4 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.778 -0.725 . . . . 62.23 112.511 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -124.99 -32.39 3.03 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.909 0.385 . . . . 74.41 110.88 -179.818 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.24 -26.15 2.78 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 72.34 110.876 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.29 134.63 45.36 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.628 0.728 . . . . 74.32 110.889 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . 0.45 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.7 Cg_endo -69.75 -34.94 13.61 Favored 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.675 2.25 . . . . 74.42 112.357 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.45 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.17 -55.75 0.5 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.194 -0.457 . . . . 75.21 110.917 -179.986 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.422 ' CD1' ' HZ2' ' A' ' 10' ' ' TRP . 6.7 m-85 -129.19 16.08 6.15 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 75.34 110.893 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 C-N-CA 120.77 -0.729 . . . . 52.01 112.518 -179.995 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 58.3 m . . . . . 0 C--O 1.232 0.134 0 CA-C-O 120.895 0.378 . . . . 72.41 110.879 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -54.17 -26.77 29.74 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.142 -0.481 . . . . 74.32 110.907 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.9 t -62.22 -16.62 16.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.211 -0.45 . . . . 75.22 111.165 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.23 -23.74 2.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.14 -0.482 . . . . 75.33 111.124 179.849 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.1 -24.96 1.83 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.174 -0.466 . . . . 74.12 110.872 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.88 -46.16 31.95 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.753 -0.737 . . . . 54.25 112.484 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' TRP . . . . . 0.42 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.0 p90 -126.26 -125.48 0.24 Allowed 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.79 0.329 . . . . 75.13 110.917 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.75 -122.03 2.4 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.727 -0.749 . . . . 74.14 112.466 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.1 ptp180 -125.03 -32.47 3.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.858 0.361 . . . . 75.24 110.882 -179.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.13 -26.2 2.63 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.161 -0.472 . . . . 74.1 110.939 179.946 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.16 134.66 45.65 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.629 0.728 . . . . 74.04 110.891 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . 0.447 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.9 Cg_endo -69.75 -34.84 13.8 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.68 2.253 . . . . 73.44 112.374 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.447 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.27 -55.77 0.51 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.183 -0.462 . . . . 72.21 110.941 179.961 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.42 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 6.6 m-85 -129.14 16.13 6.18 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.224 -0.444 . . . . 74.21 110.894 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.343 0 C-N-CA 120.753 -0.737 . . . . 74.42 112.472 -179.943 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 39.9 m . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.872 0.368 . . . . 40.1 110.879 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 4.3 ttt180 -54.1 -26.84 29.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.131 -0.486 . . . . 73.22 110.872 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.0 t -62.27 -16.56 16.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.236 -0.438 . . . . 62.42 111.093 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.32 -23.75 2.52 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.22 -0.445 . . . . 44.41 111.089 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -49.15 -24.94 1.89 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.231 -0.441 . . . . 75.31 110.853 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.83 -46.2 31.63 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.743 -0.742 . . . . 73.33 112.46 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' TRP . . . . . 0.424 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 2.9 p90 -126.27 -125.45 0.24 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.831 0.348 . . . . 72.23 110.886 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.76 -122.04 2.4 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.719 -0.753 . . . . 71.24 112.468 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.3 ptp180 -125.04 -32.35 3.02 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.895 0.379 . . . . 73.23 110.854 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.25 -26.19 2.81 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.207 -0.451 . . . . 65.14 110.865 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.26 134.69 45.35 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.62 0.724 . . . . 71.14 110.922 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . 0.452 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.7 Cg_endo -69.84 -34.79 13.63 Favored 'Trans proline' 0 C--O 1.232 0.219 0 C-N-CA 122.692 2.261 . . . . 54.32 112.315 -179.886 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.452 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.26 -55.76 0.51 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.239 -0.437 . . . . 75.34 110.929 179.948 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.424 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 6.6 m-85 -129.18 16.1 6.16 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.199 -0.455 . . . . 72.34 110.912 179.946 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.352 0 C-N-CA 120.737 -0.744 . . . . 73.03 112.5 -179.968 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 42.2 m . . . . . 0 C--O 1.231 0.122 0 CA-C-O 120.856 0.36 . . . . 64.24 110.827 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -54.3 -26.69 30.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.168 -0.469 . . . . 74.11 110.866 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.8 t -62.38 -16.48 16.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.204 -0.453 . . . . 75.33 111.148 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.36 -23.77 2.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.162 -0.472 . . . . 74.32 111.099 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.17 -24.83 1.87 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.234 -0.439 . . . . 74.44 110.89 -179.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.86 -46.22 31.83 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.747 -0.74 . . . . 61.31 112.491 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' TRP . . . . . 0.422 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 2.9 p90 -126.25 -125.42 0.24 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.756 0.312 . . . . 75.44 110.971 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.407 ' H ' ' HB2' ' A' ' 10' ' ' TRP . . . -129.74 -122.02 2.39 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.709 -0.757 . . . . 65.23 112.479 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.0 -32.36 3.03 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.908 0.385 . . . . 74.25 110.906 -179.866 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.19 -26.26 2.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.17 -0.468 . . . . 71.32 110.871 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.19 134.61 45.67 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.588 0.709 . . . . 73.51 110.863 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . 0.452 ' O ' ' C ' ' A' ' 16' ' ' LEU . 54.2 Cg_endo -69.73 -34.83 13.87 Favored 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.697 2.264 . . . . 72.45 112.386 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.452 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.24 -55.75 0.51 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.217 -0.447 . . . . 73.02 110.911 179.959 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.422 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 6.6 m-85 -129.2 16.11 6.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.195 -0.457 . . . . 72.14 110.902 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.36 0 C-N-CA 120.728 -0.749 . . . . 73.43 112.479 -179.957 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 38.3 m . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.889 0.376 . . . . 74.2 110.887 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -54.01 -27.25 30.6 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.119 -0.491 . . . . 74.43 110.847 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.0 t -61.65 -17.02 16.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 75.23 111.127 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.17 -23.81 2.42 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.171 -0.468 . . . . 71.2 111.047 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.9 ptt85 -49.13 -24.94 1.86 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.264 -0.425 . . . . 73.35 110.877 -179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.81 -46.16 31.53 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.756 -0.735 . . . . 73.21 112.454 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' TRP . . . . . 0.42 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.0 p90 -126.29 -125.43 0.24 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.797 0.332 . . . . 72.21 110.911 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.77 -122.07 2.4 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.763 -0.732 . . . . 74.01 112.475 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.01 -32.23 3.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.866 0.365 . . . . 74.5 110.865 -179.854 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.29 -26.21 2.89 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.157 -0.474 . . . . 73.44 110.888 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.31 134.63 45.32 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.639 0.733 . . . . 64.32 110.86 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . 0.429 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.9 Cg_endo -69.7 -34.89 13.88 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.684 2.256 . . . . 75.01 112.361 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.429 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.19 -55.78 0.5 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.206 -0.452 . . . . 74.03 110.909 179.979 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.42 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 6.7 m-85 -129.24 16.1 6.12 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.168 -0.469 . . . . 72.25 110.852 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.334 0 C-N-CA 120.779 -0.724 . . . . 61.31 112.488 -179.963 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 40.5 m . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.826 0.346 . . . . 65.43 110.859 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -54.01 -27.3 31.04 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.114 -0.494 . . . . 71.3 110.835 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.2 t -61.8 -16.81 16.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.462 . . . . 72.25 111.102 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.23 -23.72 2.41 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.188 -0.46 . . . . 75.31 111.094 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.15 -24.96 1.89 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.198 -0.455 . . . . 63.43 110.877 -179.91 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.69 -46.24 30.76 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.748 -0.739 . . . . 72.23 112.507 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' TRP . . . . . 0.423 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 2.9 p90 -126.28 -125.46 0.24 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.764 0.316 . . . . 73.23 110.925 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.74 -122.07 2.4 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.737 -0.744 . . . . 64.14 112.493 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -124.96 -32.36 3.04 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.926 0.393 . . . . 74.44 110.909 -179.822 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -49.22 -26.21 2.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 75.34 110.909 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.31 134.66 45.26 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.656 0.741 . . . . 51.11 110.88 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . 0.451 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.7 Cg_endo -69.77 -34.76 13.9 Favored 'Trans proline' 0 C--N 1.342 0.215 0 C-N-CA 122.67 2.247 . . . . 75.25 112.347 -179.935 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.451 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.33 -55.7 0.52 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.234 -0.439 . . . . 73.45 110.915 179.984 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.423 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 6.6 m-85 -129.23 16.12 6.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.188 -0.46 . . . . 72.33 110.908 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.268 0 C-N-CA 120.761 -0.733 . . . . 64.2 112.481 -179.938 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 50.2 m . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.846 0.355 . . . . 64.33 110.841 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 1.6 ttp180 -54.19 -26.79 30.03 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.155 -0.475 . . . . 74.15 110.878 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.2 t -62.29 -16.37 16.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.213 -0.449 . . . . 64.32 111.111 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.28 -23.88 2.57 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.174 -0.466 . . . . 75.35 111.073 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -49.11 -24.93 1.83 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.251 -0.432 . . . . 75.53 110.857 -179.884 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.94 -45.94 32.33 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.706 -0.759 . . . . 75.02 112.516 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' TRP . . . . . 0.434 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.1 p90 -126.32 -125.37 0.24 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.832 0.348 . . . . 75.14 110.893 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.23 -122.1 2.42 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.778 -0.725 . . . . 72.43 112.51 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.55 -32.7 2.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.832 0.348 . . . . 70.5 110.843 -179.882 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.64 -25.79 3.14 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.192 -0.458 . . . . 74.2 110.854 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -82.24 134.48 48.81 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.599 0.714 . . . . 72.43 110.873 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . 0.447 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.5 Cg_endo -69.76 -34.37 14.71 Favored 'Trans proline' 0 C--O 1.232 0.177 0 C-N-CA 122.698 2.265 . . . . 74.12 112.353 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.447 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.4 OUTLIER -34.4 -55.13 0.53 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.204 -0.453 . . . . 72.04 110.927 179.948 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.434 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 6.2 m-85 -128.55 15.12 6.55 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.169 -0.468 . . . . 74.34 110.887 179.921 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.319 0 C-N-CA 120.779 -0.724 . . . . 74.31 112.468 -179.979 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 58.8 m . . . . . 0 C--O 1.231 0.089 0 CA-C-O 120.867 0.365 . . . . 73.43 110.839 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 1.3 ttt-85 -54.33 -26.74 31.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 75.3 110.872 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.8 t -63.19 -15.9 16.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.456 . . . . 72.32 111.098 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.51 -23.56 2.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.154 -0.475 . . . . 74.54 111.053 179.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.14 -24.92 1.86 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.247 -0.433 . . . . 75.53 110.857 -179.878 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.78 -46.25 31.31 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.703 -0.76 . . . . 73.05 112.538 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' TRP . . . . . 0.423 ' HZ2' ' CD1' ' A' ' 17' ' ' PHE . 2.9 p90 -126.29 -125.38 0.24 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.796 0.332 . . . . 74.21 110.882 -179.913 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.7 -122.1 2.4 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.748 -0.739 . . . . 62.01 112.475 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -125.02 -32.45 3.01 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.878 0.37 . . . . 74.14 110.836 -179.842 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.06 -26.23 2.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 73.14 110.946 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.31 134.62 45.33 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.611 0.719 . . . . 72.35 110.887 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . 0.449 ' O ' ' C ' ' A' ' 16' ' ' LEU . 54.0 Cg_endo -69.81 -34.73 13.85 Favored 'Trans proline' 0 C--N 1.342 0.215 0 C-N-CA 122.678 2.252 . . . . 72.51 112.353 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.449 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.33 -55.66 0.52 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.203 -0.453 . . . . 73.43 110.936 179.989 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.423 ' CD1' ' HZ2' ' A' ' 10' ' ' TRP . 6.5 m-85 -129.21 16.05 6.14 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 64.21 110.854 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 C-N-CA 120.743 -0.742 . . . . 73.13 112.514 -179.957 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 56.9 m . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.878 0.371 . . . . 74.35 110.831 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -54.32 -26.76 31.39 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.1 -0.5 . . . . 75.01 110.889 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 13.1 t -63.23 -15.85 16.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.17 -0.468 . . . . 75.12 111.13 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.5 -23.57 2.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.166 -0.47 . . . . 74.1 111.098 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.7 ptt85 -49.16 -24.88 1.87 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.224 -0.443 . . . . 74.43 110.86 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.83 -46.2 31.65 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.721 -0.752 . . . . 74.22 112.466 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' TRP . . . . . 0.425 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.0 p90 -126.27 -125.43 0.24 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.876 0.37 . . . . 75.33 110.906 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.64 -122.13 2.41 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.744 -0.741 . . . . 61.12 112.515 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -124.99 -32.4 3.03 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.909 0.385 . . . . 75.13 110.882 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.17 -26.2 2.69 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.201 -0.454 . . . . 74.14 110.904 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.34 134.59 45.3 Favored Pre-proline 0 C--N 1.328 -0.368 0 CA-C-O 121.595 0.712 . . . . 72.25 110.886 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . 0.451 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.2 Cg_endo -69.8 -34.8 13.73 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.655 2.237 . . . . 74.45 112.316 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.451 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.24 -55.74 0.51 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.238 -0.437 . . . . 75.04 110.874 179.994 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.425 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 6.5 m-85 -129.18 16.07 6.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.178 -0.464 . . . . 75.14 110.856 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.346 0 C-N-CA 120.736 -0.745 . . . . 64.11 112.479 -179.951 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 35.3 m . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.903 0.382 . . . . 71.04 110.887 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 2.6 ttt180 -55.67 -25.67 40.81 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.127 -0.488 . . . . 71.22 110.888 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 18.5 t -67.02 -12.27 14.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 73.01 111.078 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.81 -23.13 2.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.177 -0.465 . . . . 75.53 111.124 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.3 mtp180 -48.52 -25.77 1.85 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.236 -0.438 . . . . 75.03 110.897 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.48 -47.01 23.17 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.738 -0.744 . . . . 44.04 112.462 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' TRP . . . . . 0.451 ' HZ2' ' CD1' ' A' ' 17' ' ' PHE . 2.9 p90 -126.31 -125.3 0.24 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.852 0.358 . . . . 71.11 110.944 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.3 -122.42 2.45 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.715 -0.755 . . . . 43.43 112.495 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.2 ptp180 -125.11 -32.57 2.98 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.879 0.371 . . . . 74.52 110.884 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -48.99 -26.28 2.44 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.191 -0.459 . . . . 74.24 110.917 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.21 134.43 45.96 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.624 0.726 . . . . 73.11 110.891 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . 0.443 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.4 Cg_endo -69.79 -34.33 14.68 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.693 2.262 . . . . 74.22 112.302 -179.904 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.443 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.65 -55.62 0.55 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.246 -0.434 . . . . 75.51 110.927 179.979 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.451 ' CD1' ' HZ2' ' A' ' 10' ' ' TRP . 6.0 m-85 -128.5 15.6 6.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.158 -0.474 . . . . 75.34 110.837 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.279 0 C-N-CA 120.727 -0.749 . . . . 74.53 112.483 -179.945 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 35.2 m . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.88 0.371 . . . . 71.44 110.88 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -55.64 -25.69 40.4 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.123 -0.49 . . . . 74.41 110.868 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 18.4 t -67.01 -12.24 14.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.166 -0.47 . . . . 74.2 111.14 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.72 -23.24 2.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.16 -0.473 . . . . 75.23 111.077 179.875 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.1 mtp85 -48.44 -25.86 1.85 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 73.05 110.891 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.5 -46.9 23.28 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.724 -0.75 . . . . 71.31 112.475 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' TRP . . . . . 0.452 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.0 p90 -126.44 -125.28 0.24 Allowed 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.805 0.336 . . . . 74.53 110.954 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.33 -122.45 2.45 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.736 -0.745 . . . . 62.14 112.503 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.3 ptp180 -125.08 -32.5 2.99 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.9 0.381 . . . . 71.34 110.867 -179.899 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.05 -26.24 2.51 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 74.13 110.895 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.27 134.45 45.74 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.6 0.714 . . . . 75.11 110.867 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . 0.443 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.3 Cg_endo -69.79 -34.32 14.72 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.666 2.244 . . . . 74.41 112.338 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.443 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.68 -55.64 0.55 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.221 -0.445 . . . . 73.5 110.887 179.968 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.452 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 5.9 m-85 -128.44 15.56 6.58 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.188 -0.46 . . . . 74.54 110.919 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 C-N-CA 120.752 -0.737 . . . . 65.4 112.491 -179.938 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 24.3 m . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.841 0.353 . . . . 63.45 110.85 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 3.0 mtp180 -54.41 -26.65 31.79 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.125 -0.489 . . . . 74.1 110.863 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 13.1 t -62.57 -16.16 16.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.19 -0.459 . . . . 60.13 111.145 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.16 -23.6 2.27 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.164 -0.471 . . . . 61.41 111.148 179.86 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -49.03 -24.99 1.76 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 74.02 110.893 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.56 -46.47 29.95 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.78 -0.724 . . . . 71.04 112.476 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' TRP . . . . . 0.417 ' HZ2' ' CD1' ' A' ' 17' ' ' PHE . 2.9 p90 -126.23 -125.39 0.24 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.827 0.346 . . . . 75.31 110.88 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.76 -122.18 2.41 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.752 -0.737 . . . . 64.01 112.493 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.0 -31.86 3.08 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.866 0.365 . . . . 75.41 110.847 -179.878 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.71 -25.73 3.19 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.235 -0.439 . . . . 74.03 110.872 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.88 134.79 43.53 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.552 0.691 . . . . 64.34 110.942 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . 0.454 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.6 Cg_endo -69.73 -35.1 13.35 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.694 2.262 . . . . 65.33 112.356 -179.909 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.454 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.07 -55.83 0.49 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.164 -0.471 . . . . 65.34 110.922 -179.99 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.417 ' CD1' ' HZ2' ' A' ' 10' ' ' TRP . 6.5 m-85 -129.05 16.04 6.23 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.174 -0.467 . . . . 73.13 110.872 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.247 0 C-N-CA 120.713 -0.756 . . . . 75.04 112.463 -179.952 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 35.4 m . . . . . 0 C--O 1.231 0.122 0 CA-C-O 120.851 0.358 . . . . 62.43 110.872 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 2.1 mtt180 -55.76 -25.47 40.94 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.11 -0.495 . . . . 71.11 110.873 -179.924 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 18.4 t -67.2 -12.21 14.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.216 -0.447 . . . . 74.11 111.116 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.83 -23.18 2.59 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 75.31 111.072 179.899 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -48.51 -25.75 1.84 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.234 -0.439 . . . . 75.32 110.884 -179.905 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.53 -46.93 23.48 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.728 -0.749 . . . . 74.21 112.474 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' TRP . . . . . 0.448 ' HZ2' ' CD1' ' A' ' 17' ' ' PHE . 2.9 p90 -126.44 -125.31 0.24 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.773 0.321 . . . . 73.51 110.922 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.24 -122.43 2.45 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.768 -0.73 . . . . 64.21 112.527 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.12 -32.47 2.99 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.865 0.364 . . . . 74.11 110.842 -179.865 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.08 -26.23 2.55 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.214 -0.448 . . . . 73.54 110.878 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.32 134.42 45.68 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.668 0.747 . . . . 73.11 110.87 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . 0.44 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.8 Cg_endo -69.73 -34.38 14.8 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.7 2.267 . . . . 71.4 112.35 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.44 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.62 -55.64 0.55 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.21 -0.45 . . . . 71.42 110.898 179.943 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.448 ' CD1' ' HZ2' ' A' ' 10' ' ' TRP . 6.0 m-85 -128.49 15.53 6.56 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.196 -0.456 . . . . 74.33 110.884 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.287 0 C-N-CA 120.717 -0.754 . . . . 73.13 112.498 -179.983 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 58.6 m . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.882 0.372 . . . . 61.22 110.845 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 4.7 mtt180 -55.58 -25.69 39.57 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.117 -0.492 . . . . 73.32 110.855 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 13.1 t -66.12 -12.81 14.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.197 -0.456 . . . . 75.22 111.152 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.93 -23.45 2.88 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.166 -0.47 . . . . 61.43 111.115 179.856 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.1 mtm180 -48.56 -25.91 1.95 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.202 -0.453 . . . . 73.21 110.891 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.58 -46.78 23.75 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.759 -0.734 . . . . 71.34 112.506 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' TRP . . . . . 0.447 ' HZ2' ' CD1' ' A' ' 17' ' ' PHE . 3.0 p90 -126.44 -125.38 0.24 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.825 0.345 . . . . 75.13 110.909 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.412 ' H ' ' HB2' ' A' ' 10' ' ' TRP . . . -129.49 -122.38 2.44 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.705 -0.76 . . . . 73.1 112.448 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.03 -32.37 3.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.826 0.346 . . . . 72.23 110.883 -179.881 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.17 -26.12 2.63 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.188 -0.46 . . . . 75.3 110.919 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.42 134.53 45.2 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.635 0.731 . . . . 73.34 110.871 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . 0.451 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.7 Cg_endo -69.75 -34.44 14.61 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.699 2.266 . . . . 74.31 112.352 -179.923 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.451 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.63 -55.63 0.55 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.213 -0.449 . . . . 73.33 110.881 179.984 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.447 ' CD1' ' HZ2' ' A' ' 10' ' ' TRP . 6.1 m-85 -128.65 15.72 6.46 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.199 -0.455 . . . . 70.24 110.824 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 C-N-CA 120.721 -0.752 . . . . 64.34 112.46 179.977 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 35.4 m . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.906 0.384 . . . . 75.03 110.858 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 4.3 mtp180 -55.83 -25.44 41.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.105 -0.498 . . . . 71.34 110.812 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 18.4 t -67.32 -12.04 14.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.23 -0.441 . . . . 74.35 111.134 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.9 -23.1 2.58 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.182 -0.463 . . . . 74.24 111.093 179.864 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 2.9 mtp180 -48.47 -25.84 1.86 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.243 -0.435 . . . . 74.31 110.89 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.52 -46.92 23.4 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.731 -0.747 . . . . 54.15 112.527 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' TRP . . . . . 0.451 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.0 p90 -126.4 -125.34 0.24 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.833 0.349 . . . . 72.22 110.92 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.28 -122.42 2.45 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.722 -0.751 . . . . 63.31 112.505 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.1 -32.53 2.99 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.879 0.371 . . . . 73.44 110.883 -179.853 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -49.04 -26.28 2.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.158 -0.473 . . . . 74.23 110.86 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.2 134.36 46.1 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-O 121.602 0.715 . . . . 70.45 110.883 179.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . 0.445 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.6 Cg_endo -69.76 -34.31 14.85 Favored 'Trans proline' 0 C--O 1.232 0.222 0 C-N-CA 122.653 2.236 . . . . 74.0 112.347 -179.933 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.445 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.67 -55.63 0.55 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.263 -0.426 . . . . 73.25 110.914 179.957 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.451 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 5.9 m-85 -128.51 15.65 6.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.18 -0.463 . . . . 71.54 110.919 179.888 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 C-N-CA 120.714 -0.755 . . . . 74.22 112.498 -179.989 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 34.2 m . . . . . 0 C--O 1.231 0.09 0 CA-C-O 120.893 0.378 . . . . 70.43 110.914 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -55.74 -25.49 40.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.08 -0.509 . . . . 74.41 110.875 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 18.7 t -67.27 -11.95 14.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.179 -0.464 . . . . 71.55 111.142 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.73 -23.28 2.57 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.129 -0.487 . . . . 75.44 111.095 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 3.3 mtp180 -48.69 -25.66 1.9 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.212 -0.449 . . . . 74.13 110.823 -179.85 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.55 -46.63 23.55 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.736 -0.745 . . . . 65.02 112.464 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' TRP . . . . . 0.461 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.1 p90 -126.43 -125.31 0.24 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.832 0.349 . . . . 74.41 110.941 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.06 -122.33 2.45 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.701 -0.762 . . . . 75.24 112.482 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -125.49 -32.65 2.88 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.848 0.356 . . . . 75.4 110.878 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -49.46 -25.92 2.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.194 -0.457 . . . . 70.23 110.91 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -82.89 133.87 47.89 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.591 0.71 . . . . 63.2 110.891 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . 0.441 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.3 Cg_endo -69.74 -33.8 15.95 Favored 'Trans proline' 0 C--O 1.233 0.233 0 C-N-CA 122.738 2.292 . . . . 71.15 112.291 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.441 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.74 -55.13 0.56 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.245 -0.434 . . . . 64.24 110.96 179.968 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.461 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 5.7 m-85 -128.14 15.04 6.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.229 -0.441 . . . . 73.23 110.845 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.334 0 C-N-CA 120.769 -0.729 . . . . 64.4 112.49 -179.974 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 30.3 m . . . . . 0 C--O 1.231 0.086 0 CA-C-O 120.943 0.402 . . . . 70.24 110.887 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -55.25 -26.43 39.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.094 -0.503 . . . . 73.1 110.896 -179.914 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 15.3 t -65.9 -12.83 14.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.164 -0.471 . . . . 75.01 111.133 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.66 -23.45 2.63 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 52.23 111.066 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 2.2 mtt180 -48.46 -25.94 1.89 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.213 -0.449 . . . . 73.33 110.905 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.48 -46.86 23.14 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.747 -0.74 . . . . 72.01 112.492 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' TRP . . . . . 0.45 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 2.9 p90 -126.45 -125.33 0.24 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.769 0.319 . . . . 73.54 110.96 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.33 -122.37 2.44 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.78 -0.724 . . . . 64.22 112.469 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.6 ptp180 -125.14 -32.6 2.97 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.909 0.385 . . . . 74.34 110.854 -179.806 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.03 -26.27 2.49 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.19 -0.459 . . . . 74.42 110.889 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.07 134.46 46.27 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.573 0.701 . . . . 74.1 110.91 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . 0.445 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.2 Cg_endo -69.77 -34.42 14.59 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.665 2.243 . . . . 75.44 112.341 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.445 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.65 -55.6 0.55 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.178 -0.465 . . . . 74.04 110.92 179.996 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.45 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 6.0 m-85 -128.57 15.61 6.51 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.216 -0.447 . . . . 75.34 110.9 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.29 0 C-N-CA 120.732 -0.747 . . . . 71.43 112.506 -179.951 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 31.0 m . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.855 0.359 . . . . 72.35 110.857 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -55.42 -26.29 41.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.165 -0.47 . . . . 73.3 110.855 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 18.8 t -66.52 -12.25 14.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.203 -0.453 . . . . 70.13 111.118 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.58 -23.31 2.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.19 -0.459 . . . . 71.31 111.136 179.886 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.8 mtp180 -48.57 -25.78 1.89 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.219 -0.446 . . . . 74.4 110.828 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.48 -46.58 23.1 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.669 -0.777 . . . . 65.14 112.524 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' TRP . . . . . 0.458 ' HZ2' ' CD1' ' A' ' 17' ' ' PHE . 3.0 p90 -126.49 -125.27 0.24 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.831 0.348 . . . . 74.51 110.922 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.09 -122.33 2.45 Favored Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.715 -0.755 . . . . 71.24 112.443 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.51 -32.51 2.89 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.855 0.359 . . . . 75.13 110.856 -179.842 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.56 -25.87 3.08 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.197 -0.456 . . . . 74.51 110.883 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -82.93 133.87 47.73 Favored Pre-proline 0 C--N 1.328 -0.365 0 CA-C-O 121.606 0.717 . . . . 70.32 110.91 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . 0.446 ' O ' ' C ' ' A' ' 16' ' ' LEU . 54.0 Cg_endo -69.82 -33.57 16.1 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.688 2.259 . . . . 73.33 112.357 -179.918 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.446 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.86 -55.14 0.58 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 74.5 110.917 179.957 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.458 ' CD1' ' HZ2' ' A' ' 10' ' ' TRP . 5.7 m-85 -128.13 15.01 6.78 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.183 -0.462 . . . . 71.32 110.859 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 C-N-CA 120.697 -0.763 . . . . 74.04 112.511 -179.994 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 75.6 m . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.88 0.371 . . . . 71.32 110.868 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 2.1 ttt180 -55.5 -25.61 38.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.121 -0.49 . . . . 75.12 110.865 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 14.7 t -66.5 -12.66 15.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.183 -0.462 . . . . 71.25 111.135 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.82 -23.39 2.73 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 61.14 111.156 179.822 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -48.58 -25.8 1.9 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.16 -0.473 . . . . 75.21 110.889 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.63 -46.82 24.08 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.739 -0.743 . . . . 62.01 112.484 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' TRP . . . . . 0.449 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.0 p90 -126.39 -125.34 0.24 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.813 0.339 . . . . 74.0 110.906 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.4 ' H ' ' HB2' ' A' ' 10' ' ' TRP . . . -129.33 -122.37 2.44 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.718 -0.753 . . . . 63.33 112.491 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 3.6 ptp85 -125.18 -32.49 2.97 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.84 0.352 . . . . 74.43 110.848 -179.869 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.11 -26.15 2.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 71.23 110.902 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.18 134.44 46.0 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.566 0.698 . . . . 73.1 110.909 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' PRO . . . . . 0.448 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.5 Cg_endo -69.75 -34.49 14.51 Favored 'Trans proline' 0 C--O 1.232 0.214 0 C-N-CA 122.718 2.279 . . . . 74.41 112.338 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.448 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.6 -55.66 0.54 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.223 -0.444 . . . . 74.4 110.916 179.989 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' PHE . . . . . 0.449 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 6.0 m-85 -128.59 15.63 6.5 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.208 -0.451 . . . . 74.24 110.836 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.283 0 C-N-CA 120.729 -0.748 . . . . 73.03 112.48 -179.969 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 3.0 pttt . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.811 0.339 . . . . 75.05 110.887 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 79.7 m-20 -109.68 108.72 19.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.217 -0.447 . . . . 73.01 110.907 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 3.4 mtmt -82.23 -44.6 16.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.193 -0.458 . . . . 74.35 110.943 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 56.2 m -121.91 -23.35 5.47 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.185 -0.461 . . . . 71.41 110.866 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -55.17 -26.54 39.5 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.132 -0.486 . . . . 73.41 110.917 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 15.2 t -65.87 -12.61 14.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.183 -0.462 . . . . 71.34 111.153 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.65 -23.52 2.68 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.103 -0.499 . . . . 72.2 111.138 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 2.3 mtm-85 -48.6 -25.77 1.9 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.219 -0.446 . . . . 75.33 110.892 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.57 -46.46 23.64 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.711 -0.757 . . . . 52.41 112.474 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' TRP . . . . . 0.456 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.1 p90 -126.52 -125.34 0.24 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.837 0.351 . . . . 71.13 110.883 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.18 -122.22 2.43 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.715 -0.755 . . . . 75.15 112.512 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.7 ptp85 -125.45 -32.68 2.89 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.89 0.376 . . . . 75.22 110.892 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.57 -25.78 3.02 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.152 -0.476 . . . . 72.41 110.883 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -82.94 133.87 47.7 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.638 0.733 . . . . 73.43 110.856 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.448 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.4 Cg_endo -69.77 -33.78 15.86 Favored 'Trans proline' 0 C--O 1.232 0.19 0 C-N-CA 122.648 2.232 . . . . 74.42 112.311 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.448 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.66 -55.18 0.55 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.239 -0.437 . . . . 71.05 110.92 179.994 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.456 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 5.8 m-85 -128.21 15.08 6.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.154 -0.476 . . . . 73.02 110.89 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 C-N-CA 120.775 -0.726 . . . . 64.02 112.482 -179.942 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 1.3 ptmt . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.744 0.307 . . . . 75.34 110.964 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 13.1 m-20 -66.67 108.44 2.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.273 -0.422 . . . . 71.4 110.874 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 9.2 mmpt? -84.74 -44.8 13.02 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.157 -0.474 . . . . 74.21 110.863 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 39.1 m -121.13 -25.75 5.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 73.44 110.829 -179.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -54.08 -26.92 29.56 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.167 -0.469 . . . . 73.53 110.843 -179.949 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.0 t -62.07 -16.68 16.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.189 -0.46 . . . . 72.55 111.134 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.33 -23.76 2.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.177 -0.465 . . . . 70.3 111.069 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.07 -24.99 1.81 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 74.4 110.898 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.82 -46.11 31.58 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.703 -0.76 . . . . 72.4 112.512 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' TRP . . . . . 0.422 ' HZ2' ' CD1' ' A' ' 17' ' ' PHE . 2.9 p90 -126.26 -125.45 0.24 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.829 0.347 . . . . 74.32 110.926 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.74 -122.05 2.4 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.778 -0.725 . . . . 62.23 112.511 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -124.99 -32.39 3.03 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.909 0.385 . . . . 74.41 110.88 -179.818 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.24 -26.15 2.78 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 72.34 110.876 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.29 134.63 45.36 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.628 0.728 . . . . 74.32 110.889 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.45 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.7 Cg_endo -69.75 -34.94 13.61 Favored 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.675 2.25 . . . . 74.42 112.357 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.45 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.17 -55.75 0.5 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.194 -0.457 . . . . 75.21 110.917 -179.986 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.422 ' CD1' ' HZ2' ' A' ' 10' ' ' TRP . 6.7 m-85 -129.19 16.08 6.15 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 75.34 110.893 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 C-N-CA 120.77 -0.729 . . . . 52.01 112.518 -179.995 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.23 0.069 0 CA-C-O 120.811 0.339 . . . . 75.34 110.879 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 37.7 m-20 -107.61 108.51 19.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.214 -0.448 . . . . 74.44 110.877 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -84.58 -44.76 13.23 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.201 -0.454 . . . . 74.41 110.882 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 58.3 m -121.2 -25.64 5.23 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.266 -0.424 . . . . 72.41 110.879 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -54.17 -26.77 29.74 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.142 -0.481 . . . . 74.32 110.907 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.9 t -62.22 -16.62 16.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.211 -0.45 . . . . 75.22 111.165 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.23 -23.74 2.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.14 -0.482 . . . . 75.33 111.124 179.849 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.1 -24.96 1.83 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.174 -0.466 . . . . 74.12 110.872 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.88 -46.16 31.95 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.753 -0.737 . . . . 54.25 112.484 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' TRP . . . . . 0.42 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.0 p90 -126.26 -125.48 0.24 Allowed 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.79 0.329 . . . . 75.13 110.917 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.75 -122.03 2.4 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.727 -0.749 . . . . 74.14 112.466 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.1 ptp180 -125.03 -32.47 3.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.858 0.361 . . . . 75.24 110.882 -179.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.13 -26.2 2.63 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.161 -0.472 . . . . 74.1 110.939 179.946 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.16 134.66 45.65 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.629 0.728 . . . . 74.04 110.891 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.447 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.9 Cg_endo -69.75 -34.84 13.8 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.68 2.253 . . . . 73.44 112.374 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.447 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.27 -55.77 0.51 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.183 -0.462 . . . . 72.21 110.941 179.961 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.42 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 6.6 m-85 -129.14 16.13 6.18 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.224 -0.444 . . . . 74.21 110.894 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.343 0 C-N-CA 120.753 -0.737 . . . . 74.42 112.472 -179.943 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.23 0.043 0 CA-C-O 120.821 0.343 . . . . 73.15 110.874 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 78.2 m-20 -112.93 108.27 17.15 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.217 -0.447 . . . . 75.11 110.896 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 20.4 mmtt -84.64 -44.81 13.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.185 -0.461 . . . . 74.34 110.916 179.875 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 39.9 m -121.14 -25.63 5.26 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.232 -0.44 . . . . 40.1 110.879 -179.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 4.3 ttt180 -54.1 -26.84 29.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.131 -0.486 . . . . 73.22 110.872 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.0 t -62.27 -16.56 16.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.236 -0.438 . . . . 62.42 111.093 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.32 -23.75 2.52 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.22 -0.445 . . . . 44.41 111.089 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -49.15 -24.94 1.89 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.231 -0.441 . . . . 75.31 110.853 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.83 -46.2 31.63 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.743 -0.742 . . . . 73.33 112.46 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' TRP . . . . . 0.424 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 2.9 p90 -126.27 -125.45 0.24 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.831 0.348 . . . . 72.23 110.886 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.76 -122.04 2.4 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.719 -0.753 . . . . 71.24 112.468 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.3 ptp180 -125.04 -32.35 3.02 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.895 0.379 . . . . 73.23 110.854 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.25 -26.19 2.81 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.207 -0.451 . . . . 65.14 110.865 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.26 134.69 45.35 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.62 0.724 . . . . 71.14 110.922 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.452 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.7 Cg_endo -69.84 -34.79 13.63 Favored 'Trans proline' 0 C--O 1.232 0.219 0 C-N-CA 122.692 2.261 . . . . 54.32 112.315 -179.886 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.452 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.26 -55.76 0.51 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.239 -0.437 . . . . 75.34 110.929 179.948 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.424 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 6.6 m-85 -129.18 16.1 6.16 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.199 -0.455 . . . . 72.34 110.912 179.946 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.352 0 C-N-CA 120.737 -0.744 . . . . 73.03 112.5 -179.968 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.23 0.07 0 CA-C-O 120.74 0.305 . . . . 73.13 110.907 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 92.5 m-20 -63.55 108.39 1.36 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.2 -0.455 . . . . 74.15 110.853 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.9 mtmt -84.71 -44.73 13.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.18 -0.464 . . . . 74.45 110.897 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 42.2 m -121.26 -25.5 5.24 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.201 -0.454 . . . . 64.24 110.827 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -54.3 -26.69 30.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.168 -0.469 . . . . 74.11 110.866 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.8 t -62.38 -16.48 16.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.204 -0.453 . . . . 75.33 111.148 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.36 -23.77 2.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.162 -0.472 . . . . 74.32 111.099 179.852 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.17 -24.83 1.87 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.234 -0.439 . . . . 74.44 110.89 -179.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.86 -46.22 31.83 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.747 -0.74 . . . . 61.31 112.491 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' TRP . . . . . 0.422 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 2.9 p90 -126.25 -125.42 0.24 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.756 0.312 . . . . 75.44 110.971 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.407 ' H ' ' HB2' ' A' ' 10' ' ' TRP . . . -129.74 -122.02 2.39 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.709 -0.757 . . . . 65.23 112.479 179.945 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.0 -32.36 3.03 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.908 0.385 . . . . 74.25 110.906 -179.866 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.19 -26.26 2.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.17 -0.468 . . . . 71.32 110.871 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.19 134.61 45.67 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.588 0.709 . . . . 73.51 110.863 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.452 ' O ' ' C ' ' A' ' 16' ' ' LEU . 54.2 Cg_endo -69.73 -34.83 13.87 Favored 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.697 2.264 . . . . 72.45 112.386 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.452 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.24 -55.75 0.51 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.217 -0.447 . . . . 73.02 110.911 179.959 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.422 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 6.6 m-85 -129.2 16.11 6.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.195 -0.457 . . . . 72.14 110.902 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.36 0 C-N-CA 120.728 -0.749 . . . . 73.43 112.479 -179.957 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.23 0.072 0 CA-C-O 120.814 0.34 . . . . 65.03 110.917 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 72.6 m-80 -81.53 108.35 15.04 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.23 -0.441 . . . . 73.54 110.913 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 9.2 mmtt -84.65 -44.75 13.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.188 -0.46 . . . . 75.31 110.917 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 38.3 m -121.17 -25.73 5.23 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 74.2 110.887 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -54.01 -27.25 30.6 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.119 -0.491 . . . . 74.43 110.847 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.0 t -61.65 -17.02 16.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 75.23 111.127 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.17 -23.81 2.42 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.171 -0.468 . . . . 71.2 111.047 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.9 ptt85 -49.13 -24.94 1.86 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.264 -0.425 . . . . 73.35 110.877 -179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.81 -46.16 31.53 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.756 -0.735 . . . . 73.21 112.454 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' TRP . . . . . 0.42 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.0 p90 -126.29 -125.43 0.24 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.797 0.332 . . . . 72.21 110.911 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.77 -122.07 2.4 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.763 -0.732 . . . . 74.01 112.475 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.01 -32.23 3.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.866 0.365 . . . . 74.5 110.865 -179.854 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.29 -26.21 2.89 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.157 -0.474 . . . . 73.44 110.888 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.31 134.63 45.32 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.639 0.733 . . . . 64.32 110.86 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.429 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.9 Cg_endo -69.7 -34.89 13.88 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.684 2.256 . . . . 75.01 112.361 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.429 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.19 -55.78 0.5 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.206 -0.452 . . . . 74.03 110.909 179.979 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.42 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 6.7 m-85 -129.24 16.1 6.12 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.168 -0.469 . . . . 72.25 110.852 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.334 0 C-N-CA 120.779 -0.724 . . . . 61.31 112.488 -179.963 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 22.6 mttt . . . . . 0 N--CA 1.458 -0.057 0 CA-C-O 120.809 0.338 . . . . 72.41 110.907 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 29.1 m120 -81.25 108.39 14.84 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.241 -0.436 . . . . 62.1 110.904 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 3.0 mmpt? -84.65 -44.78 13.13 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.161 -0.472 . . . . 75.41 110.866 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 40.5 m -121.23 -25.65 5.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.213 -0.449 . . . . 65.43 110.859 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -54.01 -27.3 31.04 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.114 -0.494 . . . . 71.3 110.835 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.2 t -61.8 -16.81 16.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.462 . . . . 72.25 111.102 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.23 -23.72 2.41 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.188 -0.46 . . . . 75.31 111.094 179.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.15 -24.96 1.89 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.198 -0.455 . . . . 63.43 110.877 -179.91 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.69 -46.24 30.76 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.748 -0.739 . . . . 72.23 112.507 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' TRP . . . . . 0.423 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 2.9 p90 -126.28 -125.46 0.24 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.764 0.316 . . . . 73.23 110.925 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.74 -122.07 2.4 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.737 -0.744 . . . . 64.14 112.493 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -124.96 -32.36 3.04 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.926 0.393 . . . . 74.44 110.909 -179.822 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -49.22 -26.21 2.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 75.34 110.909 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.31 134.66 45.26 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.656 0.741 . . . . 51.11 110.88 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.451 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.7 Cg_endo -69.77 -34.76 13.9 Favored 'Trans proline' 0 C--N 1.342 0.215 0 C-N-CA 122.67 2.247 . . . . 75.25 112.347 -179.935 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.451 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.33 -55.7 0.52 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.234 -0.439 . . . . 73.45 110.915 179.984 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.423 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 6.6 m-85 -129.23 16.12 6.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.188 -0.46 . . . . 72.33 110.908 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.268 0 C-N-CA 120.761 -0.733 . . . . 64.2 112.481 -179.938 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.458 -0.069 0 CA-C-O 120.767 0.318 . . . . 73.34 110.876 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 93.7 m-20 -91.0 108.45 19.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 72.52 110.91 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 12.3 mmtt -85.12 -44.71 12.74 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.21 -0.45 . . . . 75.42 110.888 179.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 50.2 m -120.84 -26.02 5.31 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.239 -0.437 . . . . 64.33 110.841 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 1.6 ttp180 -54.19 -26.79 30.03 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.155 -0.475 . . . . 74.15 110.878 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.2 t -62.29 -16.37 16.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.213 -0.449 . . . . 64.32 111.111 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.28 -23.88 2.57 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.174 -0.466 . . . . 75.35 111.073 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -49.11 -24.93 1.83 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.251 -0.432 . . . . 75.53 110.857 -179.884 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.94 -45.94 32.33 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.706 -0.759 . . . . 75.02 112.516 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' TRP . . . . . 0.434 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.1 p90 -126.32 -125.37 0.24 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.832 0.348 . . . . 75.14 110.893 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.23 -122.1 2.42 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.778 -0.725 . . . . 72.43 112.51 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.55 -32.7 2.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.832 0.348 . . . . 70.5 110.843 -179.882 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.64 -25.79 3.14 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.192 -0.458 . . . . 74.2 110.854 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -82.24 134.48 48.81 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.599 0.714 . . . . 72.43 110.873 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.447 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.5 Cg_endo -69.76 -34.37 14.71 Favored 'Trans proline' 0 C--O 1.232 0.177 0 C-N-CA 122.698 2.265 . . . . 74.12 112.353 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.447 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.4 OUTLIER -34.4 -55.13 0.53 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.204 -0.453 . . . . 72.04 110.927 179.948 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.434 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 6.2 m-85 -128.55 15.12 6.55 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.169 -0.468 . . . . 74.34 110.887 179.921 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.319 0 C-N-CA 120.779 -0.724 . . . . 74.31 112.468 -179.979 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 8.9 mttt . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.763 0.316 . . . . 74.55 110.869 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 31.0 m120 -105.02 108.0 19.28 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.263 -0.426 . . . . 74.31 110.878 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 25.9 mmmt -82.87 -45.47 14.19 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.145 -0.479 . . . . 74.04 110.876 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 58.8 m -121.44 -24.49 5.39 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.217 -0.447 . . . . 73.43 110.839 -179.883 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 1.3 ttt-85 -54.33 -26.74 31.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 75.3 110.872 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.8 t -63.19 -15.9 16.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.456 . . . . 72.32 111.098 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.51 -23.56 2.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.154 -0.475 . . . . 74.54 111.053 179.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.14 -24.92 1.86 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.247 -0.433 . . . . 75.53 110.857 -179.878 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.78 -46.25 31.31 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.703 -0.76 . . . . 73.05 112.538 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' TRP . . . . . 0.423 ' HZ2' ' CD1' ' A' ' 17' ' ' PHE . 2.9 p90 -126.29 -125.38 0.24 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.796 0.332 . . . . 74.21 110.882 -179.913 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.7 -122.1 2.4 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.748 -0.739 . . . . 62.01 112.475 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -125.02 -32.45 3.01 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.878 0.37 . . . . 74.14 110.836 -179.842 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.06 -26.23 2.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 73.14 110.946 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.31 134.62 45.33 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.611 0.719 . . . . 72.35 110.887 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.449 ' O ' ' C ' ' A' ' 16' ' ' LEU . 54.0 Cg_endo -69.81 -34.73 13.85 Favored 'Trans proline' 0 C--N 1.342 0.215 0 C-N-CA 122.678 2.252 . . . . 72.51 112.353 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.449 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.33 -55.66 0.52 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.203 -0.453 . . . . 73.43 110.936 179.989 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.423 ' CD1' ' HZ2' ' A' ' 10' ' ' TRP . 6.5 m-85 -129.21 16.05 6.14 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 64.21 110.854 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 C-N-CA 120.743 -0.742 . . . . 73.13 112.514 -179.957 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.231 0.092 0 CA-C-O 120.844 0.354 . . . . 73.13 110.874 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 31.1 m120 -103.7 107.84 18.88 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.226 -0.443 . . . . 74.41 110.931 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 13.3 mmmm -82.65 -45.48 14.47 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.17 -0.468 . . . . 71.11 110.937 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 56.9 m -121.48 -24.46 5.38 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.243 -0.435 . . . . 74.35 110.831 -179.884 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -54.32 -26.76 31.39 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.1 -0.5 . . . . 75.01 110.889 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 13.1 t -63.23 -15.85 16.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.17 -0.468 . . . . 75.12 111.13 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.5 -23.57 2.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.166 -0.47 . . . . 74.1 111.098 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.7 ptt85 -49.16 -24.88 1.87 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.224 -0.443 . . . . 74.43 110.86 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.83 -46.2 31.65 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.721 -0.752 . . . . 74.22 112.466 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' TRP . . . . . 0.425 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.0 p90 -126.27 -125.43 0.24 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.876 0.37 . . . . 75.33 110.906 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.64 -122.13 2.41 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.744 -0.741 . . . . 61.12 112.515 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -124.99 -32.4 3.03 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.909 0.385 . . . . 75.13 110.882 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.17 -26.2 2.69 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.201 -0.454 . . . . 74.14 110.904 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.34 134.59 45.3 Favored Pre-proline 0 C--N 1.328 -0.368 0 CA-C-O 121.595 0.712 . . . . 72.25 110.886 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.451 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.2 Cg_endo -69.8 -34.8 13.73 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.655 2.237 . . . . 74.45 112.316 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.451 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.24 -55.74 0.51 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.238 -0.437 . . . . 75.04 110.874 179.994 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.425 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 6.5 m-85 -129.18 16.07 6.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.178 -0.464 . . . . 75.14 110.856 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.346 0 C-N-CA 120.736 -0.745 . . . . 64.11 112.479 -179.951 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 6.5 tttt . . . . . 0 N--CA 1.458 -0.04 0 CA-C-O 120.802 0.334 . . . . 74.14 110.936 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 73.6 m-20 -101.47 109.27 21.06 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.236 -0.438 . . . . 74.34 110.864 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 18.9 mtmt -80.45 -44.71 18.8 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.195 -0.457 . . . . 74.22 110.841 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 35.3 m -122.08 -22.92 5.5 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.267 -0.424 . . . . 71.04 110.887 -179.866 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 2.6 ttt180 -55.67 -25.67 40.81 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.127 -0.488 . . . . 71.22 110.888 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 18.5 t -67.02 -12.27 14.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 73.01 111.078 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.81 -23.13 2.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.177 -0.465 . . . . 75.53 111.124 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.3 mtp180 -48.52 -25.77 1.85 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.236 -0.438 . . . . 75.03 110.897 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.48 -47.01 23.17 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.738 -0.744 . . . . 44.04 112.462 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' TRP . . . . . 0.451 ' HZ2' ' CD1' ' A' ' 17' ' ' PHE . 2.9 p90 -126.31 -125.3 0.24 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.852 0.358 . . . . 71.11 110.944 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.3 -122.42 2.45 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.715 -0.755 . . . . 43.43 112.495 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.2 ptp180 -125.11 -32.57 2.98 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.879 0.371 . . . . 74.52 110.884 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -48.99 -26.28 2.44 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.191 -0.459 . . . . 74.24 110.917 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.21 134.43 45.96 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.624 0.726 . . . . 73.11 110.891 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.443 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.4 Cg_endo -69.79 -34.33 14.68 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.693 2.262 . . . . 74.22 112.302 -179.904 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.443 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.65 -55.62 0.55 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.246 -0.434 . . . . 75.51 110.927 179.979 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.451 ' CD1' ' HZ2' ' A' ' 10' ' ' TRP . 6.0 m-85 -128.5 15.6 6.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.158 -0.474 . . . . 75.34 110.837 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.279 0 C-N-CA 120.727 -0.749 . . . . 74.53 112.483 -179.945 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 1.7 mptm? . . . . . 0 C--O 1.23 0.069 0 CA-C-O 120.814 0.34 . . . . 74.24 110.873 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 90.3 m-20 -89.22 109.32 20.21 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.2 -0.454 . . . . 73.12 110.875 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 36.7 mtmt -80.41 -44.72 18.87 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.149 -0.478 . . . . 73.1 110.911 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 35.2 m -122.1 -22.95 5.49 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.192 -0.458 . . . . 71.44 110.88 -179.909 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -55.64 -25.69 40.4 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.123 -0.49 . . . . 74.41 110.868 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 18.4 t -67.01 -12.24 14.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.166 -0.47 . . . . 74.2 111.14 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.72 -23.24 2.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.16 -0.473 . . . . 75.23 111.077 179.875 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.1 mtp85 -48.44 -25.86 1.85 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 73.05 110.891 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.5 -46.9 23.28 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.724 -0.75 . . . . 71.31 112.475 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' TRP . . . . . 0.452 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.0 p90 -126.44 -125.28 0.24 Allowed 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.805 0.336 . . . . 74.53 110.954 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.33 -122.45 2.45 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.736 -0.745 . . . . 62.14 112.503 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.3 ptp180 -125.08 -32.5 2.99 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.9 0.381 . . . . 71.34 110.867 -179.899 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.05 -26.24 2.51 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 74.13 110.895 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.27 134.45 45.74 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.6 0.714 . . . . 75.11 110.867 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.443 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.3 Cg_endo -69.79 -34.32 14.72 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.666 2.244 . . . . 74.41 112.338 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.443 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.68 -55.64 0.55 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.221 -0.445 . . . . 73.5 110.887 179.968 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.452 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 5.9 m-85 -128.44 15.56 6.58 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.188 -0.46 . . . . 74.54 110.919 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 C-N-CA 120.752 -0.737 . . . . 65.4 112.491 -179.938 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.23 0.044 0 CA-C-O 120.791 0.329 . . . . 74.44 110.886 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 -97.91 108.51 21.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.252 -0.431 . . . . 72.33 110.863 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 18.9 mtmt -84.68 -44.75 13.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.206 -0.452 . . . . 75.03 110.904 179.879 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 24.3 m -121.12 -25.48 5.3 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.22 -0.445 . . . . 63.45 110.85 -179.875 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 3.0 mtp180 -54.41 -26.65 31.79 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.125 -0.489 . . . . 74.1 110.863 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 13.1 t -62.57 -16.16 16.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.19 -0.459 . . . . 60.13 111.145 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.16 -23.6 2.27 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.164 -0.471 . . . . 61.41 111.148 179.86 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -49.03 -24.99 1.76 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 74.02 110.893 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.56 -46.47 29.95 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.78 -0.724 . . . . 71.04 112.476 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' TRP . . . . . 0.417 ' HZ2' ' CD1' ' A' ' 17' ' ' PHE . 2.9 p90 -126.23 -125.39 0.24 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.827 0.346 . . . . 75.31 110.88 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.76 -122.18 2.41 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.752 -0.737 . . . . 64.01 112.493 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.0 -31.86 3.08 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.866 0.365 . . . . 75.41 110.847 -179.878 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.71 -25.73 3.19 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.235 -0.439 . . . . 74.03 110.872 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.88 134.79 43.53 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.552 0.691 . . . . 64.34 110.942 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.454 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.6 Cg_endo -69.73 -35.1 13.35 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.694 2.262 . . . . 65.33 112.356 -179.909 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.454 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.07 -55.83 0.49 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.164 -0.471 . . . . 65.34 110.922 -179.99 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.417 ' CD1' ' HZ2' ' A' ' 10' ' ' TRP . 6.5 m-85 -129.05 16.04 6.23 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.174 -0.467 . . . . 73.13 110.872 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.247 0 C-N-CA 120.713 -0.756 . . . . 75.04 112.463 -179.952 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.23 0.053 0 CA-C-O 120.799 0.333 . . . . 72.12 110.914 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 76.7 m-20 -71.06 109.18 4.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.236 -0.438 . . . . 73.4 110.9 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 1.8 mmpt? -80.36 -44.69 19.02 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.216 -0.447 . . . . 75.2 110.916 179.93 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 35.4 m -122.1 -22.88 5.51 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.195 -0.457 . . . . 62.43 110.872 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 2.1 mtt180 -55.76 -25.47 40.94 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.11 -0.495 . . . . 71.11 110.873 -179.924 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 18.4 t -67.2 -12.21 14.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.216 -0.447 . . . . 74.11 111.116 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.83 -23.18 2.59 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 75.31 111.072 179.899 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -48.51 -25.75 1.84 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.234 -0.439 . . . . 75.32 110.884 -179.905 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.53 -46.93 23.48 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.728 -0.749 . . . . 74.21 112.474 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' TRP . . . . . 0.448 ' HZ2' ' CD1' ' A' ' 17' ' ' PHE . 2.9 p90 -126.44 -125.31 0.24 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.773 0.321 . . . . 73.51 110.922 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.24 -122.43 2.45 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.768 -0.73 . . . . 64.21 112.527 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.12 -32.47 2.99 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.865 0.364 . . . . 74.11 110.842 -179.865 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.08 -26.23 2.55 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.214 -0.448 . . . . 73.54 110.878 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.32 134.42 45.68 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.668 0.747 . . . . 73.11 110.87 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.44 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.8 Cg_endo -69.73 -34.38 14.8 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.7 2.267 . . . . 71.4 112.35 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.44 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.62 -55.64 0.55 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.21 -0.45 . . . . 71.42 110.898 179.943 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.448 ' CD1' ' HZ2' ' A' ' 10' ' ' TRP . 6.0 m-85 -128.49 15.53 6.56 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.196 -0.456 . . . . 74.33 110.884 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.287 0 C-N-CA 120.717 -0.754 . . . . 73.13 112.498 -179.983 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.746 0.308 . . . . 74.42 110.956 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 29.8 m120 -87.0 108.66 18.95 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.241 -0.436 . . . . 74.25 110.907 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 4.5 mtmm -83.02 -44.69 14.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.187 -0.461 . . . . 74.34 110.927 179.88 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 58.6 m -121.81 -23.37 5.51 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.238 -0.437 . . . . 61.22 110.845 -179.858 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 4.7 mtt180 -55.58 -25.69 39.57 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.117 -0.492 . . . . 73.32 110.855 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 13.1 t -66.12 -12.81 14.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.197 -0.456 . . . . 75.22 111.152 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.93 -23.45 2.88 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.166 -0.47 . . . . 61.43 111.115 179.856 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.1 mtm180 -48.56 -25.91 1.95 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.202 -0.453 . . . . 73.21 110.891 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.58 -46.78 23.75 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.759 -0.734 . . . . 71.34 112.506 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' TRP . . . . . 0.447 ' HZ2' ' CD1' ' A' ' 17' ' ' PHE . 3.0 p90 -126.44 -125.38 0.24 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.825 0.345 . . . . 75.13 110.909 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.412 ' H ' ' HB2' ' A' ' 10' ' ' TRP . . . -129.49 -122.38 2.44 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.705 -0.76 . . . . 73.1 112.448 -179.994 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.03 -32.37 3.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.826 0.346 . . . . 72.23 110.883 -179.881 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.17 -26.12 2.63 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.188 -0.46 . . . . 75.3 110.919 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.42 134.53 45.2 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.635 0.731 . . . . 73.34 110.871 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.451 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.7 Cg_endo -69.75 -34.44 14.61 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.699 2.266 . . . . 74.31 112.352 -179.923 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.451 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.63 -55.63 0.55 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.213 -0.449 . . . . 73.33 110.881 179.984 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.447 ' CD1' ' HZ2' ' A' ' 10' ' ' TRP . 6.1 m-85 -128.65 15.72 6.46 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.199 -0.455 . . . . 70.24 110.824 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 C-N-CA 120.721 -0.752 . . . . 64.34 112.46 179.977 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.457 -0.076 0 CA-C-O 120.797 0.332 . . . . 73.41 110.866 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 59.0 m-20 -117.69 109.26 16.42 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.204 -0.453 . . . . 54.53 110.915 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.36 -44.64 19.11 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.155 -0.475 . . . . 72.14 110.921 179.902 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 35.4 m -122.09 -22.84 5.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.217 -0.447 . . . . 75.03 110.858 -179.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 4.3 mtp180 -55.83 -25.44 41.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.105 -0.498 . . . . 71.34 110.812 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 18.4 t -67.32 -12.04 14.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.23 -0.441 . . . . 74.35 111.134 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.9 -23.1 2.58 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.182 -0.463 . . . . 74.24 111.093 179.864 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 2.9 mtp180 -48.47 -25.84 1.86 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.243 -0.435 . . . . 74.31 110.89 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.52 -46.92 23.4 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.731 -0.747 . . . . 54.15 112.527 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' TRP . . . . . 0.451 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.0 p90 -126.4 -125.34 0.24 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.833 0.349 . . . . 72.22 110.92 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.28 -122.42 2.45 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.722 -0.751 . . . . 63.31 112.505 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.1 -32.53 2.99 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.879 0.371 . . . . 73.44 110.883 -179.853 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -49.04 -26.28 2.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.158 -0.473 . . . . 74.23 110.86 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.2 134.36 46.1 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-O 121.602 0.715 . . . . 70.45 110.883 179.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.445 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.6 Cg_endo -69.76 -34.31 14.85 Favored 'Trans proline' 0 C--O 1.232 0.222 0 C-N-CA 122.653 2.236 . . . . 74.0 112.347 -179.933 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.445 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.67 -55.63 0.55 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.263 -0.426 . . . . 73.25 110.914 179.957 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.451 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 5.9 m-85 -128.51 15.65 6.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.18 -0.463 . . . . 71.54 110.919 179.888 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 C-N-CA 120.714 -0.755 . . . . 74.22 112.498 -179.989 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 1.5 ttmt . . . . . 0 C--O 1.23 0.05 0 CA-C-O 120.74 0.305 . . . . 74.53 110.948 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 96.4 m-20 -78.95 109.36 13.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.246 -0.434 . . . . 60.12 110.892 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 3.7 mtmt -80.6 -44.74 18.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.159 -0.473 . . . . 72.31 110.906 179.892 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 34.2 m -121.82 -23.05 5.58 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 70.43 110.914 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -55.74 -25.49 40.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.08 -0.509 . . . . 74.41 110.875 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 18.7 t -67.27 -11.95 14.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.179 -0.464 . . . . 71.55 111.142 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.73 -23.28 2.57 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.129 -0.487 . . . . 75.44 111.095 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 3.3 mtp180 -48.69 -25.66 1.9 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.212 -0.449 . . . . 74.13 110.823 -179.85 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.55 -46.63 23.55 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.736 -0.745 . . . . 65.02 112.464 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' TRP . . . . . 0.461 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.1 p90 -126.43 -125.31 0.24 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.832 0.349 . . . . 74.41 110.941 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.06 -122.33 2.45 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.701 -0.762 . . . . 75.24 112.482 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -125.49 -32.65 2.88 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.848 0.356 . . . . 75.4 110.878 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -49.46 -25.92 2.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.194 -0.457 . . . . 70.23 110.91 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -82.89 133.87 47.89 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.591 0.71 . . . . 63.2 110.891 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.441 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.3 Cg_endo -69.74 -33.8 15.95 Favored 'Trans proline' 0 C--O 1.233 0.233 0 C-N-CA 122.738 2.292 . . . . 71.15 112.291 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.441 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.74 -55.13 0.56 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.245 -0.434 . . . . 64.24 110.96 179.968 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.461 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 5.7 m-85 -128.14 15.04 6.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.229 -0.441 . . . . 73.23 110.845 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.334 0 C-N-CA 120.769 -0.729 . . . . 64.4 112.49 -179.974 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.23 0.073 0 CA-C-O 120.791 0.329 . . . . 75.1 110.886 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 33.8 m-20 -102.78 108.95 20.37 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.221 -0.445 . . . . 64.51 110.892 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 21.1 mtmt -81.89 -44.64 16.57 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.143 -0.48 . . . . 75.52 110.891 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 30.3 m -122.01 -23.26 5.45 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.224 -0.444 . . . . 70.24 110.887 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -55.25 -26.43 39.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.094 -0.503 . . . . 73.1 110.896 -179.914 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 15.3 t -65.9 -12.83 14.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.164 -0.471 . . . . 75.01 111.133 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.66 -23.45 2.63 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 52.23 111.066 179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 2.2 mtt180 -48.46 -25.94 1.89 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.213 -0.449 . . . . 73.33 110.905 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.48 -46.86 23.14 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.747 -0.74 . . . . 72.01 112.492 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' TRP . . . . . 0.45 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 2.9 p90 -126.45 -125.33 0.24 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.769 0.319 . . . . 73.54 110.96 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.33 -122.37 2.44 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.78 -0.724 . . . . 64.22 112.469 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.6 ptp180 -125.14 -32.6 2.97 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.909 0.385 . . . . 74.34 110.854 -179.806 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.03 -26.27 2.49 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.19 -0.459 . . . . 74.42 110.889 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.07 134.46 46.27 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.573 0.701 . . . . 74.1 110.91 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.445 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.2 Cg_endo -69.77 -34.42 14.59 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.665 2.243 . . . . 75.44 112.341 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.445 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.65 -55.6 0.55 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.178 -0.465 . . . . 74.04 110.92 179.996 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.45 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 6.0 m-85 -128.57 15.61 6.51 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.216 -0.447 . . . . 75.34 110.9 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.29 0 C-N-CA 120.732 -0.747 . . . . 71.43 112.506 -179.951 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.23 0.049 0 CA-C-O 120.833 0.349 . . . . 75.44 110.881 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -86.15 109.38 18.84 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.207 -0.451 . . . . 63.23 110.897 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 34.1 mtmt -80.69 -44.62 18.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.171 -0.468 . . . . 73.14 110.899 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 31.0 m -121.95 -23.18 5.5 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.229 -0.442 . . . . 72.35 110.857 -179.886 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -55.42 -26.29 41.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.165 -0.47 . . . . 73.3 110.855 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 18.8 t -66.52 -12.25 14.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.203 -0.453 . . . . 70.13 111.118 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.58 -23.31 2.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.19 -0.459 . . . . 71.31 111.136 179.886 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.8 mtp180 -48.57 -25.78 1.89 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.219 -0.446 . . . . 74.4 110.828 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.48 -46.58 23.1 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.669 -0.777 . . . . 65.14 112.524 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' TRP . . . . . 0.458 ' HZ2' ' CD1' ' A' ' 17' ' ' PHE . 3.0 p90 -126.49 -125.27 0.24 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.831 0.348 . . . . 74.51 110.922 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.09 -122.33 2.45 Favored Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.715 -0.755 . . . . 71.24 112.443 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.51 -32.51 2.89 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.855 0.359 . . . . 75.13 110.856 -179.842 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.56 -25.87 3.08 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.197 -0.456 . . . . 74.51 110.883 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -82.93 133.87 47.73 Favored Pre-proline 0 C--N 1.328 -0.365 0 CA-C-O 121.606 0.717 . . . . 70.32 110.91 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.446 ' O ' ' C ' ' A' ' 16' ' ' LEU . 54.0 Cg_endo -69.82 -33.57 16.1 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.688 2.259 . . . . 73.33 112.357 -179.918 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.446 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.86 -55.14 0.58 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 74.5 110.917 179.957 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.458 ' CD1' ' HZ2' ' A' ' 10' ' ' TRP . 5.7 m-85 -128.13 15.01 6.78 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.183 -0.462 . . . . 71.32 110.859 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 C-N-CA 120.697 -0.763 . . . . 74.04 112.511 -179.994 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 6.0 mttp . . . . . 0 N--CA 1.458 -0.039 0 CA-C-O 120.799 0.333 . . . . 74.44 110.87 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -116.41 106.51 13.7 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.213 -0.449 . . . . 73.1 110.872 179.953 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.9 mtmm -82.3 -44.26 16.46 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.456 . . . . 75.45 110.867 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 75.6 m -120.97 -22.33 6.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.212 -0.449 . . . . 71.32 110.868 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 2.1 ttt180 -55.5 -25.61 38.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.121 -0.49 . . . . 75.12 110.865 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 14.7 t -66.5 -12.66 15.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.183 -0.462 . . . . 71.25 111.135 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.82 -23.39 2.73 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 61.14 111.156 179.822 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -48.58 -25.8 1.9 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.16 -0.473 . . . . 75.21 110.889 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.63 -46.82 24.08 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.739 -0.743 . . . . 62.01 112.484 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' TRP . . . . . 0.449 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.0 p90 -126.39 -125.34 0.24 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.813 0.339 . . . . 74.0 110.906 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.4 ' H ' ' HB2' ' A' ' 10' ' ' TRP . . . -129.33 -122.37 2.44 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.718 -0.753 . . . . 63.33 112.491 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 3.6 ptp85 -125.18 -32.49 2.97 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.84 0.352 . . . . 74.43 110.848 -179.869 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.11 -26.15 2.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 71.23 110.902 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.18 134.44 46.0 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.566 0.698 . . . . 73.1 110.909 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' PRO . . . . . 0.448 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.5 Cg_endo -69.75 -34.49 14.51 Favored 'Trans proline' 0 C--O 1.232 0.214 0 C-N-CA 122.718 2.279 . . . . 74.41 112.338 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.448 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.6 -55.66 0.54 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.223 -0.444 . . . . 74.4 110.916 179.989 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.449 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 6.0 m-85 -128.59 15.63 6.5 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.208 -0.451 . . . . 74.24 110.836 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.283 0 C-N-CA 120.729 -0.748 . . . . 73.03 112.48 -179.969 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 56.2 m . . . . . 0 C--O 1.232 0.151 0 CA-C-O 120.864 0.364 . . . . 71.41 110.866 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -55.17 -26.54 39.5 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.132 -0.486 . . . . 73.41 110.917 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 15.2 t -65.87 -12.61 14.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.183 -0.462 . . . . 61.51 111.153 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.65 -23.52 2.68 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.103 -0.499 . . . . 72.2 111.138 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 2.3 mtm-85 -48.6 -25.77 1.9 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.219 -0.446 . . . . 74.34 110.892 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.57 -46.46 23.64 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.711 -0.757 . . . . 43.42 112.474 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' TRP . . . . . 0.448 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.1 p90 -126.52 -125.34 0.24 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.837 0.351 . . . . 71.13 110.883 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.18 -122.22 2.43 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.715 -0.755 . . . . 75.15 112.512 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.7 ptp85 -125.45 -32.68 2.89 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.89 0.376 . . . . 70.44 110.892 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.57 -25.78 3.02 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.152 -0.476 . . . . 72.41 110.883 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -82.94 133.87 47.7 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.638 0.733 . . . . 73.43 110.856 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' PRO . . . . . 0.448 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.4 Cg_endo -69.77 -33.78 15.86 Favored 'Trans proline' 0 C--O 1.232 0.19 0 C-N-CA 122.648 2.232 . . . . 74.42 112.311 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.448 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.66 -55.18 0.55 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.239 -0.437 . . . . 71.05 110.92 179.994 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.448 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 5.8 m-85 -128.21 15.08 6.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.154 -0.476 . . . . 73.02 110.89 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 C-N-CA 120.775 -0.726 . . . . 61.24 112.482 -179.942 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 39.1 m . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.864 0.364 . . . . 73.44 110.829 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -54.08 -26.92 29.56 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.167 -0.469 . . . . 71.11 110.843 -179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.0 t -62.07 -16.68 16.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.189 -0.46 . . . . 54.24 111.134 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.465 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.33 -23.76 2.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.177 -0.465 . . . . 53.24 111.069 179.922 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.07 -24.99 1.81 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 74.4 110.898 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.82 -46.11 31.58 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.703 -0.76 . . . . 70.52 112.512 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' TRP . . . . . 0.415 ' HZ2' ' CD1' ' A' ' 17' ' ' PHE . 2.9 p90 -126.26 -125.45 0.24 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.829 0.347 . . . . 74.32 110.926 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.74 -122.05 2.4 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.778 -0.725 . . . . 62.23 112.511 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -124.99 -32.39 3.03 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.909 0.385 . . . . 74.41 110.88 -179.818 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.24 -26.15 2.78 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 64.15 110.876 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.29 134.63 45.36 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.628 0.728 . . . . 71.12 110.889 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' PRO . . . . . 0.45 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.7 Cg_endo -69.75 -34.94 13.61 Favored 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.675 2.25 . . . . 74.33 112.357 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.45 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.17 -55.75 0.5 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.194 -0.457 . . . . 73.35 110.917 -179.986 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.465 ' HB3' ' HB2' ' A' ' 7' ' ' ALA . 6.7 m-85 -129.19 16.08 6.15 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 74.04 110.893 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 C-N-CA 120.77 -0.729 . . . . 43.02 112.518 -179.995 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 58.3 m . . . . . 0 C--O 1.232 0.134 0 CA-C-O 120.895 0.378 . . . . 72.41 110.879 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -54.17 -26.77 29.74 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.142 -0.481 . . . . 74.32 110.907 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.9 t -62.22 -16.62 16.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.211 -0.45 . . . . 74.22 111.165 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.472 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.23 -23.74 2.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.14 -0.482 . . . . 64.22 111.124 179.849 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.1 -24.96 1.83 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.174 -0.466 . . . . 72.23 110.872 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.88 -46.16 31.95 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.753 -0.737 . . . . 54.25 112.484 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' TRP . . . . . 0.413 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.0 p90 -126.26 -125.48 0.24 Allowed 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.79 0.329 . . . . 72.02 110.917 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.75 -122.03 2.4 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.727 -0.749 . . . . 74.14 112.466 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.1 ptp180 -125.03 -32.47 3.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.858 0.361 . . . . 71.43 110.882 -179.842 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.13 -26.2 2.63 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.161 -0.472 . . . . 71.24 110.939 179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.16 134.66 45.65 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.629 0.728 . . . . 74.04 110.891 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' PRO . . . . . 0.447 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.9 Cg_endo -69.75 -34.84 13.8 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.68 2.253 . . . . 73.44 112.374 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.447 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.27 -55.77 0.51 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.183 -0.462 . . . . 71.23 110.941 179.961 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.472 ' HB3' ' HB2' ' A' ' 7' ' ' ALA . 6.6 m-85 -129.14 16.13 6.18 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.224 -0.444 . . . . 74.21 110.894 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.343 0 C-N-CA 120.753 -0.737 . . . . 62.41 112.472 -179.943 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 39.9 m . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.872 0.368 . . . . 14.33 110.879 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 4.3 ttt180 -54.1 -26.84 29.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.131 -0.486 . . . . 72.4 110.872 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.0 t -62.27 -16.56 16.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.236 -0.438 . . . . 50.13 111.093 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.467 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.32 -23.75 2.52 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.22 -0.445 . . . . 44.41 111.089 179.857 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -49.15 -24.94 1.89 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.231 -0.441 . . . . 60.1 110.853 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.83 -46.2 31.63 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.743 -0.742 . . . . 73.33 112.46 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' TRP . . . . . 0.416 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 2.9 p90 -126.27 -125.45 0.24 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.831 0.348 . . . . 63.33 110.886 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.76 -122.04 2.4 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.719 -0.753 . . . . 42.02 112.468 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.3 ptp180 -125.04 -32.35 3.02 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.895 0.379 . . . . 73.23 110.854 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.25 -26.19 2.81 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.207 -0.451 . . . . 52.21 110.865 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.26 134.69 45.35 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.62 0.724 . . . . 64.11 110.922 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' PRO . . . . . 0.452 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.7 Cg_endo -69.84 -34.79 13.63 Favored 'Trans proline' 0 C--O 1.232 0.219 0 C-N-CA 122.692 2.261 . . . . 54.32 112.315 -179.886 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.452 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.26 -55.76 0.51 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.239 -0.437 . . . . 63.14 110.929 179.948 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.467 ' HB3' ' HB2' ' A' ' 7' ' ' ALA . 6.6 m-85 -129.18 16.1 6.16 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.199 -0.455 . . . . 72.34 110.912 179.946 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.352 0 C-N-CA 120.737 -0.744 . . . . 44.33 112.5 -179.968 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 42.2 m . . . . . 0 C--O 1.231 0.122 0 CA-C-O 120.856 0.36 . . . . 64.24 110.827 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -54.3 -26.69 30.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.168 -0.469 . . . . 74.11 110.866 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.8 t -62.38 -16.48 16.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.204 -0.453 . . . . 75.33 111.148 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.462 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.36 -23.77 2.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.162 -0.472 . . . . 72.13 111.099 179.852 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.17 -24.83 1.87 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.234 -0.439 . . . . 74.44 110.89 -179.882 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.86 -46.22 31.83 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.747 -0.74 . . . . 55.22 112.491 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' TRP . . . . . 0.413 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 2.9 p90 -126.25 -125.42 0.24 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.756 0.312 . . . . 73.15 110.971 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.74 -122.02 2.39 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.709 -0.757 . . . . 65.23 112.479 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.0 -32.36 3.03 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.908 0.385 . . . . 72.53 110.906 -179.866 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.19 -26.26 2.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.17 -0.468 . . . . 71.32 110.871 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.19 134.61 45.67 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.588 0.709 . . . . 73.51 110.863 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' PRO . . . . . 0.452 ' O ' ' C ' ' A' ' 16' ' ' LEU . 54.2 Cg_endo -69.73 -34.83 13.87 Favored 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.697 2.264 . . . . 64.04 112.386 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.452 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.24 -55.75 0.51 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.217 -0.447 . . . . 70.12 110.911 179.959 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.462 ' HB3' ' HB2' ' A' ' 7' ' ' ALA . 6.6 m-85 -129.2 16.11 6.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.195 -0.457 . . . . 72.14 110.902 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.36 0 C-N-CA 120.728 -0.749 . . . . 33.44 112.479 -179.957 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 38.3 m . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.889 0.376 . . . . 42.12 110.887 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -54.01 -27.25 30.6 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.119 -0.491 . . . . 61.01 110.847 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.0 t -61.65 -17.02 16.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 72.44 111.127 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.465 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.17 -23.81 2.42 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.171 -0.468 . . . . 62.14 111.047 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.9 ptt85 -49.13 -24.94 1.86 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.264 -0.425 . . . . 73.35 110.877 -179.906 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.81 -46.16 31.53 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.756 -0.735 . . . . 73.21 112.454 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' TRP . . . . . 0.412 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.0 p90 -126.29 -125.43 0.24 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.797 0.332 . . . . 72.21 110.911 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.77 -122.07 2.4 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.763 -0.732 . . . . 60.14 112.475 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.01 -32.23 3.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.866 0.365 . . . . 71.32 110.865 -179.854 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.29 -26.21 2.89 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.157 -0.474 . . . . 64.04 110.888 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.31 134.63 45.32 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.639 0.733 . . . . 64.32 110.86 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' PRO . . . . . 0.429 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.9 Cg_endo -69.7 -34.89 13.88 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.684 2.256 . . . . 75.01 112.361 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.429 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.19 -55.78 0.5 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.206 -0.452 . . . . 63.42 110.909 179.979 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.465 ' HB3' ' HB2' ' A' ' 7' ' ' ALA . 6.7 m-85 -129.24 16.1 6.12 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.168 -0.469 . . . . 63.12 110.852 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.334 0 C-N-CA 120.779 -0.724 . . . . 61.31 112.488 -179.963 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 40.5 m . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.826 0.346 . . . . 61.31 110.859 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -54.01 -27.3 31.04 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.114 -0.494 . . . . 65.23 110.835 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.2 t -61.8 -16.81 16.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.462 . . . . 53.13 111.102 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.465 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.23 -23.72 2.41 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.188 -0.46 . . . . 75.31 111.094 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.15 -24.96 1.89 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.198 -0.455 . . . . 43.23 110.877 -179.91 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.69 -46.24 30.76 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.748 -0.739 . . . . 72.23 112.507 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' TRP . . . . . 0.416 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 2.9 p90 -126.28 -125.46 0.24 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.764 0.316 . . . . 71.11 110.925 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.74 -122.07 2.4 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.737 -0.744 . . . . 64.14 112.493 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -124.96 -32.36 3.04 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.926 0.393 . . . . 72.25 110.909 -179.822 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -49.22 -26.21 2.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 62.2 110.909 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.31 134.66 45.26 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.656 0.741 . . . . 31.54 110.88 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' PRO . . . . . 0.451 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.7 Cg_endo -69.77 -34.76 13.9 Favored 'Trans proline' 0 C--N 1.342 0.215 0 C-N-CA 122.67 2.247 . . . . 74.03 112.347 -179.935 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.451 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.33 -55.7 0.52 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.234 -0.439 . . . . 64.4 110.915 179.984 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.465 ' HB3' ' HB2' ' A' ' 7' ' ' ALA . 6.6 m-85 -129.23 16.12 6.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.188 -0.46 . . . . 72.33 110.908 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.268 0 C-N-CA 120.761 -0.733 . . . . 64.2 112.481 -179.938 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 50.2 m . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.846 0.355 . . . . 64.33 110.841 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 1.6 ttp180 -54.19 -26.79 30.03 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.155 -0.475 . . . . 73.33 110.878 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.2 t -62.29 -16.37 16.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.213 -0.449 . . . . 54.52 111.111 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.28 -23.88 2.57 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.174 -0.466 . . . . 75.35 111.073 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -49.11 -24.93 1.83 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.251 -0.432 . . . . 75.53 110.857 -179.884 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.94 -45.94 32.33 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.706 -0.759 . . . . 73.14 112.516 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' TRP . . . . . 0.427 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.1 p90 -126.32 -125.37 0.24 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.832 0.348 . . . . 75.14 110.893 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.23 -122.1 2.42 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.778 -0.725 . . . . 64.13 112.51 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.55 -32.7 2.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.832 0.348 . . . . 63.45 110.843 -179.882 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.64 -25.79 3.14 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.192 -0.458 . . . . 74.2 110.854 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -82.24 134.48 48.81 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.599 0.714 . . . . 61.53 110.873 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' PRO . . . . . 0.447 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.5 Cg_endo -69.76 -34.37 14.71 Favored 'Trans proline' 0 C--O 1.232 0.177 0 C-N-CA 122.698 2.265 . . . . 73.21 112.353 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.447 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.4 OUTLIER -34.4 -55.13 0.53 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.204 -0.453 . . . . 64.43 110.927 179.948 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.427 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 6.2 m-85 -128.55 15.12 6.55 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.169 -0.468 . . . . 72.04 110.887 179.921 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.319 0 C-N-CA 120.779 -0.724 . . . . 74.31 112.468 -179.979 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 58.8 m . . . . . 0 C--O 1.231 0.089 0 CA-C-O 120.867 0.365 . . . . 73.43 110.839 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 1.3 ttt-85 -54.33 -26.74 31.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 75.3 110.872 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.8 t -63.19 -15.9 16.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.456 . . . . 63.31 111.098 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.475 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.51 -23.56 2.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.154 -0.475 . . . . 74.54 111.053 179.897 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.14 -24.92 1.86 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.247 -0.433 . . . . 75.53 110.857 -179.878 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.78 -46.25 31.31 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.703 -0.76 . . . . 73.05 112.538 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' TRP . . . . . 0.416 ' HZ2' ' CD1' ' A' ' 17' ' ' PHE . 2.9 p90 -126.29 -125.38 0.24 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.796 0.332 . . . . 74.21 110.882 -179.913 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.7 -122.1 2.4 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.748 -0.739 . . . . 62.01 112.475 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -125.02 -32.45 3.01 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.878 0.37 . . . . 74.14 110.836 -179.842 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.06 -26.23 2.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 73.14 110.946 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.31 134.62 45.33 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.611 0.719 . . . . 72.35 110.887 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' PRO . . . . . 0.449 ' O ' ' C ' ' A' ' 16' ' ' LEU . 54.0 Cg_endo -69.81 -34.73 13.85 Favored 'Trans proline' 0 C--N 1.342 0.215 0 C-N-CA 122.678 2.252 . . . . 72.41 112.353 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.449 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.33 -55.66 0.52 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.203 -0.453 . . . . 73.43 110.936 179.989 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.475 ' HB3' ' HB2' ' A' ' 7' ' ' ALA . 6.5 m-85 -129.21 16.05 6.14 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 61.1 110.854 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 C-N-CA 120.743 -0.742 . . . . 73.13 112.514 -179.957 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 56.9 m . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.878 0.371 . . . . 63.1 110.831 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -54.32 -26.76 31.39 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.1 -0.5 . . . . 74.22 110.889 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 13.1 t -63.23 -15.85 16.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.17 -0.468 . . . . 75.12 111.13 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.467 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.5 -23.57 2.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.166 -0.47 . . . . 60.12 111.098 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.7 ptt85 -49.16 -24.88 1.87 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.224 -0.443 . . . . 72.33 110.86 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.83 -46.2 31.65 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.721 -0.752 . . . . 71.03 112.466 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' TRP . . . . . 0.417 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.0 p90 -126.27 -125.43 0.24 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.876 0.37 . . . . 75.11 110.906 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.64 -122.13 2.41 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.744 -0.741 . . . . 25.23 112.515 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -124.99 -32.4 3.03 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.909 0.385 . . . . 71.41 110.882 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.17 -26.2 2.69 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.201 -0.454 . . . . 73.21 110.904 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.34 134.59 45.3 Favored Pre-proline 0 C--N 1.328 -0.368 0 CA-C-O 121.595 0.712 . . . . 63.4 110.886 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' PRO . . . . . 0.451 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.2 Cg_endo -69.8 -34.8 13.73 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.655 2.237 . . . . 73.11 112.316 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.451 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.24 -55.74 0.51 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.238 -0.437 . . . . 75.04 110.874 179.994 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.467 ' HB3' ' HB2' ' A' ' 7' ' ' ALA . 6.5 m-85 -129.18 16.07 6.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.178 -0.464 . . . . 75.14 110.856 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.346 0 C-N-CA 120.736 -0.745 . . . . 64.11 112.479 -179.951 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 35.3 m . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.903 0.382 . . . . 55.11 110.887 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 2.6 ttt180 -55.67 -25.67 40.81 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.127 -0.488 . . . . 62.13 110.888 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 18.5 t -67.02 -12.27 14.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 72.34 111.078 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.437 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.81 -23.13 2.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.177 -0.465 . . . . 75.53 111.124 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.3 mtp180 -48.52 -25.77 1.85 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.236 -0.438 . . . . 75.03 110.897 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.48 -47.01 23.17 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.738 -0.744 . . . . 32.24 112.462 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' TRP . . . . . 0.443 ' HZ2' ' CD1' ' A' ' 17' ' ' PHE . 2.9 p90 -126.31 -125.3 0.24 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.852 0.358 . . . . 71.11 110.944 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.3 -122.42 2.45 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.715 -0.755 . . . . 41.1 112.495 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.2 ptp180 -125.11 -32.57 2.98 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.879 0.371 . . . . 73.35 110.884 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -48.99 -26.28 2.44 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.191 -0.459 . . . . 74.24 110.917 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.21 134.43 45.96 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.624 0.726 . . . . 73.11 110.891 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' PRO . . . . . 0.443 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.4 Cg_endo -69.79 -34.33 14.68 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.693 2.262 . . . . 71.34 112.302 -179.904 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.443 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.65 -55.62 0.55 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.246 -0.434 . . . . 75.51 110.927 179.979 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.443 ' CD1' ' HZ2' ' A' ' 10' ' ' TRP . 6.0 m-85 -128.5 15.6 6.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.158 -0.474 . . . . 74.21 110.837 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.279 0 C-N-CA 120.727 -0.749 . . . . 74.53 112.483 -179.945 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 35.2 m . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.88 0.371 . . . . 71.44 110.88 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -55.64 -25.69 40.4 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.123 -0.49 . . . . 74.41 110.868 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 18.4 t -67.01 -12.24 14.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.166 -0.47 . . . . 74.2 111.14 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.437 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.72 -23.24 2.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.16 -0.473 . . . . 75.23 111.077 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.1 mtp85 -48.44 -25.86 1.85 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 73.05 110.891 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.5 -46.9 23.28 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.724 -0.75 . . . . 71.31 112.475 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' TRP . . . . . 0.445 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.0 p90 -126.44 -125.28 0.24 Allowed 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.805 0.336 . . . . 70.4 110.954 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.33 -122.45 2.45 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.736 -0.745 . . . . 62.14 112.503 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.3 ptp180 -125.08 -32.5 2.99 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.9 0.381 . . . . 71.34 110.867 -179.899 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.05 -26.24 2.51 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 71.02 110.895 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.27 134.45 45.74 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.6 0.714 . . . . 75.11 110.867 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' PRO . . . . . 0.443 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.3 Cg_endo -69.79 -34.32 14.72 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.666 2.244 . . . . 74.41 112.338 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.443 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.68 -55.64 0.55 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.221 -0.445 . . . . 73.5 110.887 179.968 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.445 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 5.9 m-85 -128.44 15.56 6.58 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.188 -0.46 . . . . 74.54 110.919 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 C-N-CA 120.752 -0.737 . . . . 65.4 112.491 -179.938 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 24.3 m . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.841 0.353 . . . . 14.41 110.85 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 3.0 mtp180 -54.41 -26.65 31.79 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.125 -0.489 . . . . 74.1 110.863 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 13.1 t -62.57 -16.16 16.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.19 -0.459 . . . . 53.15 111.145 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.463 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.16 -23.6 2.27 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.164 -0.471 . . . . 61.4 111.148 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -49.03 -24.99 1.76 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 74.02 110.893 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.56 -46.47 29.95 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.78 -0.724 . . . . 63.12 112.476 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' TRP . . . . . 0.412 ' CZ2' ' HB2' ' A' ' 16' ' ' LEU . 2.9 p90 -126.23 -125.39 0.24 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.827 0.346 . . . . 75.31 110.88 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.76 -122.18 2.41 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.752 -0.737 . . . . 64.01 112.493 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.0 -31.86 3.08 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.866 0.365 . . . . 75.41 110.847 -179.878 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.71 -25.73 3.19 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.235 -0.439 . . . . 72.45 110.872 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.88 134.79 43.53 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.552 0.691 . . . . 54.25 110.942 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' PRO . . . . . 0.454 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.6 Cg_endo -69.73 -35.1 13.35 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.694 2.262 . . . . 65.33 112.356 -179.909 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.454 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.07 -55.83 0.49 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.164 -0.471 . . . . 62.5 110.922 -179.99 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.463 ' HB3' ' HB2' ' A' ' 7' ' ' ALA . 6.5 m-85 -129.05 16.04 6.23 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.174 -0.467 . . . . 73.13 110.872 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.247 0 C-N-CA 120.713 -0.756 . . . . 75.04 112.463 -179.952 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 35.4 m . . . . . 0 C--O 1.231 0.122 0 CA-C-O 120.851 0.358 . . . . 62.43 110.872 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 2.1 mtt180 -55.76 -25.47 40.94 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.11 -0.495 . . . . 71.01 110.873 -179.924 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 18.4 t -67.2 -12.21 14.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.216 -0.447 . . . . 62.43 111.116 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.439 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.83 -23.18 2.59 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 75.31 111.072 179.899 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -48.51 -25.75 1.84 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.234 -0.439 . . . . 73.1 110.884 -179.905 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.53 -46.93 23.48 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.728 -0.749 . . . . 62.24 112.474 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' TRP . . . . . 0.441 ' HZ2' ' CD1' ' A' ' 17' ' ' PHE . 2.9 p90 -126.44 -125.31 0.24 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.773 0.321 . . . . 73.51 110.922 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.24 -122.43 2.45 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.768 -0.73 . . . . 60.33 112.527 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.12 -32.47 2.99 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.865 0.364 . . . . 74.11 110.842 -179.865 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.08 -26.23 2.55 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.214 -0.448 . . . . 73.54 110.878 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.32 134.42 45.68 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.668 0.747 . . . . 73.11 110.87 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' PRO . . . . . 0.44 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.8 Cg_endo -69.73 -34.38 14.8 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.7 2.267 . . . . 62.33 112.35 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.44 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.62 -55.64 0.55 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.21 -0.45 . . . . 71.42 110.898 179.943 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.441 ' CD1' ' HZ2' ' A' ' 10' ' ' TRP . 6.0 m-85 -128.49 15.53 6.56 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.196 -0.456 . . . . 74.33 110.884 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.287 0 C-N-CA 120.717 -0.754 . . . . 73.13 112.498 -179.983 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 58.6 m . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.882 0.372 . . . . 44.52 110.845 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 4.7 mtt180 -55.58 -25.69 39.57 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.117 -0.492 . . . . 62.52 110.855 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 13.1 t -66.12 -12.81 14.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.197 -0.456 . . . . 52.25 111.152 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.425 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.93 -23.45 2.88 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.166 -0.47 . . . . 61.43 111.115 179.856 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.1 mtm180 -48.56 -25.91 1.95 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.202 -0.453 . . . . 50.11 110.891 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.58 -46.78 23.75 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.759 -0.734 . . . . 71.34 112.506 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' TRP . . . . . 0.438 ' HZ2' ' CD1' ' A' ' 17' ' ' PHE . 3.0 p90 -126.44 -125.38 0.24 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.825 0.345 . . . . 75.13 110.909 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.49 -122.38 2.44 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.705 -0.76 . . . . 53.23 112.448 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.03 -32.37 3.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.826 0.346 . . . . 72.23 110.883 -179.881 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.17 -26.12 2.63 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.188 -0.46 . . . . 61.51 110.919 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.42 134.53 45.2 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.635 0.731 . . . . 61.43 110.871 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' PRO . . . . . 0.451 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.7 Cg_endo -69.75 -34.44 14.61 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.699 2.266 . . . . 74.31 112.352 -179.923 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.451 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.63 -55.63 0.55 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.213 -0.449 . . . . 72.04 110.881 179.984 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.438 ' CD1' ' HZ2' ' A' ' 10' ' ' TRP . 6.1 m-85 -128.65 15.72 6.46 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.199 -0.455 . . . . 70.24 110.824 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 C-N-CA 120.721 -0.752 . . . . 64.34 112.46 179.977 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 35.4 m . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.906 0.384 . . . . 35.52 110.858 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 4.3 mtp180 -55.83 -25.44 41.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.105 -0.498 . . . . 61.23 110.812 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 18.4 t -67.32 -12.04 14.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.23 -0.441 . . . . 72.45 111.134 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.432 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.9 -23.1 2.58 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.182 -0.463 . . . . 52.13 111.093 179.864 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 2.9 mtp180 -48.47 -25.84 1.86 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.243 -0.435 . . . . 73.12 110.89 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.52 -46.92 23.4 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.731 -0.747 . . . . 54.15 112.527 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' TRP . . . . . 0.445 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.0 p90 -126.4 -125.34 0.24 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.833 0.349 . . . . 72.22 110.92 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.28 -122.42 2.45 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.722 -0.751 . . . . 63.31 112.505 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.1 -32.53 2.99 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.879 0.371 . . . . 71.15 110.883 -179.853 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -49.04 -26.28 2.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.158 -0.473 . . . . 72.05 110.86 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.2 134.36 46.1 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-O 121.602 0.715 . . . . 70.45 110.883 179.977 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' PRO . . . . . 0.445 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.6 Cg_endo -69.76 -34.31 14.85 Favored 'Trans proline' 0 C--O 1.232 0.222 0 C-N-CA 122.653 2.236 . . . . 74.0 112.347 -179.933 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.445 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.67 -55.63 0.55 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.263 -0.426 . . . . 73.25 110.914 179.957 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.445 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 5.9 m-85 -128.51 15.65 6.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.18 -0.463 . . . . 71.54 110.919 179.888 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 C-N-CA 120.714 -0.755 . . . . 74.22 112.498 -179.989 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 34.2 m . . . . . 0 C--O 1.231 0.09 0 CA-C-O 120.893 0.378 . . . . 70.43 110.914 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -55.74 -25.49 40.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.08 -0.509 . . . . 73.13 110.875 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 18.7 t -67.27 -11.95 14.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.179 -0.464 . . . . 71.55 111.142 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.73 -23.28 2.57 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.129 -0.487 . . . . 75.44 111.095 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 3.3 mtp180 -48.69 -25.66 1.9 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.212 -0.449 . . . . 71.35 110.823 -179.85 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.55 -46.63 23.55 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.736 -0.745 . . . . 65.02 112.464 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' TRP . . . . . 0.454 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.1 p90 -126.43 -125.31 0.24 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.832 0.349 . . . . 74.41 110.941 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.06 -122.33 2.45 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.701 -0.762 . . . . 75.24 112.482 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -125.49 -32.65 2.88 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.848 0.356 . . . . 75.4 110.878 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -49.46 -25.92 2.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.194 -0.457 . . . . 61.21 110.91 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -82.89 133.87 47.89 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.591 0.71 . . . . 32.42 110.891 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' PRO . . . . . 0.441 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.3 Cg_endo -69.74 -33.8 15.95 Favored 'Trans proline' 0 C--O 1.233 0.233 0 C-N-CA 122.738 2.292 . . . . 63.44 112.291 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.441 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.74 -55.13 0.56 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.245 -0.434 . . . . 55.54 110.96 179.968 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.454 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 5.7 m-85 -128.14 15.04 6.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.229 -0.441 . . . . 73.23 110.845 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.334 0 C-N-CA 120.769 -0.729 . . . . 63.5 112.49 -179.974 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 30.3 m . . . . . 0 C--O 1.231 0.086 0 CA-C-O 120.943 0.402 . . . . 65.33 110.887 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -55.25 -26.43 39.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.094 -0.503 . . . . 73.1 110.896 -179.914 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 15.3 t -65.9 -12.83 14.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.164 -0.471 . . . . 73.34 111.133 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.431 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.66 -23.45 2.63 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 52.23 111.066 179.902 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 2.2 mtt180 -48.46 -25.94 1.89 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.213 -0.449 . . . . 70.24 110.905 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.48 -46.86 23.14 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.747 -0.74 . . . . 72.01 112.492 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' TRP . . . . . 0.442 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 2.9 p90 -126.45 -125.33 0.24 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.769 0.319 . . . . 71.55 110.96 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.33 -122.37 2.44 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.78 -0.724 . . . . 53.03 112.469 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.6 ptp180 -125.14 -32.6 2.97 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.909 0.385 . . . . 71.12 110.854 -179.806 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.03 -26.27 2.49 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.19 -0.459 . . . . 64.31 110.889 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.07 134.46 46.27 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.573 0.701 . . . . 64.12 110.91 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' PRO . . . . . 0.445 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.2 Cg_endo -69.77 -34.42 14.59 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.665 2.243 . . . . 63.22 112.341 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.445 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.65 -55.6 0.55 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.178 -0.465 . . . . 64.35 110.92 179.996 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.442 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 6.0 m-85 -128.57 15.61 6.51 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.216 -0.447 . . . . 75.34 110.9 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.29 0 C-N-CA 120.732 -0.747 . . . . 71.43 112.506 -179.951 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 31.0 m . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.855 0.359 . . . . 52.23 110.857 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -55.42 -26.29 41.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.165 -0.47 . . . . 73.3 110.855 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 18.8 t -66.52 -12.25 14.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.203 -0.453 . . . . 70.13 111.118 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.58 -23.31 2.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.19 -0.459 . . . . 70.31 111.136 179.886 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.8 mtp180 -48.57 -25.78 1.89 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.219 -0.446 . . . . 52.22 110.828 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.48 -46.58 23.1 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.669 -0.777 . . . . 65.14 112.524 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' TRP . . . . . 0.45 ' HZ2' ' CD1' ' A' ' 17' ' ' PHE . 3.0 p90 -126.49 -125.27 0.24 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.831 0.348 . . . . 73.31 110.922 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.09 -122.33 2.45 Favored Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.715 -0.755 . . . . 71.24 112.443 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.51 -32.51 2.89 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.855 0.359 . . . . 62.54 110.856 -179.842 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.56 -25.87 3.08 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.197 -0.456 . . . . 73.13 110.883 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -82.93 133.87 47.73 Favored Pre-proline 0 C--N 1.328 -0.365 0 CA-C-O 121.606 0.717 . . . . 65.42 110.91 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' PRO . . . . . 0.446 ' O ' ' C ' ' A' ' 16' ' ' LEU . 54.0 Cg_endo -69.82 -33.57 16.1 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.688 2.259 . . . . 73.33 112.357 -179.918 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.446 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.86 -55.14 0.58 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 74.11 110.917 179.957 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.45 ' CD1' ' HZ2' ' A' ' 10' ' ' TRP . 5.7 m-85 -128.13 15.01 6.78 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.183 -0.462 . . . . 71.32 110.859 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 C-N-CA 120.697 -0.763 . . . . 64.51 112.511 -179.994 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 75.6 m . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.88 0.371 . . . . 71.32 110.868 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 2.1 ttt180 -55.5 -25.61 38.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.121 -0.49 . . . . 74.32 110.865 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 14.7 t -66.5 -12.66 15.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.183 -0.462 . . . . 71.25 111.135 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' ALA . . . . . 0.435 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.82 -23.39 2.73 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 31.55 111.156 179.822 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -48.58 -25.8 1.9 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.16 -0.473 . . . . 71.41 110.889 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.63 -46.82 24.08 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.739 -0.743 . . . . 62.01 112.484 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' TRP . . . . . 0.441 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.0 p90 -126.39 -125.34 0.24 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.813 0.339 . . . . 72.11 110.906 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.33 -122.37 2.44 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.718 -0.753 . . . . 41.02 112.491 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 3.6 ptp85 -125.18 -32.49 2.97 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.84 0.352 . . . . 74.43 110.848 -179.869 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.11 -26.15 2.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 62.31 110.902 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.18 134.44 46.0 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.566 0.698 . . . . 71.12 110.909 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' PRO . . . . . 0.448 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.5 Cg_endo -69.75 -34.49 14.51 Favored 'Trans proline' 0 C--O 1.232 0.214 0 C-N-CA 122.718 2.279 . . . . 73.32 112.338 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.448 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.6 -55.66 0.54 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.223 -0.444 . . . . 73.21 110.916 179.989 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 17' ' ' PHE . . . . . 0.441 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 6.0 m-85 -128.59 15.63 6.5 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.208 -0.451 . . . . 74.24 110.836 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.283 0 C-N-CA 120.729 -0.748 . . . . 72.05 112.48 -179.969 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 3.0 pttt . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.811 0.339 . . . . 75.05 110.887 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 79.7 m-20 -109.68 108.72 19.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.217 -0.447 . . . . 73.01 110.907 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 3.4 mtmt -82.23 -44.6 16.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.193 -0.458 . . . . 71.04 110.943 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 56.2 m -121.91 -23.35 5.47 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.185 -0.461 . . . . 71.41 110.866 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -55.17 -26.54 39.5 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.132 -0.486 . . . . 73.41 110.917 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 15.2 t -65.87 -12.61 14.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.183 -0.462 . . . . 61.51 111.153 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.65 -23.52 2.68 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.103 -0.499 . . . . 72.2 111.138 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 2.3 mtm-85 -48.6 -25.77 1.9 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.219 -0.446 . . . . 74.34 110.892 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.57 -46.46 23.64 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.711 -0.757 . . . . 43.42 112.474 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' TRP . . . . . 0.448 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.1 p90 -126.52 -125.34 0.24 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.837 0.351 . . . . 71.13 110.883 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.18 -122.22 2.43 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.715 -0.755 . . . . 75.15 112.512 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.7 ptp85 -125.45 -32.68 2.89 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.89 0.376 . . . . 70.44 110.892 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.57 -25.78 3.02 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.152 -0.476 . . . . 72.41 110.883 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -82.94 133.87 47.7 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.638 0.733 . . . . 73.43 110.856 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.448 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.4 Cg_endo -69.77 -33.78 15.86 Favored 'Trans proline' 0 C--O 1.232 0.19 0 C-N-CA 122.648 2.232 . . . . 74.42 112.311 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.448 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.66 -55.18 0.55 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.239 -0.437 . . . . 71.05 110.92 179.994 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.448 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 5.8 m-85 -128.21 15.08 6.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.154 -0.476 . . . . 73.02 110.89 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 C-N-CA 120.775 -0.726 . . . . 61.24 112.482 -179.942 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 1.3 ptmt . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.744 0.307 . . . . 70.32 110.964 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 13.1 m-20 -66.67 108.44 2.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.273 -0.422 . . . . 71.4 110.874 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 9.2 mmpt? -84.74 -44.8 13.02 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.157 -0.474 . . . . 73.5 110.863 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 39.1 m -121.13 -25.75 5.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 73.44 110.829 -179.841 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -54.08 -26.92 29.56 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.167 -0.469 . . . . 71.11 110.843 -179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.0 t -62.07 -16.68 16.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.189 -0.46 . . . . 54.24 111.134 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.465 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.33 -23.76 2.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.177 -0.465 . . . . 53.24 111.069 179.922 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.07 -24.99 1.81 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 74.4 110.898 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.82 -46.11 31.58 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.703 -0.76 . . . . 70.52 112.512 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' TRP . . . . . 0.415 ' HZ2' ' CD1' ' A' ' 17' ' ' PHE . 2.9 p90 -126.26 -125.45 0.24 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.829 0.347 . . . . 74.32 110.926 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.74 -122.05 2.4 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.778 -0.725 . . . . 62.23 112.511 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -124.99 -32.39 3.03 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.909 0.385 . . . . 74.41 110.88 -179.818 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.24 -26.15 2.78 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 64.15 110.876 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.29 134.63 45.36 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.628 0.728 . . . . 71.12 110.889 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.45 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.7 Cg_endo -69.75 -34.94 13.61 Favored 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.675 2.25 . . . . 74.33 112.357 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.45 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.17 -55.75 0.5 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.194 -0.457 . . . . 73.35 110.917 -179.986 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.465 ' HB3' ' HB2' ' A' ' 7' ' ' ALA . 6.7 m-85 -129.19 16.08 6.15 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 74.04 110.893 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 C-N-CA 120.77 -0.729 . . . . 43.02 112.518 -179.995 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.23 0.069 0 CA-C-O 120.811 0.339 . . . . 72.3 110.879 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 37.7 m-20 -107.61 108.51 19.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.214 -0.448 . . . . 61.42 110.877 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -84.58 -44.76 13.23 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.201 -0.454 . . . . 50.11 110.882 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 58.3 m -121.2 -25.64 5.23 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.266 -0.424 . . . . 72.41 110.879 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -54.17 -26.77 29.74 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.142 -0.481 . . . . 74.32 110.907 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.9 t -62.22 -16.62 16.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.211 -0.45 . . . . 74.22 111.165 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.472 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.23 -23.74 2.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.14 -0.482 . . . . 64.22 111.124 179.849 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.1 -24.96 1.83 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.174 -0.466 . . . . 72.23 110.872 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.88 -46.16 31.95 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.753 -0.737 . . . . 54.25 112.484 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' TRP . . . . . 0.413 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.0 p90 -126.26 -125.48 0.24 Allowed 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.79 0.329 . . . . 72.02 110.917 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.75 -122.03 2.4 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.727 -0.749 . . . . 74.14 112.466 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.1 ptp180 -125.03 -32.47 3.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.858 0.361 . . . . 71.43 110.882 -179.842 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.13 -26.2 2.63 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.161 -0.472 . . . . 71.24 110.939 179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.16 134.66 45.65 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.629 0.728 . . . . 74.04 110.891 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.447 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.9 Cg_endo -69.75 -34.84 13.8 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.68 2.253 . . . . 73.44 112.374 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.447 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.27 -55.77 0.51 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.183 -0.462 . . . . 71.23 110.941 179.961 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.472 ' HB3' ' HB2' ' A' ' 7' ' ' ALA . 6.6 m-85 -129.14 16.13 6.18 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.224 -0.444 . . . . 74.21 110.894 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.343 0 C-N-CA 120.753 -0.737 . . . . 62.41 112.472 -179.943 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.23 0.043 0 CA-C-O 120.821 0.343 . . . . 73.15 110.874 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 78.2 m-20 -112.93 108.27 17.15 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.217 -0.447 . . . . 75.11 110.896 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 20.4 mmtt -84.64 -44.81 13.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.185 -0.461 . . . . 62.55 110.916 179.875 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 39.9 m -121.14 -25.63 5.26 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.232 -0.44 . . . . 14.33 110.879 -179.912 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 4.3 ttt180 -54.1 -26.84 29.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.131 -0.486 . . . . 72.4 110.872 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.0 t -62.27 -16.56 16.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.236 -0.438 . . . . 50.13 111.093 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.467 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.32 -23.75 2.52 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.22 -0.445 . . . . 44.41 111.089 179.857 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -49.15 -24.94 1.89 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.231 -0.441 . . . . 60.1 110.853 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.83 -46.2 31.63 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.743 -0.742 . . . . 73.33 112.46 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' TRP . . . . . 0.416 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 2.9 p90 -126.27 -125.45 0.24 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.831 0.348 . . . . 63.33 110.886 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.76 -122.04 2.4 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.719 -0.753 . . . . 42.02 112.468 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.3 ptp180 -125.04 -32.35 3.02 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.895 0.379 . . . . 73.23 110.854 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.25 -26.19 2.81 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.207 -0.451 . . . . 52.21 110.865 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.26 134.69 45.35 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.62 0.724 . . . . 64.11 110.922 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.452 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.7 Cg_endo -69.84 -34.79 13.63 Favored 'Trans proline' 0 C--O 1.232 0.219 0 C-N-CA 122.692 2.261 . . . . 54.32 112.315 -179.886 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.452 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.26 -55.76 0.51 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.239 -0.437 . . . . 63.14 110.929 179.948 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.467 ' HB3' ' HB2' ' A' ' 7' ' ' ALA . 6.6 m-85 -129.18 16.1 6.16 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.199 -0.455 . . . . 72.34 110.912 179.946 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.352 0 C-N-CA 120.737 -0.744 . . . . 44.33 112.5 -179.968 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.23 0.07 0 CA-C-O 120.74 0.305 . . . . 65.25 110.907 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 92.5 m-20 -63.55 108.39 1.36 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.2 -0.455 . . . . 74.15 110.853 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.9 mtmt -84.71 -44.73 13.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.18 -0.464 . . . . 72.42 110.897 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 42.2 m -121.26 -25.5 5.24 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.201 -0.454 . . . . 64.24 110.827 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -54.3 -26.69 30.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.168 -0.469 . . . . 74.11 110.866 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.8 t -62.38 -16.48 16.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.204 -0.453 . . . . 75.33 111.148 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.462 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.36 -23.77 2.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.162 -0.472 . . . . 72.13 111.099 179.852 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.17 -24.83 1.87 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.234 -0.439 . . . . 74.44 110.89 -179.882 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.86 -46.22 31.83 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.747 -0.74 . . . . 55.22 112.491 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' TRP . . . . . 0.413 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 2.9 p90 -126.25 -125.42 0.24 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.756 0.312 . . . . 73.15 110.971 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.74 -122.02 2.39 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.709 -0.757 . . . . 65.23 112.479 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.0 -32.36 3.03 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.908 0.385 . . . . 72.53 110.906 -179.866 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.19 -26.26 2.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.17 -0.468 . . . . 71.32 110.871 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.19 134.61 45.67 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.588 0.709 . . . . 73.51 110.863 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.452 ' O ' ' C ' ' A' ' 16' ' ' LEU . 54.2 Cg_endo -69.73 -34.83 13.87 Favored 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.697 2.264 . . . . 64.04 112.386 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.452 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.24 -55.75 0.51 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.217 -0.447 . . . . 70.12 110.911 179.959 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.462 ' HB3' ' HB2' ' A' ' 7' ' ' ALA . 6.6 m-85 -129.2 16.11 6.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.195 -0.457 . . . . 72.14 110.902 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.36 0 C-N-CA 120.728 -0.749 . . . . 33.44 112.479 -179.957 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.23 0.072 0 CA-C-O 120.814 0.34 . . . . 60.55 110.917 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 72.6 m-80 -81.53 108.35 15.04 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.23 -0.441 . . . . 73.54 110.913 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 9.2 mmtt -84.65 -44.75 13.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.188 -0.46 . . . . 75.31 110.917 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 38.3 m -121.17 -25.73 5.23 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 42.12 110.887 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -54.01 -27.25 30.6 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.119 -0.491 . . . . 61.01 110.847 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.0 t -61.65 -17.02 16.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 72.44 111.127 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.465 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.17 -23.81 2.42 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.171 -0.468 . . . . 62.14 111.047 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.9 ptt85 -49.13 -24.94 1.86 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.264 -0.425 . . . . 73.35 110.877 -179.906 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.81 -46.16 31.53 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.756 -0.735 . . . . 73.21 112.454 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' TRP . . . . . 0.412 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.0 p90 -126.29 -125.43 0.24 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.797 0.332 . . . . 72.21 110.911 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.77 -122.07 2.4 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.763 -0.732 . . . . 60.14 112.475 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.01 -32.23 3.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.866 0.365 . . . . 71.32 110.865 -179.854 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.29 -26.21 2.89 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.157 -0.474 . . . . 64.04 110.888 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.31 134.63 45.32 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.639 0.733 . . . . 64.32 110.86 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.429 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.9 Cg_endo -69.7 -34.89 13.88 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.684 2.256 . . . . 75.01 112.361 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.429 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.19 -55.78 0.5 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.206 -0.452 . . . . 63.42 110.909 179.979 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.465 ' HB3' ' HB2' ' A' ' 7' ' ' ALA . 6.7 m-85 -129.24 16.1 6.12 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.168 -0.469 . . . . 63.12 110.852 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.334 0 C-N-CA 120.779 -0.724 . . . . 61.31 112.488 -179.963 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 22.6 mttt . . . . . 0 N--CA 1.458 -0.057 0 CA-C-O 120.809 0.338 . . . . 72.41 110.907 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 81.4 m-20 -81.25 108.39 14.84 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.241 -0.436 . . . . 42.24 110.904 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 3.0 mmpt? -84.65 -44.78 13.13 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.161 -0.472 . . . . 74.04 110.866 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 40.5 m -121.23 -25.65 5.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.213 -0.449 . . . . 61.31 110.859 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -54.01 -27.3 31.04 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.114 -0.494 . . . . 65.23 110.835 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.2 t -61.8 -16.81 16.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.462 . . . . 53.13 111.102 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.465 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.23 -23.72 2.41 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.188 -0.46 . . . . 75.31 111.094 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.15 -24.96 1.89 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.198 -0.455 . . . . 43.23 110.877 -179.91 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.69 -46.24 30.76 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.748 -0.739 . . . . 72.23 112.507 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' TRP . . . . . 0.416 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 2.9 p90 -126.28 -125.46 0.24 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.764 0.316 . . . . 71.11 110.925 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.74 -122.07 2.4 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.737 -0.744 . . . . 64.14 112.493 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -124.96 -32.36 3.04 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.926 0.393 . . . . 72.25 110.909 -179.822 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -49.22 -26.21 2.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 62.2 110.909 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.31 134.66 45.26 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.656 0.741 . . . . 31.54 110.88 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.451 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.7 Cg_endo -69.77 -34.76 13.9 Favored 'Trans proline' 0 C--N 1.342 0.215 0 C-N-CA 122.67 2.247 . . . . 74.03 112.347 -179.935 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.451 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.33 -55.7 0.52 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.234 -0.439 . . . . 64.4 110.915 179.984 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.465 ' HB3' ' HB2' ' A' ' 7' ' ' ALA . 6.6 m-85 -129.23 16.12 6.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.188 -0.46 . . . . 72.33 110.908 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.268 0 C-N-CA 120.761 -0.733 . . . . 64.2 112.481 -179.938 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.458 -0.069 0 CA-C-O 120.767 0.318 . . . . 73.34 110.876 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 93.7 m-20 -91.0 108.45 19.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 72.23 110.91 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 12.3 mmtt -85.12 -44.71 12.74 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.21 -0.45 . . . . 75.42 110.888 179.899 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 50.2 m -120.84 -26.02 5.31 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.239 -0.437 . . . . 64.33 110.841 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 1.6 ttp180 -54.19 -26.79 30.03 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.155 -0.475 . . . . 73.33 110.878 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.2 t -62.29 -16.37 16.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.213 -0.449 . . . . 54.52 111.111 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.28 -23.88 2.57 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.174 -0.466 . . . . 75.35 111.073 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -49.11 -24.93 1.83 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.251 -0.432 . . . . 75.53 110.857 -179.884 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.94 -45.94 32.33 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.706 -0.759 . . . . 73.14 112.516 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' TRP . . . . . 0.427 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.1 p90 -126.32 -125.37 0.24 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.832 0.348 . . . . 75.14 110.893 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.23 -122.1 2.42 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.778 -0.725 . . . . 64.13 112.51 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.55 -32.7 2.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.832 0.348 . . . . 63.45 110.843 -179.882 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.64 -25.79 3.14 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.192 -0.458 . . . . 74.2 110.854 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -82.24 134.48 48.81 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.599 0.714 . . . . 61.53 110.873 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.447 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.5 Cg_endo -69.76 -34.37 14.71 Favored 'Trans proline' 0 C--O 1.232 0.177 0 C-N-CA 122.698 2.265 . . . . 73.21 112.353 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.447 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.4 OUTLIER -34.4 -55.13 0.53 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.204 -0.453 . . . . 64.43 110.927 179.948 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.427 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 6.2 m-85 -128.55 15.12 6.55 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.169 -0.468 . . . . 72.04 110.887 179.921 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.319 0 C-N-CA 120.779 -0.724 . . . . 74.31 112.468 -179.979 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 8.9 mttt . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.763 0.316 . . . . 74.55 110.869 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 31.0 m120 -105.02 108.0 19.28 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.263 -0.426 . . . . 71.32 110.878 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 25.9 mmmt -82.87 -45.47 14.19 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.145 -0.479 . . . . 73.03 110.876 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 58.8 m -121.44 -24.49 5.39 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.217 -0.447 . . . . 73.43 110.839 -179.883 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 1.3 ttt-85 -54.33 -26.74 31.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 75.3 110.872 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.8 t -63.19 -15.9 16.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.456 . . . . 63.31 111.098 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.475 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.51 -23.56 2.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.154 -0.475 . . . . 74.54 111.053 179.897 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.14 -24.92 1.86 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.247 -0.433 . . . . 75.53 110.857 -179.878 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.78 -46.25 31.31 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.703 -0.76 . . . . 73.05 112.538 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' TRP . . . . . 0.416 ' HZ2' ' CD1' ' A' ' 17' ' ' PHE . 2.9 p90 -126.29 -125.38 0.24 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.796 0.332 . . . . 74.21 110.882 -179.913 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.7 -122.1 2.4 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.748 -0.739 . . . . 62.01 112.475 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -125.02 -32.45 3.01 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.878 0.37 . . . . 74.14 110.836 -179.842 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.06 -26.23 2.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 73.14 110.946 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.31 134.62 45.33 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.611 0.719 . . . . 72.35 110.887 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.449 ' O ' ' C ' ' A' ' 16' ' ' LEU . 54.0 Cg_endo -69.81 -34.73 13.85 Favored 'Trans proline' 0 C--N 1.342 0.215 0 C-N-CA 122.678 2.252 . . . . 72.41 112.353 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.449 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.33 -55.66 0.52 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.203 -0.453 . . . . 73.43 110.936 179.989 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.475 ' HB3' ' HB2' ' A' ' 7' ' ' ALA . 6.5 m-85 -129.21 16.05 6.14 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 61.1 110.854 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 C-N-CA 120.743 -0.742 . . . . 73.13 112.514 -179.957 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.231 0.092 0 CA-C-O 120.844 0.354 . . . . 72.4 110.874 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 31.1 m120 -103.7 107.84 18.88 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.226 -0.443 . . . . 74.41 110.931 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 13.3 mmmm -82.65 -45.48 14.47 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.17 -0.468 . . . . 62.35 110.937 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 56.9 m -121.48 -24.46 5.38 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.243 -0.435 . . . . 63.1 110.831 -179.884 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -54.32 -26.76 31.39 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.1 -0.5 . . . . 74.22 110.889 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 13.1 t -63.23 -15.85 16.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.17 -0.468 . . . . 75.12 111.13 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.467 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.5 -23.57 2.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.166 -0.47 . . . . 60.12 111.098 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.7 ptt85 -49.16 -24.88 1.87 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.224 -0.443 . . . . 72.33 110.86 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.83 -46.2 31.65 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.721 -0.752 . . . . 71.03 112.466 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' TRP . . . . . 0.417 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.0 p90 -126.27 -125.43 0.24 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.876 0.37 . . . . 75.11 110.906 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.64 -122.13 2.41 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.744 -0.741 . . . . 25.23 112.515 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -124.99 -32.4 3.03 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.909 0.385 . . . . 71.41 110.882 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.17 -26.2 2.69 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.201 -0.454 . . . . 73.21 110.904 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.34 134.59 45.3 Favored Pre-proline 0 C--N 1.328 -0.368 0 CA-C-O 121.595 0.712 . . . . 63.4 110.886 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.451 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.2 Cg_endo -69.8 -34.8 13.73 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.655 2.237 . . . . 73.11 112.316 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.451 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.24 -55.74 0.51 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.238 -0.437 . . . . 75.04 110.874 179.994 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.467 ' HB3' ' HB2' ' A' ' 7' ' ' ALA . 6.5 m-85 -129.18 16.07 6.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.178 -0.464 . . . . 75.14 110.856 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.346 0 C-N-CA 120.736 -0.745 . . . . 64.11 112.479 -179.951 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 6.5 tttt . . . . . 0 N--CA 1.458 -0.04 0 CA-C-O 120.802 0.334 . . . . 74.14 110.936 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 73.6 m-20 -101.47 109.27 21.06 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.236 -0.438 . . . . 71.41 110.864 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 18.9 mtmt -80.45 -44.71 18.8 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.195 -0.457 . . . . 55.02 110.841 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 35.3 m -122.08 -22.92 5.5 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.267 -0.424 . . . . 55.11 110.887 -179.866 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 2.6 ttt180 -55.67 -25.67 40.81 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.127 -0.488 . . . . 62.13 110.888 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 18.5 t -67.02 -12.27 14.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 72.34 111.078 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.437 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.81 -23.13 2.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.177 -0.465 . . . . 75.53 111.124 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.3 mtp180 -48.52 -25.77 1.85 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.236 -0.438 . . . . 75.03 110.897 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.48 -47.01 23.17 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.738 -0.744 . . . . 32.24 112.462 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' TRP . . . . . 0.443 ' HZ2' ' CD1' ' A' ' 17' ' ' PHE . 2.9 p90 -126.31 -125.3 0.24 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.852 0.358 . . . . 71.11 110.944 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.3 -122.42 2.45 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.715 -0.755 . . . . 41.1 112.495 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.2 ptp180 -125.11 -32.57 2.98 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.879 0.371 . . . . 73.35 110.884 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -48.99 -26.28 2.44 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.191 -0.459 . . . . 74.24 110.917 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.21 134.43 45.96 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.624 0.726 . . . . 73.11 110.891 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.443 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.4 Cg_endo -69.79 -34.33 14.68 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.693 2.262 . . . . 71.34 112.302 -179.904 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.443 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.65 -55.62 0.55 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.246 -0.434 . . . . 75.51 110.927 179.979 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.443 ' CD1' ' HZ2' ' A' ' 10' ' ' TRP . 6.0 m-85 -128.5 15.6 6.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.158 -0.474 . . . . 74.21 110.837 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.279 0 C-N-CA 120.727 -0.749 . . . . 74.53 112.483 -179.945 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 1.7 mptm? . . . . . 0 C--O 1.23 0.069 0 CA-C-O 120.814 0.34 . . . . 74.24 110.873 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 90.3 m-20 -89.22 109.32 20.21 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.2 -0.454 . . . . 73.12 110.875 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 36.7 mtmt -80.41 -44.72 18.87 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.149 -0.478 . . . . 70.34 110.911 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 35.2 m -122.1 -22.95 5.49 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.192 -0.458 . . . . 71.44 110.88 -179.909 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -55.64 -25.69 40.4 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.123 -0.49 . . . . 74.41 110.868 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 18.4 t -67.01 -12.24 14.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.166 -0.47 . . . . 74.2 111.14 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.437 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.72 -23.24 2.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.16 -0.473 . . . . 75.23 111.077 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.1 mtp85 -48.44 -25.86 1.85 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 73.05 110.891 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.5 -46.9 23.28 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.724 -0.75 . . . . 71.31 112.475 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' TRP . . . . . 0.445 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.0 p90 -126.44 -125.28 0.24 Allowed 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.805 0.336 . . . . 70.4 110.954 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.33 -122.45 2.45 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.736 -0.745 . . . . 62.14 112.503 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.3 ptp180 -125.08 -32.5 2.99 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.9 0.381 . . . . 71.34 110.867 -179.899 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.05 -26.24 2.51 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 71.02 110.895 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.27 134.45 45.74 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.6 0.714 . . . . 75.11 110.867 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.443 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.3 Cg_endo -69.79 -34.32 14.72 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.666 2.244 . . . . 74.41 112.338 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.443 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.68 -55.64 0.55 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.221 -0.445 . . . . 73.5 110.887 179.968 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.445 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 5.9 m-85 -128.44 15.56 6.58 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.188 -0.46 . . . . 74.54 110.919 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 C-N-CA 120.752 -0.737 . . . . 65.4 112.491 -179.938 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.23 0.044 0 CA-C-O 120.791 0.329 . . . . 74.44 110.886 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 -97.91 108.51 21.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.252 -0.431 . . . . 72.33 110.863 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 18.9 mtmt -84.68 -44.75 13.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.206 -0.452 . . . . 53.51 110.904 179.879 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 24.3 m -121.12 -25.48 5.3 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.22 -0.445 . . . . 14.41 110.85 -179.875 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 3.0 mtp180 -54.41 -26.65 31.79 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.125 -0.489 . . . . 74.1 110.863 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 13.1 t -62.57 -16.16 16.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.19 -0.459 . . . . 53.15 111.145 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.463 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.16 -23.6 2.27 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.164 -0.471 . . . . 61.4 111.148 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -49.03 -24.99 1.76 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 74.02 110.893 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.56 -46.47 29.95 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.78 -0.724 . . . . 63.12 112.476 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' TRP . . . . . 0.412 ' CZ2' ' HB2' ' A' ' 16' ' ' LEU . 2.9 p90 -126.23 -125.39 0.24 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.827 0.346 . . . . 75.31 110.88 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.76 -122.18 2.41 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.752 -0.737 . . . . 64.01 112.493 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.0 -31.86 3.08 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.866 0.365 . . . . 75.41 110.847 -179.878 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.71 -25.73 3.19 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.235 -0.439 . . . . 72.45 110.872 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.88 134.79 43.53 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.552 0.691 . . . . 54.25 110.942 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.454 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.6 Cg_endo -69.73 -35.1 13.35 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.694 2.262 . . . . 65.33 112.356 -179.909 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.454 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.07 -55.83 0.49 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.164 -0.471 . . . . 62.5 110.922 -179.99 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.463 ' HB3' ' HB2' ' A' ' 7' ' ' ALA . 6.5 m-85 -129.05 16.04 6.23 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.174 -0.467 . . . . 73.13 110.872 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.247 0 C-N-CA 120.713 -0.756 . . . . 75.04 112.463 -179.952 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.23 0.053 0 CA-C-O 120.799 0.333 . . . . 72.12 110.914 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 76.7 m-20 -71.06 109.18 4.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.236 -0.438 . . . . 73.4 110.9 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 1.8 mmpt? -80.36 -44.69 19.02 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.216 -0.447 . . . . 74.13 110.916 179.93 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 35.4 m -122.1 -22.88 5.51 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.195 -0.457 . . . . 62.43 110.872 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 2.1 mtt180 -55.76 -25.47 40.94 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.11 -0.495 . . . . 71.01 110.873 -179.924 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 18.4 t -67.2 -12.21 14.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.216 -0.447 . . . . 62.43 111.116 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.439 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.83 -23.18 2.59 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 75.31 111.072 179.899 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -48.51 -25.75 1.84 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.234 -0.439 . . . . 73.1 110.884 -179.905 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.53 -46.93 23.48 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.728 -0.749 . . . . 62.24 112.474 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' TRP . . . . . 0.441 ' HZ2' ' CD1' ' A' ' 17' ' ' PHE . 2.9 p90 -126.44 -125.31 0.24 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.773 0.321 . . . . 73.51 110.922 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.24 -122.43 2.45 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.768 -0.73 . . . . 60.33 112.527 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.12 -32.47 2.99 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.865 0.364 . . . . 74.11 110.842 -179.865 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.08 -26.23 2.55 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.214 -0.448 . . . . 73.54 110.878 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.32 134.42 45.68 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.668 0.747 . . . . 73.11 110.87 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.44 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.8 Cg_endo -69.73 -34.38 14.8 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.7 2.267 . . . . 62.33 112.35 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.44 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.62 -55.64 0.55 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.21 -0.45 . . . . 71.42 110.898 179.943 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.441 ' CD1' ' HZ2' ' A' ' 10' ' ' TRP . 6.0 m-85 -128.49 15.53 6.56 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.196 -0.456 . . . . 74.33 110.884 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.287 0 C-N-CA 120.717 -0.754 . . . . 73.13 112.498 -179.983 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.746 0.308 . . . . 73.54 110.956 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 81.4 m-20 -87.0 108.66 18.95 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.241 -0.436 . . . . 72.55 110.907 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 4.5 mtmm -83.02 -44.69 14.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.187 -0.461 . . . . 63.2 110.927 179.88 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 58.6 m -121.81 -23.37 5.51 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.238 -0.437 . . . . 44.52 110.845 -179.858 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 4.7 mtt180 -55.58 -25.69 39.57 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.117 -0.492 . . . . 62.52 110.855 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 13.1 t -66.12 -12.81 14.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.197 -0.456 . . . . 52.25 111.152 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.425 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.93 -23.45 2.88 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.166 -0.47 . . . . 61.43 111.115 179.856 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.1 mtm180 -48.56 -25.91 1.95 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.202 -0.453 . . . . 50.11 110.891 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.58 -46.78 23.75 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.759 -0.734 . . . . 71.34 112.506 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' TRP . . . . . 0.438 ' HZ2' ' CD1' ' A' ' 17' ' ' PHE . 3.0 p90 -126.44 -125.38 0.24 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.825 0.345 . . . . 75.13 110.909 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.49 -122.38 2.44 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.705 -0.76 . . . . 53.23 112.448 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.03 -32.37 3.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.826 0.346 . . . . 72.23 110.883 -179.881 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.17 -26.12 2.63 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.188 -0.46 . . . . 61.51 110.919 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.42 134.53 45.2 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.635 0.731 . . . . 61.43 110.871 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.451 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.7 Cg_endo -69.75 -34.44 14.61 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.699 2.266 . . . . 74.31 112.352 -179.923 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.451 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.63 -55.63 0.55 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.213 -0.449 . . . . 72.04 110.881 179.984 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.438 ' CD1' ' HZ2' ' A' ' 10' ' ' TRP . 6.1 m-85 -128.65 15.72 6.46 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.199 -0.455 . . . . 70.24 110.824 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 C-N-CA 120.721 -0.752 . . . . 64.34 112.46 179.977 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.457 -0.076 0 CA-C-O 120.797 0.332 . . . . 73.41 110.866 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 59.0 m-20 -117.69 109.26 16.42 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.204 -0.453 . . . . 54.53 110.915 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.36 -44.64 19.11 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.155 -0.475 . . . . 72.14 110.921 179.902 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 35.4 m -122.09 -22.84 5.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.217 -0.447 . . . . 35.52 110.858 -179.904 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 4.3 mtp180 -55.83 -25.44 41.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.105 -0.498 . . . . 61.23 110.812 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 18.4 t -67.32 -12.04 14.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.23 -0.441 . . . . 72.45 111.134 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.432 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.9 -23.1 2.58 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.182 -0.463 . . . . 52.13 111.093 179.864 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 2.9 mtp180 -48.47 -25.84 1.86 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.243 -0.435 . . . . 73.12 110.89 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.52 -46.92 23.4 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.731 -0.747 . . . . 54.15 112.527 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' TRP . . . . . 0.445 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.0 p90 -126.4 -125.34 0.24 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.833 0.349 . . . . 72.22 110.92 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.28 -122.42 2.45 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.722 -0.751 . . . . 63.31 112.505 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.1 -32.53 2.99 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.879 0.371 . . . . 71.15 110.883 -179.853 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -49.04 -26.28 2.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.158 -0.473 . . . . 72.05 110.86 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.2 134.36 46.1 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-O 121.602 0.715 . . . . 70.45 110.883 179.977 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.445 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.6 Cg_endo -69.76 -34.31 14.85 Favored 'Trans proline' 0 C--O 1.232 0.222 0 C-N-CA 122.653 2.236 . . . . 74.0 112.347 -179.933 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.445 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.67 -55.63 0.55 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.263 -0.426 . . . . 73.25 110.914 179.957 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.445 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 5.9 m-85 -128.51 15.65 6.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.18 -0.463 . . . . 71.54 110.919 179.888 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 C-N-CA 120.714 -0.755 . . . . 74.22 112.498 -179.989 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 1.5 ttmt . . . . . 0 C--O 1.23 0.05 0 CA-C-O 120.74 0.305 . . . . 74.53 110.948 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 96.4 m-20 -78.95 109.36 13.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.246 -0.434 . . . . 60.12 110.892 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 3.7 mtmt -80.6 -44.74 18.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.159 -0.473 . . . . 72.31 110.906 179.892 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 34.2 m -121.82 -23.05 5.58 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 70.43 110.914 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -55.74 -25.49 40.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.08 -0.509 . . . . 73.13 110.875 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 18.7 t -67.27 -11.95 14.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.179 -0.464 . . . . 71.55 111.142 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.73 -23.28 2.57 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.129 -0.487 . . . . 75.44 111.095 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 3.3 mtp180 -48.69 -25.66 1.9 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.212 -0.449 . . . . 71.35 110.823 -179.85 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.55 -46.63 23.55 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.736 -0.745 . . . . 65.02 112.464 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' TRP . . . . . 0.454 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.1 p90 -126.43 -125.31 0.24 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.832 0.349 . . . . 74.41 110.941 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.06 -122.33 2.45 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.701 -0.762 . . . . 75.24 112.482 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -125.49 -32.65 2.88 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.848 0.356 . . . . 75.4 110.878 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -49.46 -25.92 2.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.194 -0.457 . . . . 61.21 110.91 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -82.89 133.87 47.89 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.591 0.71 . . . . 32.42 110.891 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.441 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.3 Cg_endo -69.74 -33.8 15.95 Favored 'Trans proline' 0 C--O 1.233 0.233 0 C-N-CA 122.738 2.292 . . . . 63.44 112.291 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.441 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.74 -55.13 0.56 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.245 -0.434 . . . . 55.54 110.96 179.968 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.454 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 5.7 m-85 -128.14 15.04 6.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.229 -0.441 . . . . 73.23 110.845 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.334 0 C-N-CA 120.769 -0.729 . . . . 63.5 112.49 -179.974 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.23 0.073 0 CA-C-O 120.791 0.329 . . . . 75.1 110.886 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 33.8 m-20 -102.78 108.95 20.37 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.221 -0.445 . . . . 64.51 110.892 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 21.1 mtmt -81.89 -44.64 16.57 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.143 -0.48 . . . . 63.42 110.891 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 30.3 m -122.01 -23.26 5.45 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.224 -0.444 . . . . 65.33 110.887 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -55.25 -26.43 39.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.094 -0.503 . . . . 73.1 110.896 -179.914 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 15.3 t -65.9 -12.83 14.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.164 -0.471 . . . . 73.34 111.133 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.431 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.66 -23.45 2.63 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 52.23 111.066 179.902 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 2.2 mtt180 -48.46 -25.94 1.89 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.213 -0.449 . . . . 70.24 110.905 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.48 -46.86 23.14 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.747 -0.74 . . . . 72.01 112.492 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' TRP . . . . . 0.442 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 2.9 p90 -126.45 -125.33 0.24 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.769 0.319 . . . . 71.55 110.96 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.33 -122.37 2.44 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.78 -0.724 . . . . 53.03 112.469 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.6 ptp180 -125.14 -32.6 2.97 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.909 0.385 . . . . 71.12 110.854 -179.806 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.03 -26.27 2.49 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.19 -0.459 . . . . 64.31 110.889 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.07 134.46 46.27 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.573 0.701 . . . . 64.12 110.91 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.445 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.2 Cg_endo -69.77 -34.42 14.59 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.665 2.243 . . . . 63.22 112.341 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.445 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.65 -55.6 0.55 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.178 -0.465 . . . . 64.35 110.92 179.996 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.442 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 6.0 m-85 -128.57 15.61 6.51 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.216 -0.447 . . . . 75.34 110.9 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.29 0 C-N-CA 120.732 -0.747 . . . . 71.43 112.506 -179.951 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.23 0.049 0 CA-C-O 120.833 0.349 . . . . 70.11 110.881 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -86.15 109.38 18.84 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.207 -0.451 . . . . 63.23 110.897 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 34.1 mtmt -80.69 -44.62 18.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.171 -0.468 . . . . 73.14 110.899 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 31.0 m -121.95 -23.18 5.5 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.229 -0.442 . . . . 52.23 110.857 -179.886 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -55.42 -26.29 41.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.165 -0.47 . . . . 73.3 110.855 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 18.8 t -66.52 -12.25 14.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.203 -0.453 . . . . 70.13 111.118 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.58 -23.31 2.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.19 -0.459 . . . . 70.31 111.136 179.886 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.8 mtp180 -48.57 -25.78 1.89 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.219 -0.446 . . . . 52.22 110.828 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.48 -46.58 23.1 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.669 -0.777 . . . . 65.14 112.524 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' TRP . . . . . 0.45 ' HZ2' ' CD1' ' A' ' 17' ' ' PHE . 3.0 p90 -126.49 -125.27 0.24 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.831 0.348 . . . . 73.31 110.922 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.09 -122.33 2.45 Favored Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.715 -0.755 . . . . 71.24 112.443 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.51 -32.51 2.89 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.855 0.359 . . . . 62.54 110.856 -179.842 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.56 -25.87 3.08 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.197 -0.456 . . . . 73.13 110.883 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -82.93 133.87 47.73 Favored Pre-proline 0 C--N 1.328 -0.365 0 CA-C-O 121.606 0.717 . . . . 65.42 110.91 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.446 ' O ' ' C ' ' A' ' 16' ' ' LEU . 54.0 Cg_endo -69.82 -33.57 16.1 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.688 2.259 . . . . 73.33 112.357 -179.918 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.446 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.86 -55.14 0.58 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 74.11 110.917 179.957 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.45 ' CD1' ' HZ2' ' A' ' 10' ' ' TRP . 5.7 m-85 -128.13 15.01 6.78 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.183 -0.462 . . . . 71.32 110.859 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 C-N-CA 120.697 -0.763 . . . . 64.51 112.511 -179.994 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 6.0 mttp . . . . . 0 N--CA 1.458 -0.039 0 CA-C-O 120.799 0.333 . . . . 74.44 110.87 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' ASN . . . . . 0.428 ' HB2' HG23 ' A' ' 6' ' ' VAL . 0.8 OUTLIER -116.41 106.51 13.7 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.213 -0.449 . . . . 73.1 110.872 179.953 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.9 mtmm -82.3 -44.26 16.46 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.456 . . . . 75.45 110.867 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 75.6 m -120.97 -22.33 6.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.212 -0.449 . . . . 71.32 110.868 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 2.1 ttt180 -55.5 -25.61 38.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.121 -0.49 . . . . 74.32 110.865 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.428 HG23 ' HB2' ' A' ' 2' ' ' ASN . 14.7 t -66.5 -12.66 15.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.183 -0.462 . . . . 71.25 111.135 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' ALA . . . . . 0.435 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.82 -23.39 2.73 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 31.55 111.156 179.822 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -48.58 -25.8 1.9 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.16 -0.473 . . . . 71.41 110.889 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.63 -46.82 24.08 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.739 -0.743 . . . . 62.01 112.484 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' TRP . . . . . 0.441 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.0 p90 -126.39 -125.34 0.24 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.813 0.339 . . . . 72.11 110.906 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.33 -122.37 2.44 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.718 -0.753 . . . . 41.02 112.491 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 3.6 ptp85 -125.18 -32.49 2.97 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.84 0.352 . . . . 74.43 110.848 -179.869 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.11 -26.15 2.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 62.31 110.902 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.18 134.44 46.0 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.566 0.698 . . . . 71.12 110.909 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' PRO . . . . . 0.448 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.5 Cg_endo -69.75 -34.49 14.51 Favored 'Trans proline' 0 C--O 1.232 0.214 0 C-N-CA 122.718 2.279 . . . . 73.32 112.338 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.448 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.6 -55.66 0.54 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.223 -0.444 . . . . 73.21 110.916 179.989 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.441 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 6.0 m-85 -128.59 15.63 6.5 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.208 -0.451 . . . . 74.24 110.836 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.283 0 C-N-CA 120.729 -0.748 . . . . 72.05 112.48 -179.969 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 56.2 m . . . . . 0 C--O 1.232 0.151 0 CA-C-O 120.864 0.364 . . . . 71.41 110.866 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -55.17 -26.54 39.5 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.132 -0.486 . . . . 73.41 110.917 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 15.2 t -65.87 -12.61 14.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.183 -0.462 . . . . 61.51 111.153 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.65 -23.52 2.68 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.103 -0.499 . . . . 72.2 111.138 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 2.3 mtm-85 -48.6 -25.77 1.9 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.219 -0.446 . . . . 74.34 110.892 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.57 -46.46 23.64 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.711 -0.757 . . . . 43.42 112.474 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' TRP . . . . . 0.448 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.1 p90 -126.52 -125.34 0.24 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.837 0.351 . . . . 71.13 110.883 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.18 -122.22 2.43 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.715 -0.755 . . . . 75.15 112.512 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.7 ptp85 -125.45 -32.68 2.89 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.89 0.376 . . . . 70.44 110.892 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.57 -25.78 3.02 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.152 -0.476 . . . . 72.41 110.883 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -82.94 133.87 47.7 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.638 0.733 . . . . 73.43 110.856 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . 0.448 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.4 Cg_endo -69.77 -33.78 15.86 Favored 'Trans proline' 0 C--O 1.232 0.19 0 C-N-CA 122.648 2.232 . . . . 74.42 112.311 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.448 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.66 -55.18 0.55 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.239 -0.437 . . . . 71.05 110.92 179.994 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.448 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 5.8 m-85 -128.21 15.08 6.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.154 -0.476 . . . . 73.02 110.89 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 C-N-CA 120.775 -0.726 . . . . 61.24 112.482 -179.942 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 39.1 m . . . . . 0 C--O 1.232 0.138 0 CA-C-O 120.864 0.364 . . . . 73.44 110.829 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -54.08 -26.92 29.56 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.167 -0.469 . . . . 71.11 110.843 -179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.0 t -62.07 -16.68 16.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.189 -0.46 . . . . 54.24 111.134 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.465 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.33 -23.76 2.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.177 -0.465 . . . . 53.24 111.069 179.922 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.07 -24.99 1.81 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 74.4 110.898 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.82 -46.11 31.58 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.703 -0.76 . . . . 70.52 112.512 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' TRP . . . . . 0.415 ' HZ2' ' CD1' ' A' ' 17' ' ' PHE . 2.9 p90 -126.26 -125.45 0.24 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.829 0.347 . . . . 74.32 110.926 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.74 -122.05 2.4 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.778 -0.725 . . . . 62.23 112.511 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -124.99 -32.39 3.03 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.909 0.385 . . . . 74.41 110.88 -179.818 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.24 -26.15 2.78 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 64.15 110.876 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.29 134.63 45.36 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.628 0.728 . . . . 71.12 110.889 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . 0.45 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.7 Cg_endo -69.75 -34.94 13.61 Favored 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.675 2.25 . . . . 74.33 112.357 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.45 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.17 -55.75 0.5 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.194 -0.457 . . . . 73.35 110.917 -179.986 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.465 ' HB3' ' HB2' ' A' ' 7' ' ' ALA . 6.7 m-85 -129.19 16.08 6.15 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 74.04 110.893 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 C-N-CA 120.77 -0.729 . . . . 43.02 112.518 -179.995 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 58.3 m . . . . . 0 C--O 1.232 0.134 0 CA-C-O 120.895 0.378 . . . . 72.41 110.879 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -54.17 -26.77 29.74 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.142 -0.481 . . . . 74.32 110.907 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.9 t -62.22 -16.62 16.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.211 -0.45 . . . . 74.22 111.165 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.472 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.23 -23.74 2.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.14 -0.482 . . . . 64.22 111.124 179.849 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.1 -24.96 1.83 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.174 -0.466 . . . . 72.23 110.872 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.88 -46.16 31.95 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.753 -0.737 . . . . 54.25 112.484 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' TRP . . . . . 0.413 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.0 p90 -126.26 -125.48 0.24 Allowed 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.79 0.329 . . . . 72.02 110.917 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.75 -122.03 2.4 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.727 -0.749 . . . . 74.14 112.466 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.1 ptp180 -125.03 -32.47 3.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.858 0.361 . . . . 71.43 110.882 -179.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.13 -26.2 2.63 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.161 -0.472 . . . . 71.24 110.939 179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.16 134.66 45.65 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.629 0.728 . . . . 74.04 110.891 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . 0.447 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.9 Cg_endo -69.75 -34.84 13.8 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.68 2.253 . . . . 73.44 112.374 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.447 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.27 -55.77 0.51 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.183 -0.462 . . . . 71.23 110.941 179.961 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.472 ' HB3' ' HB2' ' A' ' 7' ' ' ALA . 6.6 m-85 -129.14 16.13 6.18 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.224 -0.444 . . . . 74.21 110.894 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.343 0 C-N-CA 120.753 -0.737 . . . . 62.41 112.472 -179.943 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 39.9 m . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.872 0.368 . . . . 14.33 110.879 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 4.3 ttt180 -54.1 -26.84 29.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.131 -0.486 . . . . 72.4 110.872 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.0 t -62.27 -16.56 16.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.236 -0.438 . . . . 50.13 111.093 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.467 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.32 -23.75 2.52 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.22 -0.445 . . . . 44.41 111.089 179.857 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -49.15 -24.94 1.89 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.231 -0.441 . . . . 60.1 110.853 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.83 -46.2 31.63 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.743 -0.742 . . . . 73.33 112.46 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' TRP . . . . . 0.416 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 2.9 p90 -126.27 -125.45 0.24 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.831 0.348 . . . . 63.33 110.886 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.76 -122.04 2.4 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.719 -0.753 . . . . 42.02 112.468 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.3 ptp180 -125.04 -32.35 3.02 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.895 0.379 . . . . 73.23 110.854 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.25 -26.19 2.81 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.207 -0.451 . . . . 52.21 110.865 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.26 134.69 45.35 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.62 0.724 . . . . 64.11 110.922 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . 0.452 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.7 Cg_endo -69.84 -34.79 13.63 Favored 'Trans proline' 0 C--O 1.232 0.219 0 C-N-CA 122.692 2.261 . . . . 54.32 112.315 -179.886 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.452 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.26 -55.76 0.51 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.239 -0.437 . . . . 63.14 110.929 179.948 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.467 ' HB3' ' HB2' ' A' ' 7' ' ' ALA . 6.6 m-85 -129.18 16.1 6.16 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.199 -0.455 . . . . 72.34 110.912 179.946 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.352 0 C-N-CA 120.737 -0.744 . . . . 44.33 112.5 -179.968 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 42.2 m . . . . . 0 C--O 1.231 0.122 0 CA-C-O 120.856 0.36 . . . . 64.24 110.827 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -54.3 -26.69 30.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.168 -0.469 . . . . 74.11 110.866 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.8 t -62.38 -16.48 16.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.204 -0.453 . . . . 75.33 111.148 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.462 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.36 -23.77 2.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.162 -0.472 . . . . 72.13 111.099 179.852 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.17 -24.83 1.87 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.234 -0.439 . . . . 74.44 110.89 -179.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.86 -46.22 31.83 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.747 -0.74 . . . . 55.22 112.491 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' TRP . . . . . 0.413 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 2.9 p90 -126.25 -125.42 0.24 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.756 0.312 . . . . 73.15 110.971 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.74 -122.02 2.39 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.709 -0.757 . . . . 65.23 112.479 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.0 -32.36 3.03 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.908 0.385 . . . . 72.53 110.906 -179.866 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.19 -26.26 2.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.17 -0.468 . . . . 71.32 110.871 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.19 134.61 45.67 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.588 0.709 . . . . 73.51 110.863 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . 0.452 ' O ' ' C ' ' A' ' 16' ' ' LEU . 54.2 Cg_endo -69.73 -34.83 13.87 Favored 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.697 2.264 . . . . 64.04 112.386 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.452 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.24 -55.75 0.51 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.217 -0.447 . . . . 70.12 110.911 179.959 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.462 ' HB3' ' HB2' ' A' ' 7' ' ' ALA . 6.6 m-85 -129.2 16.11 6.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.195 -0.457 . . . . 72.14 110.902 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.36 0 C-N-CA 120.728 -0.749 . . . . 33.44 112.479 -179.957 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 38.3 m . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.889 0.376 . . . . 42.12 110.887 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -54.01 -27.25 30.6 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.119 -0.491 . . . . 61.01 110.847 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.0 t -61.65 -17.02 16.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 72.44 111.127 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.465 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.17 -23.81 2.42 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.171 -0.468 . . . . 62.14 111.047 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.9 ptt85 -49.13 -24.94 1.86 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.264 -0.425 . . . . 73.35 110.877 -179.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.81 -46.16 31.53 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.756 -0.735 . . . . 73.21 112.454 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' TRP . . . . . 0.412 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.0 p90 -126.29 -125.43 0.24 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.797 0.332 . . . . 72.21 110.911 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.77 -122.07 2.4 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.763 -0.732 . . . . 60.14 112.475 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.01 -32.23 3.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.866 0.365 . . . . 71.32 110.865 -179.854 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.29 -26.21 2.89 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.157 -0.474 . . . . 64.04 110.888 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.31 134.63 45.32 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.639 0.733 . . . . 64.32 110.86 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . 0.429 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.9 Cg_endo -69.7 -34.89 13.88 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.684 2.256 . . . . 75.01 112.361 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.429 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.19 -55.78 0.5 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.206 -0.452 . . . . 63.42 110.909 179.979 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.465 ' HB3' ' HB2' ' A' ' 7' ' ' ALA . 6.7 m-85 -129.24 16.1 6.12 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.168 -0.469 . . . . 63.12 110.852 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.334 0 C-N-CA 120.779 -0.724 . . . . 61.31 112.488 -179.963 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 40.5 m . . . . . 0 C--O 1.231 0.11 0 CA-C-O 120.826 0.346 . . . . 61.31 110.859 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -54.01 -27.3 31.04 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.114 -0.494 . . . . 65.23 110.835 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.2 t -61.8 -16.81 16.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.462 . . . . 53.13 111.102 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.465 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.23 -23.72 2.41 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.188 -0.46 . . . . 75.31 111.094 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.15 -24.96 1.89 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.198 -0.455 . . . . 43.23 110.877 -179.91 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.69 -46.24 30.76 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.748 -0.739 . . . . 72.23 112.507 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' TRP . . . . . 0.416 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 2.9 p90 -126.28 -125.46 0.24 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.764 0.316 . . . . 71.11 110.925 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.74 -122.07 2.4 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.737 -0.744 . . . . 64.14 112.493 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -124.96 -32.36 3.04 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.926 0.393 . . . . 72.25 110.909 -179.822 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -49.22 -26.21 2.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 62.2 110.909 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.31 134.66 45.26 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.656 0.741 . . . . 31.54 110.88 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . 0.451 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.7 Cg_endo -69.77 -34.76 13.9 Favored 'Trans proline' 0 C--N 1.342 0.215 0 C-N-CA 122.67 2.247 . . . . 74.03 112.347 -179.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.451 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.33 -55.7 0.52 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.234 -0.439 . . . . 64.4 110.915 179.984 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.465 ' HB3' ' HB2' ' A' ' 7' ' ' ALA . 6.6 m-85 -129.23 16.12 6.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.188 -0.46 . . . . 72.33 110.908 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.268 0 C-N-CA 120.761 -0.733 . . . . 64.2 112.481 -179.938 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 50.2 m . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.846 0.355 . . . . 64.33 110.841 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 1.6 ttp180 -54.19 -26.79 30.03 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.155 -0.475 . . . . 73.33 110.878 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.2 t -62.29 -16.37 16.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.213 -0.449 . . . . 54.52 111.111 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.28 -23.88 2.57 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.174 -0.466 . . . . 75.35 111.073 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -49.11 -24.93 1.83 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.251 -0.432 . . . . 75.53 110.857 -179.884 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.94 -45.94 32.33 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.706 -0.759 . . . . 73.14 112.516 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' TRP . . . . . 0.427 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.1 p90 -126.32 -125.37 0.24 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.832 0.348 . . . . 75.14 110.893 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.23 -122.1 2.42 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.778 -0.725 . . . . 64.13 112.51 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.55 -32.7 2.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.832 0.348 . . . . 63.45 110.843 -179.882 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.64 -25.79 3.14 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.192 -0.458 . . . . 74.2 110.854 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -82.24 134.48 48.81 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.599 0.714 . . . . 61.53 110.873 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . 0.447 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.5 Cg_endo -69.76 -34.37 14.71 Favored 'Trans proline' 0 C--O 1.232 0.177 0 C-N-CA 122.698 2.265 . . . . 73.21 112.353 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.447 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.4 OUTLIER -34.4 -55.13 0.53 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.204 -0.453 . . . . 64.43 110.927 179.948 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.427 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 6.2 m-85 -128.55 15.12 6.55 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.169 -0.468 . . . . 72.04 110.887 179.921 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.319 0 C-N-CA 120.779 -0.724 . . . . 74.31 112.468 -179.979 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 58.8 m . . . . . 0 C--O 1.231 0.089 0 CA-C-O 120.867 0.365 . . . . 73.43 110.839 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 1.3 ttt-85 -54.33 -26.74 31.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 75.3 110.872 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.8 t -63.19 -15.9 16.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.456 . . . . 63.31 111.098 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.475 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.51 -23.56 2.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.154 -0.475 . . . . 74.54 111.053 179.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.14 -24.92 1.86 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.247 -0.433 . . . . 75.53 110.857 -179.878 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.78 -46.25 31.31 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.703 -0.76 . . . . 73.05 112.538 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' TRP . . . . . 0.416 ' HZ2' ' CD1' ' A' ' 17' ' ' PHE . 2.9 p90 -126.29 -125.38 0.24 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.796 0.332 . . . . 74.21 110.882 -179.913 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.7 -122.1 2.4 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.748 -0.739 . . . . 62.01 112.475 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -125.02 -32.45 3.01 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.878 0.37 . . . . 74.14 110.836 -179.842 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.06 -26.23 2.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 73.14 110.946 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.31 134.62 45.33 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.611 0.719 . . . . 72.35 110.887 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . 0.449 ' O ' ' C ' ' A' ' 16' ' ' LEU . 54.0 Cg_endo -69.81 -34.73 13.85 Favored 'Trans proline' 0 C--N 1.342 0.215 0 C-N-CA 122.678 2.252 . . . . 72.41 112.353 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.449 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.33 -55.66 0.52 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.203 -0.453 . . . . 73.43 110.936 179.989 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.475 ' HB3' ' HB2' ' A' ' 7' ' ' ALA . 6.5 m-85 -129.21 16.05 6.14 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 61.1 110.854 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 C-N-CA 120.743 -0.742 . . . . 73.13 112.514 -179.957 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 56.9 m . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.878 0.371 . . . . 63.1 110.831 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -54.32 -26.76 31.39 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.1 -0.5 . . . . 74.22 110.889 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 13.1 t -63.23 -15.85 16.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.17 -0.468 . . . . 75.12 111.13 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.467 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.5 -23.57 2.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.166 -0.47 . . . . 60.12 111.098 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.7 ptt85 -49.16 -24.88 1.87 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.224 -0.443 . . . . 72.33 110.86 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.83 -46.2 31.65 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.721 -0.752 . . . . 71.03 112.466 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' TRP . . . . . 0.417 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.0 p90 -126.27 -125.43 0.24 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.876 0.37 . . . . 75.11 110.906 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.64 -122.13 2.41 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.744 -0.741 . . . . 25.23 112.515 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -124.99 -32.4 3.03 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.909 0.385 . . . . 71.41 110.882 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.17 -26.2 2.69 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.201 -0.454 . . . . 73.21 110.904 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.34 134.59 45.3 Favored Pre-proline 0 C--N 1.328 -0.368 0 CA-C-O 121.595 0.712 . . . . 63.4 110.886 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . 0.451 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.2 Cg_endo -69.8 -34.8 13.73 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.655 2.237 . . . . 73.11 112.316 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.451 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.24 -55.74 0.51 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.238 -0.437 . . . . 75.04 110.874 179.994 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.467 ' HB3' ' HB2' ' A' ' 7' ' ' ALA . 6.5 m-85 -129.18 16.07 6.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.178 -0.464 . . . . 75.14 110.856 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.346 0 C-N-CA 120.736 -0.745 . . . . 64.11 112.479 -179.951 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 35.3 m . . . . . 0 C--O 1.231 0.1 0 CA-C-O 120.903 0.382 . . . . 55.11 110.887 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 2.6 ttt180 -55.67 -25.67 40.81 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.127 -0.488 . . . . 62.13 110.888 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 18.5 t -67.02 -12.27 14.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 72.34 111.078 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.437 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.81 -23.13 2.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.177 -0.465 . . . . 75.53 111.124 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.3 mtp180 -48.52 -25.77 1.85 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.236 -0.438 . . . . 75.03 110.897 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.48 -47.01 23.17 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.738 -0.744 . . . . 32.24 112.462 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' TRP . . . . . 0.443 ' HZ2' ' CD1' ' A' ' 17' ' ' PHE . 2.9 p90 -126.31 -125.3 0.24 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.852 0.358 . . . . 71.11 110.944 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.3 -122.42 2.45 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.715 -0.755 . . . . 41.1 112.495 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.2 ptp180 -125.11 -32.57 2.98 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.879 0.371 . . . . 73.35 110.884 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -48.99 -26.28 2.44 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.191 -0.459 . . . . 74.24 110.917 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.21 134.43 45.96 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.624 0.726 . . . . 73.11 110.891 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . 0.443 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.4 Cg_endo -69.79 -34.33 14.68 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.693 2.262 . . . . 71.34 112.302 -179.904 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.443 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.65 -55.62 0.55 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.246 -0.434 . . . . 75.51 110.927 179.979 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.443 ' CD1' ' HZ2' ' A' ' 10' ' ' TRP . 6.0 m-85 -128.5 15.6 6.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.158 -0.474 . . . . 74.21 110.837 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.279 0 C-N-CA 120.727 -0.749 . . . . 74.53 112.483 -179.945 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 35.2 m . . . . . 0 C--O 1.231 0.121 0 CA-C-O 120.88 0.371 . . . . 71.44 110.88 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -55.64 -25.69 40.4 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.123 -0.49 . . . . 74.41 110.868 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 18.4 t -67.01 -12.24 14.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.166 -0.47 . . . . 74.2 111.14 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.437 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.72 -23.24 2.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.16 -0.473 . . . . 75.23 111.077 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.1 mtp85 -48.44 -25.86 1.85 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 73.05 110.891 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.5 -46.9 23.28 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.724 -0.75 . . . . 71.31 112.475 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' TRP . . . . . 0.445 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.0 p90 -126.44 -125.28 0.24 Allowed 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.805 0.336 . . . . 70.4 110.954 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.33 -122.45 2.45 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.736 -0.745 . . . . 62.14 112.503 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.3 ptp180 -125.08 -32.5 2.99 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.9 0.381 . . . . 71.34 110.867 -179.899 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.05 -26.24 2.51 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 71.02 110.895 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.27 134.45 45.74 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.6 0.714 . . . . 75.11 110.867 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . 0.443 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.3 Cg_endo -69.79 -34.32 14.72 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.666 2.244 . . . . 74.41 112.338 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.443 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.68 -55.64 0.55 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.221 -0.445 . . . . 73.5 110.887 179.968 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.445 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 5.9 m-85 -128.44 15.56 6.58 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.188 -0.46 . . . . 74.54 110.919 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 C-N-CA 120.752 -0.737 . . . . 65.4 112.491 -179.938 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 24.3 m . . . . . 0 C--O 1.231 0.101 0 CA-C-O 120.841 0.353 . . . . 14.41 110.85 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 3.0 mtp180 -54.41 -26.65 31.79 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.125 -0.489 . . . . 74.1 110.863 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 13.1 t -62.57 -16.16 16.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.19 -0.459 . . . . 53.15 111.145 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.463 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.16 -23.6 2.27 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.164 -0.471 . . . . 61.4 111.148 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -49.03 -24.99 1.76 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 74.02 110.893 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.56 -46.47 29.95 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.78 -0.724 . . . . 63.12 112.476 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' TRP . . . . . 0.412 ' CZ2' ' HB2' ' A' ' 16' ' ' LEU . 2.9 p90 -126.23 -125.39 0.24 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.827 0.346 . . . . 75.31 110.88 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.76 -122.18 2.41 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.752 -0.737 . . . . 64.01 112.493 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.0 -31.86 3.08 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.866 0.365 . . . . 75.41 110.847 -179.878 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.71 -25.73 3.19 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.235 -0.439 . . . . 72.45 110.872 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.88 134.79 43.53 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.552 0.691 . . . . 54.25 110.942 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . 0.454 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.6 Cg_endo -69.73 -35.1 13.35 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.694 2.262 . . . . 65.33 112.356 -179.909 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.454 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.07 -55.83 0.49 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.164 -0.471 . . . . 62.5 110.922 -179.99 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.463 ' HB3' ' HB2' ' A' ' 7' ' ' ALA . 6.5 m-85 -129.05 16.04 6.23 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.174 -0.467 . . . . 73.13 110.872 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.247 0 C-N-CA 120.713 -0.756 . . . . 75.04 112.463 -179.952 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 35.4 m . . . . . 0 C--O 1.231 0.122 0 CA-C-O 120.851 0.358 . . . . 62.43 110.872 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 2.1 mtt180 -55.76 -25.47 40.94 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.11 -0.495 . . . . 71.01 110.873 -179.924 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 18.4 t -67.2 -12.21 14.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.216 -0.447 . . . . 62.43 111.116 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.439 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.83 -23.18 2.59 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 75.31 111.072 179.899 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -48.51 -25.75 1.84 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.234 -0.439 . . . . 73.1 110.884 -179.905 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.53 -46.93 23.48 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.728 -0.749 . . . . 62.24 112.474 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' TRP . . . . . 0.441 ' HZ2' ' CD1' ' A' ' 17' ' ' PHE . 2.9 p90 -126.44 -125.31 0.24 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.773 0.321 . . . . 73.51 110.922 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.24 -122.43 2.45 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.768 -0.73 . . . . 60.33 112.527 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.12 -32.47 2.99 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.865 0.364 . . . . 74.11 110.842 -179.865 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.08 -26.23 2.55 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.214 -0.448 . . . . 73.54 110.878 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.32 134.42 45.68 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.668 0.747 . . . . 73.11 110.87 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . 0.44 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.8 Cg_endo -69.73 -34.38 14.8 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.7 2.267 . . . . 62.33 112.35 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.44 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.62 -55.64 0.55 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.21 -0.45 . . . . 71.42 110.898 179.943 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.441 ' CD1' ' HZ2' ' A' ' 10' ' ' TRP . 6.0 m-85 -128.49 15.53 6.56 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.196 -0.456 . . . . 74.33 110.884 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.287 0 C-N-CA 120.717 -0.754 . . . . 73.13 112.498 -179.983 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 58.6 m . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.882 0.372 . . . . 44.52 110.845 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 4.7 mtt180 -55.58 -25.69 39.57 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.117 -0.492 . . . . 62.52 110.855 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 13.1 t -66.12 -12.81 14.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.197 -0.456 . . . . 52.25 111.152 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.425 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.93 -23.45 2.88 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.166 -0.47 . . . . 61.43 111.115 179.856 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.1 mtm180 -48.56 -25.91 1.95 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.202 -0.453 . . . . 50.11 110.891 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.58 -46.78 23.75 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.759 -0.734 . . . . 71.34 112.506 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' TRP . . . . . 0.438 ' HZ2' ' CD1' ' A' ' 17' ' ' PHE . 3.0 p90 -126.44 -125.38 0.24 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.825 0.345 . . . . 75.13 110.909 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.49 -122.38 2.44 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.705 -0.76 . . . . 53.23 112.448 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.03 -32.37 3.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.826 0.346 . . . . 72.23 110.883 -179.881 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.17 -26.12 2.63 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.188 -0.46 . . . . 61.51 110.919 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.42 134.53 45.2 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.635 0.731 . . . . 61.43 110.871 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . 0.451 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.7 Cg_endo -69.75 -34.44 14.61 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.699 2.266 . . . . 74.31 112.352 -179.923 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.451 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.63 -55.63 0.55 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.213 -0.449 . . . . 72.04 110.881 179.984 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.438 ' CD1' ' HZ2' ' A' ' 10' ' ' TRP . 6.1 m-85 -128.65 15.72 6.46 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.199 -0.455 . . . . 70.24 110.824 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 C-N-CA 120.721 -0.752 . . . . 64.34 112.46 179.977 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 35.4 m . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.906 0.384 . . . . 35.52 110.858 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 4.3 mtp180 -55.83 -25.44 41.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.105 -0.498 . . . . 61.23 110.812 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 18.4 t -67.32 -12.04 14.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.23 -0.441 . . . . 72.45 111.134 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.432 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.9 -23.1 2.58 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.182 -0.463 . . . . 52.13 111.093 179.864 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 2.9 mtp180 -48.47 -25.84 1.86 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.243 -0.435 . . . . 73.12 110.89 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.52 -46.92 23.4 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.731 -0.747 . . . . 54.15 112.527 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' TRP . . . . . 0.445 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.0 p90 -126.4 -125.34 0.24 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.833 0.349 . . . . 72.22 110.92 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.28 -122.42 2.45 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.722 -0.751 . . . . 63.31 112.505 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.1 -32.53 2.99 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.879 0.371 . . . . 71.15 110.883 -179.853 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -49.04 -26.28 2.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.158 -0.473 . . . . 72.05 110.86 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.2 134.36 46.1 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-O 121.602 0.715 . . . . 70.45 110.883 179.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . 0.445 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.6 Cg_endo -69.76 -34.31 14.85 Favored 'Trans proline' 0 C--O 1.232 0.222 0 C-N-CA 122.653 2.236 . . . . 74.0 112.347 -179.933 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.445 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.67 -55.63 0.55 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.263 -0.426 . . . . 73.25 110.914 179.957 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.445 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 5.9 m-85 -128.51 15.65 6.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.18 -0.463 . . . . 71.54 110.919 179.888 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 C-N-CA 120.714 -0.755 . . . . 74.22 112.498 -179.989 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 34.2 m . . . . . 0 C--O 1.231 0.09 0 CA-C-O 120.893 0.378 . . . . 70.43 110.914 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -55.74 -25.49 40.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.08 -0.509 . . . . 73.13 110.875 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 18.7 t -67.27 -11.95 14.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.179 -0.464 . . . . 71.55 111.142 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.73 -23.28 2.57 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.129 -0.487 . . . . 75.44 111.095 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 3.3 mtp180 -48.69 -25.66 1.9 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.212 -0.449 . . . . 71.35 110.823 -179.85 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.55 -46.63 23.55 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.736 -0.745 . . . . 65.02 112.464 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' TRP . . . . . 0.454 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.1 p90 -126.43 -125.31 0.24 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.832 0.349 . . . . 74.41 110.941 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.06 -122.33 2.45 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.701 -0.762 . . . . 75.24 112.482 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -125.49 -32.65 2.88 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.848 0.356 . . . . 75.4 110.878 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -49.46 -25.92 2.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.194 -0.457 . . . . 61.21 110.91 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -82.89 133.87 47.89 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.591 0.71 . . . . 32.42 110.891 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . 0.441 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.3 Cg_endo -69.74 -33.8 15.95 Favored 'Trans proline' 0 C--O 1.233 0.233 0 C-N-CA 122.738 2.292 . . . . 63.44 112.291 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.441 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.74 -55.13 0.56 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.245 -0.434 . . . . 55.54 110.96 179.968 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.454 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 5.7 m-85 -128.14 15.04 6.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.229 -0.441 . . . . 73.23 110.845 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.334 0 C-N-CA 120.769 -0.729 . . . . 63.5 112.49 -179.974 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 30.3 m . . . . . 0 C--O 1.231 0.086 0 CA-C-O 120.943 0.402 . . . . 65.33 110.887 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -55.25 -26.43 39.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.094 -0.503 . . . . 73.1 110.896 -179.914 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 15.3 t -65.9 -12.83 14.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.164 -0.471 . . . . 73.34 111.133 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.431 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.66 -23.45 2.63 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 52.23 111.066 179.902 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 2.2 mtt180 -48.46 -25.94 1.89 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.213 -0.449 . . . . 70.24 110.905 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.48 -46.86 23.14 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.747 -0.74 . . . . 72.01 112.492 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' TRP . . . . . 0.442 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 2.9 p90 -126.45 -125.33 0.24 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.769 0.319 . . . . 71.55 110.96 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.33 -122.37 2.44 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.78 -0.724 . . . . 53.03 112.469 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.6 ptp180 -125.14 -32.6 2.97 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.909 0.385 . . . . 71.12 110.854 -179.806 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.03 -26.27 2.49 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.19 -0.459 . . . . 64.31 110.889 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.07 134.46 46.27 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.573 0.701 . . . . 64.12 110.91 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . 0.445 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.2 Cg_endo -69.77 -34.42 14.59 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.665 2.243 . . . . 63.22 112.341 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.445 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.65 -55.6 0.55 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.178 -0.465 . . . . 64.35 110.92 179.996 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.442 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 6.0 m-85 -128.57 15.61 6.51 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.216 -0.447 . . . . 75.34 110.9 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.29 0 C-N-CA 120.732 -0.747 . . . . 71.43 112.506 -179.951 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 31.0 m . . . . . 0 C--O 1.231 0.117 0 CA-C-O 120.855 0.359 . . . . 52.23 110.857 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -55.42 -26.29 41.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.165 -0.47 . . . . 73.3 110.855 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 18.8 t -66.52 -12.25 14.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.203 -0.453 . . . . 70.13 111.118 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.58 -23.31 2.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.19 -0.459 . . . . 70.31 111.136 179.886 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.8 mtp180 -48.57 -25.78 1.89 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.219 -0.446 . . . . 52.22 110.828 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.48 -46.58 23.1 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.669 -0.777 . . . . 65.14 112.524 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' TRP . . . . . 0.45 ' HZ2' ' CD1' ' A' ' 17' ' ' PHE . 3.0 p90 -126.49 -125.27 0.24 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.831 0.348 . . . . 73.31 110.922 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.09 -122.33 2.45 Favored Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.715 -0.755 . . . . 71.24 112.443 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.51 -32.51 2.89 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.855 0.359 . . . . 62.54 110.856 -179.842 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.56 -25.87 3.08 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.197 -0.456 . . . . 73.13 110.883 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -82.93 133.87 47.73 Favored Pre-proline 0 C--N 1.328 -0.365 0 CA-C-O 121.606 0.717 . . . . 65.42 110.91 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . 0.446 ' O ' ' C ' ' A' ' 16' ' ' LEU . 54.0 Cg_endo -69.82 -33.57 16.1 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.688 2.259 . . . . 73.33 112.357 -179.918 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.446 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.86 -55.14 0.58 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 74.11 110.917 179.957 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.45 ' CD1' ' HZ2' ' A' ' 10' ' ' TRP . 5.7 m-85 -128.13 15.01 6.78 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.183 -0.462 . . . . 71.32 110.859 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 C-N-CA 120.697 -0.763 . . . . 64.51 112.511 -179.994 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 75.6 m . . . . . 0 C--O 1.231 0.093 0 CA-C-O 120.88 0.371 . . . . 71.32 110.868 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 2.1 ttt180 -55.5 -25.61 38.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.121 -0.49 . . . . 74.32 110.865 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 14.7 t -66.5 -12.66 15.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.183 -0.462 . . . . 71.25 111.135 179.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' ALA . . . . . 0.435 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.82 -23.39 2.73 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 31.55 111.156 179.822 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -48.58 -25.8 1.9 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.16 -0.473 . . . . 71.41 110.889 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.63 -46.82 24.08 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.739 -0.743 . . . . 62.01 112.484 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' TRP . . . . . 0.441 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.0 p90 -126.39 -125.34 0.24 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.813 0.339 . . . . 72.11 110.906 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.33 -122.37 2.44 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.718 -0.753 . . . . 41.02 112.491 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 3.6 ptp85 -125.18 -32.49 2.97 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.84 0.352 . . . . 74.43 110.848 -179.869 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.11 -26.15 2.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 62.31 110.902 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.18 134.44 46.0 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.566 0.698 . . . . 71.12 110.909 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' PRO . . . . . 0.448 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.5 Cg_endo -69.75 -34.49 14.51 Favored 'Trans proline' 0 C--O 1.232 0.214 0 C-N-CA 122.718 2.279 . . . . 73.32 112.338 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.448 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.6 -55.66 0.54 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.223 -0.444 . . . . 73.21 110.916 179.989 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' PHE . . . . . 0.441 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 6.0 m-85 -128.59 15.63 6.5 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.208 -0.451 . . . . 74.24 110.836 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.283 0 C-N-CA 120.729 -0.748 . . . . 72.05 112.48 -179.969 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 3.0 pttt . . . . . 0 C--O 1.231 0.082 0 CA-C-O 120.811 0.339 . . . . 75.05 110.887 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 79.7 m-20 -109.68 108.72 19.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.217 -0.447 . . . . 73.01 110.907 179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 3.4 mtmt -82.23 -44.6 16.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.193 -0.458 . . . . 71.04 110.943 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 56.2 m -121.91 -23.35 5.47 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.185 -0.461 . . . . 71.41 110.866 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -55.17 -26.54 39.5 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.132 -0.486 . . . . 73.41 110.917 -179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 15.2 t -65.87 -12.61 14.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.183 -0.462 . . . . 61.51 111.153 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.65 -23.52 2.68 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.103 -0.499 . . . . 72.2 111.138 179.868 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 2.3 mtm-85 -48.6 -25.77 1.9 Allowed 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.219 -0.446 . . . . 74.34 110.892 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.57 -46.46 23.64 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.711 -0.757 . . . . 43.42 112.474 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' TRP . . . . . 0.448 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.1 p90 -126.52 -125.34 0.24 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.837 0.351 . . . . 71.13 110.883 -179.894 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.18 -122.22 2.43 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.715 -0.755 . . . . 75.15 112.512 -179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.7 ptp85 -125.45 -32.68 2.89 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.89 0.376 . . . . 70.44 110.892 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.57 -25.78 3.02 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.152 -0.476 . . . . 72.41 110.883 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -82.94 133.87 47.7 Favored Pre-proline 0 C--N 1.328 -0.345 0 CA-C-O 121.638 0.733 . . . . 73.43 110.856 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.448 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.4 Cg_endo -69.77 -33.78 15.86 Favored 'Trans proline' 0 C--O 1.232 0.19 0 C-N-CA 122.648 2.232 . . . . 74.42 112.311 -179.952 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.448 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.66 -55.18 0.55 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.239 -0.437 . . . . 71.05 110.92 179.994 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.448 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 5.8 m-85 -128.21 15.08 6.73 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.154 -0.476 . . . . 73.02 110.89 179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.32 0 C-N-CA 120.775 -0.726 . . . . 61.24 112.482 -179.942 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 1.3 ptmt . . . . . 0 C--O 1.231 0.106 0 CA-C-O 120.744 0.307 . . . . 70.32 110.964 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 13.1 m-20 -66.67 108.44 2.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.273 -0.422 . . . . 71.4 110.874 179.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 9.2 mmpt? -84.74 -44.8 13.02 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.157 -0.474 . . . . 73.5 110.863 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 39.1 m -121.13 -25.75 5.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.197 -0.456 . . . . 73.44 110.829 -179.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -54.08 -26.92 29.56 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.167 -0.469 . . . . 71.11 110.843 -179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.0 t -62.07 -16.68 16.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 116.189 -0.46 . . . . 54.24 111.134 179.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.465 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.33 -23.76 2.54 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.177 -0.465 . . . . 53.24 111.069 179.922 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.07 -24.99 1.81 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.217 -0.447 . . . . 74.4 110.898 -179.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.82 -46.11 31.58 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.703 -0.76 . . . . 70.52 112.512 -179.946 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' TRP . . . . . 0.415 ' HZ2' ' CD1' ' A' ' 17' ' ' PHE . 2.9 p90 -126.26 -125.45 0.24 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.829 0.347 . . . . 74.32 110.926 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.74 -122.05 2.4 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.778 -0.725 . . . . 62.23 112.511 179.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -124.99 -32.39 3.03 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.909 0.385 . . . . 74.41 110.88 -179.818 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.24 -26.15 2.78 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.192 -0.458 . . . . 64.15 110.876 179.994 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.29 134.63 45.36 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-O 121.628 0.728 . . . . 71.12 110.889 179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.45 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.7 Cg_endo -69.75 -34.94 13.61 Favored 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.675 2.25 . . . . 74.33 112.357 -179.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.45 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.17 -55.75 0.5 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.194 -0.457 . . . . 73.35 110.917 -179.986 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.465 ' HB3' ' HB2' ' A' ' 7' ' ' ALA . 6.7 m-85 -129.19 16.08 6.15 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 74.04 110.893 179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.335 0 C-N-CA 120.77 -0.729 . . . . 43.02 112.518 -179.995 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.23 0.069 0 CA-C-O 120.811 0.339 . . . . 72.3 110.879 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 37.7 m-20 -107.61 108.51 19.81 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.214 -0.448 . . . . 61.42 110.877 179.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -84.58 -44.76 13.23 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.201 -0.454 . . . . 50.11 110.882 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 58.3 m -121.2 -25.64 5.23 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.266 -0.424 . . . . 72.41 110.879 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -54.17 -26.77 29.74 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.142 -0.481 . . . . 74.32 110.907 -179.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.9 t -62.22 -16.62 16.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.211 -0.45 . . . . 74.22 111.165 179.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.472 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.23 -23.74 2.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.14 -0.482 . . . . 64.22 111.124 179.849 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.1 -24.96 1.83 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.174 -0.466 . . . . 72.23 110.872 -179.886 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.88 -46.16 31.95 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.753 -0.737 . . . . 54.25 112.484 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' TRP . . . . . 0.413 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.0 p90 -126.26 -125.48 0.24 Allowed 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 120.79 0.329 . . . . 72.02 110.917 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.75 -122.03 2.4 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.727 -0.749 . . . . 74.14 112.466 179.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.1 ptp180 -125.03 -32.47 3.01 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.858 0.361 . . . . 71.43 110.882 -179.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.13 -26.2 2.63 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.161 -0.472 . . . . 71.24 110.939 179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.16 134.66 45.65 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 121.629 0.728 . . . . 74.04 110.891 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.447 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.9 Cg_endo -69.75 -34.84 13.8 Favored 'Trans proline' 0 C--N 1.342 0.202 0 C-N-CA 122.68 2.253 . . . . 73.44 112.374 179.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.447 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.27 -55.77 0.51 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.183 -0.462 . . . . 71.23 110.941 179.961 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.472 ' HB3' ' HB2' ' A' ' 7' ' ' ALA . 6.6 m-85 -129.14 16.13 6.18 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.224 -0.444 . . . . 74.21 110.894 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.343 0 C-N-CA 120.753 -0.737 . . . . 62.41 112.472 -179.943 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.23 0.043 0 CA-C-O 120.821 0.343 . . . . 73.15 110.874 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 78.2 m-20 -112.93 108.27 17.15 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.217 -0.447 . . . . 75.11 110.896 179.95 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 20.4 mmtt -84.64 -44.81 13.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.185 -0.461 . . . . 62.55 110.916 179.875 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 39.9 m -121.14 -25.63 5.26 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.232 -0.44 . . . . 14.33 110.879 -179.912 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 4.3 ttt180 -54.1 -26.84 29.36 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.131 -0.486 . . . . 72.4 110.872 179.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.0 t -62.27 -16.56 16.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.236 -0.438 . . . . 50.13 111.093 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.467 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.32 -23.75 2.52 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.22 -0.445 . . . . 44.41 111.089 179.857 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -49.15 -24.94 1.89 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.231 -0.441 . . . . 60.1 110.853 -179.909 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.83 -46.2 31.63 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.743 -0.742 . . . . 73.33 112.46 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' TRP . . . . . 0.416 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 2.9 p90 -126.27 -125.45 0.24 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.831 0.348 . . . . 63.33 110.886 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.76 -122.04 2.4 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.719 -0.753 . . . . 42.02 112.468 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.3 ptp180 -125.04 -32.35 3.02 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.895 0.379 . . . . 73.23 110.854 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.25 -26.19 2.81 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.207 -0.451 . . . . 52.21 110.865 179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.26 134.69 45.35 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-O 121.62 0.724 . . . . 64.11 110.922 179.919 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.452 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.7 Cg_endo -69.84 -34.79 13.63 Favored 'Trans proline' 0 C--O 1.232 0.219 0 C-N-CA 122.692 2.261 . . . . 54.32 112.315 -179.886 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.452 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.26 -55.76 0.51 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.239 -0.437 . . . . 63.14 110.929 179.948 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.467 ' HB3' ' HB2' ' A' ' 7' ' ' ALA . 6.6 m-85 -129.18 16.1 6.16 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.199 -0.455 . . . . 72.34 110.912 179.946 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.352 0 C-N-CA 120.737 -0.744 . . . . 44.33 112.5 -179.968 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.23 0.07 0 CA-C-O 120.74 0.305 . . . . 65.25 110.907 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 92.5 m-20 -63.55 108.39 1.36 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.2 -0.455 . . . . 74.15 110.853 179.955 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.9 mtmt -84.71 -44.73 13.11 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.18 -0.464 . . . . 72.42 110.897 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 42.2 m -121.26 -25.5 5.24 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.201 -0.454 . . . . 64.24 110.827 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -54.3 -26.69 30.73 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.168 -0.469 . . . . 74.11 110.866 -179.932 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 11.8 t -62.38 -16.48 16.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.204 -0.453 . . . . 75.33 111.148 179.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.462 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.36 -23.77 2.57 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.162 -0.472 . . . . 72.13 111.099 179.852 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.17 -24.83 1.87 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.234 -0.439 . . . . 74.44 110.89 -179.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.86 -46.22 31.83 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.747 -0.74 . . . . 55.22 112.491 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' TRP . . . . . 0.413 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 2.9 p90 -126.25 -125.42 0.24 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 120.756 0.312 . . . . 73.15 110.971 -179.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.74 -122.02 2.39 Favored Glycine 0 N--CA 1.452 -0.288 0 C-N-CA 120.709 -0.757 . . . . 65.23 112.479 179.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.0 -32.36 3.03 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.908 0.385 . . . . 72.53 110.906 -179.866 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.19 -26.26 2.76 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.17 -0.468 . . . . 71.32 110.871 179.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.19 134.61 45.67 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-O 121.588 0.709 . . . . 73.51 110.863 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.452 ' O ' ' C ' ' A' ' 16' ' ' LEU . 54.2 Cg_endo -69.73 -34.83 13.87 Favored 'Trans proline' 0 C--O 1.232 0.193 0 C-N-CA 122.697 2.264 . . . . 64.04 112.386 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.452 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.24 -55.75 0.51 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.217 -0.447 . . . . 70.12 110.911 179.959 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.462 ' HB3' ' HB2' ' A' ' 7' ' ' ALA . 6.6 m-85 -129.2 16.11 6.14 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.195 -0.457 . . . . 72.14 110.902 179.905 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.36 0 C-N-CA 120.728 -0.749 . . . . 33.44 112.479 -179.957 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.23 0.072 0 CA-C-O 120.814 0.34 . . . . 60.55 110.917 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 72.6 m-80 -81.53 108.35 15.04 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.23 -0.441 . . . . 73.54 110.913 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 9.2 mmtt -84.65 -44.75 13.15 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.188 -0.46 . . . . 75.31 110.917 179.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 38.3 m -121.17 -25.73 5.23 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.216 -0.447 . . . . 42.12 110.887 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -54.01 -27.25 30.6 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.119 -0.491 . . . . 61.01 110.847 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.0 t -61.65 -17.02 16.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.225 -0.443 . . . . 72.44 111.127 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.465 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.17 -23.81 2.42 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.171 -0.468 . . . . 62.14 111.047 179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.9 ptt85 -49.13 -24.94 1.86 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.264 -0.425 . . . . 73.35 110.877 -179.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.81 -46.16 31.53 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.756 -0.735 . . . . 73.21 112.454 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' TRP . . . . . 0.412 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.0 p90 -126.29 -125.43 0.24 Allowed 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 120.797 0.332 . . . . 72.21 110.911 -179.901 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.77 -122.07 2.4 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.763 -0.732 . . . . 60.14 112.475 -179.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.01 -32.23 3.04 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.866 0.365 . . . . 71.32 110.865 -179.854 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.29 -26.21 2.89 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.157 -0.474 . . . . 64.04 110.888 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.31 134.63 45.32 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.639 0.733 . . . . 64.32 110.86 179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.429 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.9 Cg_endo -69.7 -34.89 13.88 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.684 2.256 . . . . 75.01 112.361 -179.994 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.429 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.19 -55.78 0.5 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.206 -0.452 . . . . 63.42 110.909 179.979 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.465 ' HB3' ' HB2' ' A' ' 7' ' ' ALA . 6.7 m-85 -129.24 16.1 6.12 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.168 -0.469 . . . . 63.12 110.852 179.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.334 0 C-N-CA 120.779 -0.724 . . . . 61.31 112.488 -179.963 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 22.6 mttt . . . . . 0 N--CA 1.458 -0.057 0 CA-C-O 120.809 0.338 . . . . 72.41 110.907 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 29.1 m120 -81.25 108.39 14.84 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.241 -0.436 . . . . 42.24 110.904 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 3.0 mmpt? -84.65 -44.78 13.13 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.161 -0.472 . . . . 74.04 110.866 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 40.5 m -121.23 -25.65 5.22 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.213 -0.449 . . . . 61.31 110.859 -179.888 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -54.01 -27.3 31.04 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.114 -0.494 . . . . 65.23 110.835 -179.929 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.2 t -61.8 -16.81 16.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.185 -0.462 . . . . 53.13 111.102 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.465 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.23 -23.72 2.41 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.188 -0.46 . . . . 75.31 111.094 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.15 -24.96 1.89 Allowed 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.198 -0.455 . . . . 43.23 110.877 -179.91 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.69 -46.24 30.76 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.748 -0.739 . . . . 72.23 112.507 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' TRP . . . . . 0.416 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 2.9 p90 -126.28 -125.46 0.24 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.764 0.316 . . . . 71.11 110.925 -179.865 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.74 -122.07 2.4 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.737 -0.744 . . . . 64.14 112.493 179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -124.96 -32.36 3.04 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.926 0.393 . . . . 72.25 110.909 -179.822 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -49.22 -26.21 2.78 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.153 -0.476 . . . . 62.2 110.909 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.31 134.66 45.26 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-O 121.656 0.741 . . . . 31.54 110.88 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.451 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.7 Cg_endo -69.77 -34.76 13.9 Favored 'Trans proline' 0 C--N 1.342 0.215 0 C-N-CA 122.67 2.247 . . . . 74.03 112.347 -179.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.451 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.33 -55.7 0.52 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.234 -0.439 . . . . 64.4 110.915 179.984 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.465 ' HB3' ' HB2' ' A' ' 7' ' ' ALA . 6.6 m-85 -129.23 16.12 6.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.188 -0.46 . . . . 72.33 110.908 179.918 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.268 0 C-N-CA 120.761 -0.733 . . . . 64.2 112.481 -179.938 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.458 -0.069 0 CA-C-O 120.767 0.318 . . . . 73.34 110.876 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 93.7 m-20 -91.0 108.45 19.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.196 -0.456 . . . . 72.23 110.91 179.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 12.3 mmtt -85.12 -44.71 12.74 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.21 -0.45 . . . . 75.42 110.888 179.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 50.2 m -120.84 -26.02 5.31 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.239 -0.437 . . . . 64.33 110.841 -179.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 1.6 ttp180 -54.19 -26.79 30.03 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.155 -0.475 . . . . 73.33 110.878 -179.909 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.2 t -62.29 -16.37 16.16 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.213 -0.449 . . . . 54.52 111.111 179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.28 -23.88 2.57 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.174 -0.466 . . . . 75.35 111.073 179.851 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -49.11 -24.93 1.83 Allowed 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.251 -0.432 . . . . 75.53 110.857 -179.884 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.94 -45.94 32.33 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.706 -0.759 . . . . 73.14 112.516 -179.971 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' TRP . . . . . 0.427 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.1 p90 -126.32 -125.37 0.24 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.832 0.348 . . . . 75.14 110.893 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.23 -122.1 2.42 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.778 -0.725 . . . . 64.13 112.51 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.55 -32.7 2.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.832 0.348 . . . . 63.45 110.843 -179.882 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.64 -25.79 3.14 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.192 -0.458 . . . . 74.2 110.854 179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -82.24 134.48 48.81 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 121.599 0.714 . . . . 61.53 110.873 -179.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.447 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.5 Cg_endo -69.76 -34.37 14.71 Favored 'Trans proline' 0 C--O 1.232 0.177 0 C-N-CA 122.698 2.265 . . . . 73.21 112.353 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.447 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.4 OUTLIER -34.4 -55.13 0.53 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.204 -0.453 . . . . 64.43 110.927 179.948 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.427 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 6.2 m-85 -128.55 15.12 6.55 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.169 -0.468 . . . . 72.04 110.887 179.921 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.319 0 C-N-CA 120.779 -0.724 . . . . 74.31 112.468 -179.979 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 8.9 mttt . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.763 0.316 . . . . 74.55 110.869 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 31.0 m120 -105.02 108.0 19.28 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.263 -0.426 . . . . 71.32 110.878 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 25.9 mmmt -82.87 -45.47 14.19 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.145 -0.479 . . . . 73.03 110.876 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 58.8 m -121.44 -24.49 5.39 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.217 -0.447 . . . . 73.43 110.839 -179.883 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 1.3 ttt-85 -54.33 -26.74 31.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.118 -0.492 . . . . 75.3 110.872 -179.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 12.8 t -63.19 -15.9 16.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.198 -0.456 . . . . 63.31 111.098 -179.983 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.475 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.51 -23.56 2.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.154 -0.475 . . . . 74.54 111.053 179.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -49.14 -24.92 1.86 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.247 -0.433 . . . . 75.53 110.857 -179.878 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.78 -46.25 31.31 Favored Glycine 0 N--CA 1.451 -0.352 0 C-N-CA 120.703 -0.76 . . . . 73.05 112.538 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' TRP . . . . . 0.416 ' HZ2' ' CD1' ' A' ' 17' ' ' PHE . 2.9 p90 -126.29 -125.38 0.24 Allowed 'General case' 0 C--N 1.328 -0.361 0 CA-C-O 120.796 0.332 . . . . 74.21 110.882 -179.913 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.7 -122.1 2.4 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.748 -0.739 . . . . 62.01 112.475 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -125.02 -32.45 3.01 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.878 0.37 . . . . 74.14 110.836 -179.842 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.06 -26.23 2.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.19 -0.459 . . . . 73.14 110.946 179.924 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.31 134.62 45.33 Favored Pre-proline 0 C--N 1.329 -0.319 0 CA-C-O 121.611 0.719 . . . . 72.35 110.887 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.449 ' O ' ' C ' ' A' ' 16' ' ' LEU . 54.0 Cg_endo -69.81 -34.73 13.85 Favored 'Trans proline' 0 C--N 1.342 0.215 0 C-N-CA 122.678 2.252 . . . . 72.41 112.353 -179.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.449 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.33 -55.66 0.52 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.203 -0.453 . . . . 73.43 110.936 179.989 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.475 ' HB3' ' HB2' ' A' ' 7' ' ' ALA . 6.5 m-85 -129.21 16.05 6.14 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 61.1 110.854 179.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.315 0 C-N-CA 120.743 -0.742 . . . . 73.13 112.514 -179.957 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.231 0.092 0 CA-C-O 120.844 0.354 . . . . 72.4 110.874 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 31.1 m120 -103.7 107.84 18.88 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.226 -0.443 . . . . 74.41 110.931 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 13.3 mmmm -82.65 -45.48 14.47 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.17 -0.468 . . . . 62.35 110.937 179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 56.9 m -121.48 -24.46 5.38 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.243 -0.435 . . . . 63.1 110.831 -179.884 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -54.32 -26.76 31.39 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.1 -0.5 . . . . 74.22 110.889 -179.931 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 13.1 t -63.23 -15.85 16.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.17 -0.468 . . . . 75.12 111.13 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.467 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.5 -23.57 2.58 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.166 -0.47 . . . . 60.12 111.098 179.877 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.7 ptt85 -49.16 -24.88 1.87 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.224 -0.443 . . . . 72.33 110.86 -179.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.83 -46.2 31.65 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.721 -0.752 . . . . 71.03 112.466 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' TRP . . . . . 0.417 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.0 p90 -126.27 -125.43 0.24 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.876 0.37 . . . . 75.11 110.906 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.64 -122.13 2.41 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.744 -0.741 . . . . 25.23 112.515 179.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -124.99 -32.4 3.03 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.909 0.385 . . . . 71.41 110.882 -179.9 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.17 -26.2 2.69 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.201 -0.454 . . . . 73.21 110.904 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.34 134.59 45.3 Favored Pre-proline 0 C--N 1.328 -0.368 0 CA-C-O 121.595 0.712 . . . . 63.4 110.886 179.97 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.451 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.2 Cg_endo -69.8 -34.8 13.73 Favored 'Trans proline' 0 C--O 1.231 0.174 0 C-N-CA 122.655 2.237 . . . . 73.11 112.316 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.451 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.24 -55.74 0.51 Allowed 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.238 -0.437 . . . . 75.04 110.874 179.994 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.467 ' HB3' ' HB2' ' A' ' 7' ' ' ALA . 6.5 m-85 -129.18 16.07 6.16 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.178 -0.464 . . . . 75.14 110.856 179.968 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.346 0 C-N-CA 120.736 -0.745 . . . . 64.11 112.479 -179.951 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 6.5 tttt . . . . . 0 N--CA 1.458 -0.04 0 CA-C-O 120.802 0.334 . . . . 74.14 110.936 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 73.6 m-20 -101.47 109.27 21.06 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.236 -0.438 . . . . 71.41 110.864 179.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 18.9 mtmt -80.45 -44.71 18.8 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.195 -0.457 . . . . 55.02 110.841 179.938 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 35.3 m -122.08 -22.92 5.5 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.267 -0.424 . . . . 55.11 110.887 -179.866 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 2.6 ttt180 -55.67 -25.67 40.81 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.127 -0.488 . . . . 62.13 110.888 -179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 18.5 t -67.02 -12.27 14.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.177 -0.465 . . . . 72.34 111.078 179.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.437 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.81 -23.13 2.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.177 -0.465 . . . . 75.53 111.124 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.3 mtp180 -48.52 -25.77 1.85 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.236 -0.438 . . . . 75.03 110.897 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.48 -47.01 23.17 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.738 -0.744 . . . . 32.24 112.462 -179.997 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' TRP . . . . . 0.443 ' HZ2' ' CD1' ' A' ' 17' ' ' PHE . 2.9 p90 -126.31 -125.3 0.24 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.852 0.358 . . . . 71.11 110.944 -179.928 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.3 -122.42 2.45 Favored Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.715 -0.755 . . . . 41.1 112.495 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.2 ptp180 -125.11 -32.57 2.98 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.879 0.371 . . . . 73.35 110.884 -179.888 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -48.99 -26.28 2.44 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.191 -0.459 . . . . 74.24 110.917 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.21 134.43 45.96 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 121.624 0.726 . . . . 73.11 110.891 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.443 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.4 Cg_endo -69.79 -34.33 14.68 Favored 'Trans proline' 0 C--O 1.232 0.181 0 C-N-CA 122.693 2.262 . . . . 71.34 112.302 -179.904 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.443 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.65 -55.62 0.55 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.246 -0.434 . . . . 75.51 110.927 179.979 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.443 ' CD1' ' HZ2' ' A' ' 10' ' ' TRP . 6.0 m-85 -128.5 15.6 6.55 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.158 -0.474 . . . . 74.21 110.837 179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.279 0 C-N-CA 120.727 -0.749 . . . . 74.53 112.483 -179.945 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 1.7 mptm? . . . . . 0 C--O 1.23 0.069 0 CA-C-O 120.814 0.34 . . . . 74.24 110.873 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 90.3 m-20 -89.22 109.32 20.21 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.2 -0.454 . . . . 73.12 110.875 179.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 36.7 mtmt -80.41 -44.72 18.87 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.149 -0.478 . . . . 70.34 110.911 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 35.2 m -122.1 -22.95 5.49 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.192 -0.458 . . . . 71.44 110.88 -179.909 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -55.64 -25.69 40.4 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.123 -0.49 . . . . 74.41 110.868 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 18.4 t -67.01 -12.24 14.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.166 -0.47 . . . . 74.2 111.14 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.437 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.72 -23.24 2.54 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.16 -0.473 . . . . 75.23 111.077 179.875 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.1 mtp85 -48.44 -25.86 1.85 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.21 -0.45 . . . . 73.05 110.891 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.5 -46.9 23.28 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.724 -0.75 . . . . 71.31 112.475 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' TRP . . . . . 0.445 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.0 p90 -126.44 -125.28 0.24 Allowed 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.805 0.336 . . . . 70.4 110.954 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.33 -122.45 2.45 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.736 -0.745 . . . . 62.14 112.503 -179.996 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.3 ptp180 -125.08 -32.5 2.99 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.9 0.381 . . . . 71.34 110.867 -179.899 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.05 -26.24 2.51 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.199 -0.455 . . . . 71.02 110.895 -179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.27 134.45 45.74 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-O 121.6 0.714 . . . . 75.11 110.867 179.972 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.443 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.3 Cg_endo -69.79 -34.32 14.72 Favored 'Trans proline' 0 C--O 1.231 0.173 0 C-N-CA 122.666 2.244 . . . . 74.41 112.338 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.443 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.68 -55.64 0.55 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.221 -0.445 . . . . 73.5 110.887 179.968 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.445 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 5.9 m-85 -128.44 15.56 6.58 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.188 -0.46 . . . . 74.54 110.919 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.323 0 C-N-CA 120.752 -0.737 . . . . 65.4 112.491 -179.938 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.23 0.044 0 CA-C-O 120.791 0.329 . . . . 74.44 110.886 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 -97.91 108.51 21.24 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.252 -0.431 . . . . 72.33 110.863 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 18.9 mtmt -84.68 -44.75 13.12 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.206 -0.452 . . . . 53.51 110.904 179.879 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 24.3 m -121.12 -25.48 5.3 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.22 -0.445 . . . . 14.41 110.85 -179.875 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 3.0 mtp180 -54.41 -26.65 31.79 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.125 -0.489 . . . . 74.1 110.863 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 13.1 t -62.57 -16.16 16.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.19 -0.459 . . . . 53.15 111.145 179.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.463 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.16 -23.6 2.27 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.164 -0.471 . . . . 61.4 111.148 179.86 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -49.03 -24.99 1.76 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.155 -0.475 . . . . 74.02 110.893 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -48.56 -46.47 29.95 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.78 -0.724 . . . . 63.12 112.476 -179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' TRP . . . . . 0.412 ' CZ2' ' HB2' ' A' ' 16' ' ' LEU . 2.9 p90 -126.23 -125.39 0.24 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.827 0.346 . . . . 75.31 110.88 -179.89 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.76 -122.18 2.41 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.752 -0.737 . . . . 64.01 112.493 -179.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.0 -31.86 3.08 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.866 0.365 . . . . 75.41 110.847 -179.878 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.71 -25.73 3.19 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.235 -0.439 . . . . 72.45 110.872 -179.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.88 134.79 43.53 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-O 121.552 0.691 . . . . 54.25 110.942 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.454 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.6 Cg_endo -69.73 -35.1 13.35 Favored 'Trans proline' 0 C--O 1.231 0.165 0 C-N-CA 122.694 2.262 . . . . 65.33 112.356 -179.909 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.454 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.07 -55.83 0.49 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.164 -0.471 . . . . 62.5 110.922 -179.99 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.463 ' HB3' ' HB2' ' A' ' 7' ' ' ALA . 6.5 m-85 -129.05 16.04 6.23 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.174 -0.467 . . . . 73.13 110.872 179.941 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.247 0 C-N-CA 120.713 -0.756 . . . . 75.04 112.463 -179.952 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.23 0.053 0 CA-C-O 120.799 0.333 . . . . 72.12 110.914 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 76.7 m-20 -71.06 109.18 4.99 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.236 -0.438 . . . . 73.4 110.9 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 1.8 mmpt? -80.36 -44.69 19.02 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.216 -0.447 . . . . 74.13 110.916 179.93 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 35.4 m -122.1 -22.88 5.51 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.195 -0.457 . . . . 62.43 110.872 -179.918 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 2.1 mtt180 -55.76 -25.47 40.94 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.11 -0.495 . . . . 71.01 110.873 -179.924 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 18.4 t -67.2 -12.21 14.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.216 -0.447 . . . . 62.43 111.116 179.988 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.439 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.83 -23.18 2.59 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.459 . . . . 75.31 111.072 179.899 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -48.51 -25.75 1.84 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.234 -0.439 . . . . 73.1 110.884 -179.905 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.53 -46.93 23.48 Favored Glycine 0 N--CA 1.451 -0.302 0 C-N-CA 120.728 -0.749 . . . . 62.24 112.474 -179.96 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' TRP . . . . . 0.441 ' HZ2' ' CD1' ' A' ' 17' ' ' PHE . 2.9 p90 -126.44 -125.31 0.24 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.773 0.321 . . . . 73.51 110.922 -179.912 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.24 -122.43 2.45 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.768 -0.73 . . . . 60.33 112.527 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.12 -32.47 2.99 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.865 0.364 . . . . 74.11 110.842 -179.865 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.08 -26.23 2.55 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.214 -0.448 . . . . 73.54 110.878 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.32 134.42 45.68 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-O 121.668 0.747 . . . . 73.11 110.87 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.44 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.8 Cg_endo -69.73 -34.38 14.8 Favored 'Trans proline' 0 C--O 1.232 0.187 0 C-N-CA 122.7 2.267 . . . . 62.33 112.35 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.44 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.62 -55.64 0.55 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.21 -0.45 . . . . 71.42 110.898 179.943 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.441 ' CD1' ' HZ2' ' A' ' 10' ' ' TRP . 6.0 m-85 -128.49 15.53 6.56 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.196 -0.456 . . . . 74.33 110.884 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.287 0 C-N-CA 120.717 -0.754 . . . . 73.13 112.498 -179.983 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.746 0.308 . . . . 73.54 110.956 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 29.8 m120 -87.0 108.66 18.95 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.241 -0.436 . . . . 72.55 110.907 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 4.5 mtmm -83.02 -44.69 14.94 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.187 -0.461 . . . . 63.2 110.927 179.88 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 58.6 m -121.81 -23.37 5.51 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.238 -0.437 . . . . 44.52 110.845 -179.858 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 4.7 mtt180 -55.58 -25.69 39.57 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.117 -0.492 . . . . 62.52 110.855 -179.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 13.1 t -66.12 -12.81 14.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.197 -0.456 . . . . 52.25 111.152 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.425 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.93 -23.45 2.88 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.166 -0.47 . . . . 61.43 111.115 179.856 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.1 mtm180 -48.56 -25.91 1.95 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.202 -0.453 . . . . 50.11 110.891 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.58 -46.78 23.75 Favored Glycine 0 N--CA 1.45 -0.385 0 C-N-CA 120.759 -0.734 . . . . 71.34 112.506 -179.973 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' TRP . . . . . 0.438 ' HZ2' ' CD1' ' A' ' 17' ' ' PHE . 3.0 p90 -126.44 -125.38 0.24 Allowed 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 120.825 0.345 . . . . 75.13 110.909 -179.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.49 -122.38 2.44 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.705 -0.76 . . . . 53.23 112.448 -179.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.03 -32.37 3.02 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.826 0.346 . . . . 72.23 110.883 -179.881 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.17 -26.12 2.63 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.188 -0.46 . . . . 61.51 110.919 179.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.42 134.53 45.2 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-O 121.635 0.731 . . . . 61.43 110.871 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.451 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.7 Cg_endo -69.75 -34.44 14.61 Favored 'Trans proline' 0 C--O 1.232 0.204 0 C-N-CA 122.699 2.266 . . . . 74.31 112.352 -179.923 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.451 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.63 -55.63 0.55 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.213 -0.449 . . . . 72.04 110.881 179.984 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.438 ' CD1' ' HZ2' ' A' ' 10' ' ' TRP . 6.1 m-85 -128.65 15.72 6.46 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.199 -0.455 . . . . 70.24 110.824 -179.998 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.306 0 C-N-CA 120.721 -0.752 . . . . 64.34 112.46 179.977 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.457 -0.076 0 CA-C-O 120.797 0.332 . . . . 73.41 110.866 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 59.0 m-20 -117.69 109.26 16.42 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.204 -0.453 . . . . 54.53 110.915 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -80.36 -44.64 19.11 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.155 -0.475 . . . . 72.14 110.921 179.902 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 35.4 m -122.09 -22.84 5.52 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.217 -0.447 . . . . 35.52 110.858 -179.904 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 4.3 mtp180 -55.83 -25.44 41.82 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.105 -0.498 . . . . 61.23 110.812 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 18.4 t -67.32 -12.04 14.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.23 -0.441 . . . . 72.45 111.134 -179.996 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.432 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.9 -23.1 2.58 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.182 -0.463 . . . . 52.13 111.093 179.864 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 2.9 mtp180 -48.47 -25.84 1.86 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.243 -0.435 . . . . 73.12 110.89 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.52 -46.92 23.4 Favored Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.731 -0.747 . . . . 54.15 112.527 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' TRP . . . . . 0.445 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.0 p90 -126.4 -125.34 0.24 Allowed 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.833 0.349 . . . . 72.22 110.92 -179.929 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.28 -122.42 2.45 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.722 -0.751 . . . . 63.31 112.505 179.95 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.1 -32.53 2.99 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.879 0.371 . . . . 71.15 110.883 -179.853 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -49.04 -26.28 2.52 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.158 -0.473 . . . . 72.05 110.86 -179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.2 134.36 46.1 Favored Pre-proline 0 C--N 1.328 -0.36 0 CA-C-O 121.602 0.715 . . . . 70.45 110.883 179.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.445 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.6 Cg_endo -69.76 -34.31 14.85 Favored 'Trans proline' 0 C--O 1.232 0.222 0 C-N-CA 122.653 2.236 . . . . 74.0 112.347 -179.933 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.445 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.67 -55.63 0.55 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.263 -0.426 . . . . 73.25 110.914 179.957 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.445 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 5.9 m-85 -128.51 15.65 6.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.18 -0.463 . . . . 71.54 110.919 179.888 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.326 0 C-N-CA 120.714 -0.755 . . . . 74.22 112.498 -179.989 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 1.5 ttmt . . . . . 0 C--O 1.23 0.05 0 CA-C-O 120.74 0.305 . . . . 74.53 110.948 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 96.4 m-20 -78.95 109.36 13.16 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.246 -0.434 . . . . 60.12 110.892 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 3.7 mtmt -80.6 -44.74 18.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.159 -0.473 . . . . 72.31 110.906 179.892 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 34.2 m -121.82 -23.05 5.58 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.194 -0.457 . . . . 70.43 110.914 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -55.74 -25.49 40.78 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.08 -0.509 . . . . 73.13 110.875 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 18.7 t -67.27 -11.95 14.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 116.179 -0.464 . . . . 71.55 111.142 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.73 -23.28 2.57 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.129 -0.487 . . . . 75.44 111.095 179.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 3.3 mtp180 -48.69 -25.66 1.9 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.212 -0.449 . . . . 71.35 110.823 -179.85 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.55 -46.63 23.55 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.736 -0.745 . . . . 65.02 112.464 -179.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' TRP . . . . . 0.454 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.1 p90 -126.43 -125.31 0.24 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.832 0.349 . . . . 74.41 110.941 -179.92 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.06 -122.33 2.45 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.701 -0.762 . . . . 75.24 112.482 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -125.49 -32.65 2.88 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.848 0.356 . . . . 75.4 110.878 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -49.46 -25.92 2.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.194 -0.457 . . . . 61.21 110.91 179.949 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -82.89 133.87 47.89 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-O 121.591 0.71 . . . . 32.42 110.891 179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.441 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.3 Cg_endo -69.74 -33.8 15.95 Favored 'Trans proline' 0 C--O 1.233 0.233 0 C-N-CA 122.738 2.292 . . . . 63.44 112.291 -179.944 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.441 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.74 -55.13 0.56 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.245 -0.434 . . . . 55.54 110.96 179.968 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.454 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 5.7 m-85 -128.14 15.04 6.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.229 -0.441 . . . . 73.23 110.845 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.334 0 C-N-CA 120.769 -0.729 . . . . 63.5 112.49 -179.974 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.23 0.073 0 CA-C-O 120.791 0.329 . . . . 75.1 110.886 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 33.8 m-20 -102.78 108.95 20.37 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.221 -0.445 . . . . 64.51 110.892 179.956 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 21.1 mtmt -81.89 -44.64 16.57 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.143 -0.48 . . . . 63.42 110.891 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 30.3 m -122.01 -23.26 5.45 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.224 -0.444 . . . . 65.33 110.887 -179.893 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -55.25 -26.43 39.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.094 -0.503 . . . . 73.1 110.896 -179.914 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 15.3 t -65.9 -12.83 14.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 116.164 -0.471 . . . . 73.34 111.133 179.983 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.431 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.66 -23.45 2.63 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.202 -0.454 . . . . 52.23 111.066 179.902 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 2.2 mtt180 -48.46 -25.94 1.89 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.213 -0.449 . . . . 70.24 110.905 -179.927 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.48 -46.86 23.14 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.747 -0.74 . . . . 72.01 112.492 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' TRP . . . . . 0.442 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 2.9 p90 -126.45 -125.33 0.24 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.769 0.319 . . . . 71.55 110.96 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.33 -122.37 2.44 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.78 -0.724 . . . . 53.03 112.469 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.6 ptp180 -125.14 -32.6 2.97 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.909 0.385 . . . . 71.12 110.854 -179.806 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.03 -26.27 2.49 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.19 -0.459 . . . . 64.31 110.889 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.07 134.46 46.27 Favored Pre-proline 0 C--N 1.328 -0.342 0 CA-C-O 121.573 0.701 . . . . 64.12 110.91 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.445 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.2 Cg_endo -69.77 -34.42 14.59 Favored 'Trans proline' 0 C--O 1.232 0.196 0 C-N-CA 122.665 2.243 . . . . 63.22 112.341 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.445 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.65 -55.6 0.55 Allowed 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.178 -0.465 . . . . 64.35 110.92 179.996 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.442 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 6.0 m-85 -128.57 15.61 6.51 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.216 -0.447 . . . . 75.34 110.9 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.29 0 C-N-CA 120.732 -0.747 . . . . 71.43 112.506 -179.951 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.23 0.049 0 CA-C-O 120.833 0.349 . . . . 70.11 110.881 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . . . . . . . . . 94.6 m-20 -86.15 109.38 18.84 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.207 -0.451 . . . . 63.23 110.897 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 34.1 mtmt -80.69 -44.62 18.45 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.171 -0.468 . . . . 73.14 110.899 179.915 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 31.0 m -121.95 -23.18 5.5 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.229 -0.442 . . . . 52.23 110.857 -179.886 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -55.42 -26.29 41.01 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.165 -0.47 . . . . 73.3 110.855 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 18.8 t -66.52 -12.25 14.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.203 -0.453 . . . . 70.13 111.118 179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . . . . . . . . . . . -50.58 -23.31 2.47 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.19 -0.459 . . . . 70.31 111.136 179.886 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 1.8 mtp180 -48.57 -25.78 1.89 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.219 -0.446 . . . . 52.22 110.828 -179.911 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.48 -46.58 23.1 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.669 -0.777 . . . . 65.14 112.524 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' TRP . . . . . 0.45 ' HZ2' ' CD1' ' A' ' 17' ' ' PHE . 3.0 p90 -126.49 -125.27 0.24 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.831 0.348 . . . . 73.31 110.922 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.09 -122.33 2.45 Favored Glycine 0 N--CA 1.452 -0.249 0 C-N-CA 120.715 -0.755 . . . . 71.24 112.443 179.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.51 -32.51 2.89 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.855 0.359 . . . . 62.54 110.856 -179.842 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.56 -25.87 3.08 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.197 -0.456 . . . . 73.13 110.883 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -82.93 133.87 47.73 Favored Pre-proline 0 C--N 1.328 -0.365 0 CA-C-O 121.606 0.717 . . . . 65.42 110.91 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.446 ' O ' ' C ' ' A' ' 16' ' ' LEU . 54.0 Cg_endo -69.82 -33.57 16.1 Favored 'Trans proline' 0 C--N 1.342 0.197 0 C-N-CA 122.688 2.259 . . . . 73.33 112.357 -179.918 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.446 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.86 -55.14 0.58 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.223 -0.444 . . . . 74.11 110.917 179.957 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.45 ' CD1' ' HZ2' ' A' ' 10' ' ' TRP . 5.7 m-85 -128.13 15.01 6.78 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.183 -0.462 . . . . 71.32 110.859 179.936 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.451 -0.325 0 C-N-CA 120.697 -0.763 . . . . 64.51 112.511 -179.994 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 6.0 mttp . . . . . 0 N--CA 1.458 -0.039 0 CA-C-O 120.799 0.333 . . . . 74.44 110.87 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' ASN . . . . . 0.428 ' HB2' HG23 ' A' ' 6' ' ' VAL . 0.8 OUTLIER -116.41 106.51 13.7 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.213 -0.449 . . . . 73.1 110.872 179.953 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 5.9 mtmm -82.3 -44.26 16.46 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.196 -0.456 . . . . 75.45 110.867 179.898 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' SER . . . . . . . . . . . . . 75.6 m -120.97 -22.33 6.21 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.212 -0.449 . . . . 71.32 110.868 -179.844 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' ARG . . . . . . . . . . . . . 2.1 ttt180 -55.5 -25.61 38.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.121 -0.49 . . . . 74.32 110.865 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.428 HG23 ' HB2' ' A' ' 2' ' ' ASN . 14.7 t -66.5 -12.66 15.01 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.183 -0.462 . . . . 71.25 111.135 179.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' ALA . . . . . 0.435 ' HB2' ' HB3' ' A' ' 17' ' ' PHE . . . -50.82 -23.39 2.73 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.195 -0.457 . . . . 31.55 111.156 179.822 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -48.58 -25.8 1.9 Allowed 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.16 -0.473 . . . . 71.41 110.889 -179.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . -47.63 -46.82 24.08 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.739 -0.743 . . . . 62.01 112.484 -179.945 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' TRP . . . . . 0.441 ' HZ2' ' CD2' ' A' ' 17' ' ' PHE . 3.0 p90 -126.39 -125.34 0.24 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.813 0.339 . . . . 72.11 110.906 -179.918 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -129.33 -122.37 2.44 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.718 -0.753 . . . . 41.02 112.491 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 3.6 ptp85 -125.18 -32.49 2.97 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.84 0.352 . . . . 74.43 110.848 -179.869 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.11 -26.15 2.56 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 62.31 110.902 179.957 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -83.18 134.44 46.0 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 121.566 0.698 . . . . 71.12 110.909 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' PRO . . . . . 0.448 ' O ' ' C ' ' A' ' 16' ' ' LEU . 53.5 Cg_endo -69.75 -34.49 14.51 Favored 'Trans proline' 0 C--O 1.232 0.214 0 C-N-CA 122.718 2.279 . . . . 73.32 112.338 -179.948 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.448 ' C ' ' O ' ' A' ' 15' ' ' PRO . 0.3 OUTLIER -34.6 -55.66 0.54 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.223 -0.444 . . . . 73.21 110.916 179.989 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.441 ' CD2' ' HZ2' ' A' ' 10' ' ' TRP . 6.0 m-85 -128.59 15.63 6.5 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.208 -0.451 . . . . 74.24 110.836 179.975 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.452 -0.283 0 C-N-CA 120.729 -0.748 . . . . 72.05 112.48 -179.969 . . . . . . . . 0 0 . 1 stop_ save_